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CDB cell dissociation buffer 
CHO Chinese hamster ovary (cells) 
CRD carbohydrate recognition domain 
COP  Coat proteine  
C-terminal carboxy terminal 
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ECM Extracellular matrix 
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ER endoplasmatic reticulum 
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GalNAc N-acetylgalactosamine 
GFP green fluorescence protein 
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GTP guanosine triphosphate 
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HASPB hydrophilic acylated surface protein B 
HCl hydrochlorid acid 
HEK 293T Human endothelial kidney cells 
HIV human immunodeficiency virus 
HMGB high mobility group protein 
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HS heparan sulfate 
HSPG heparan sulfate proteoglycans 
HUT78 T-cell lymphoma cell line HUT78 
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IgG Immunoglobulin G 
IL interleukin 
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L1-CAM L1 cell adhesion molecule 
LTR long terminal repeat 
Man Mannose 
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MIF migration inhibtory factor 
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NLS nuclear localization signal 
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PE phycoerythrin 
POD peroxidase 
PVDF polyvinyliden fluoride 
RNA ribonucleic acid 
RT Room temperature 
SDS sodium dodecyl sulfate 
SNAP Soluble NSF attachment protein 
SNARE SNAP receptors 
SRP signal recognition particle 
Tat HIV transactivator protein 
TEMED N,N;N´,N´-tetramethylethylenediamine 
Tris Tris[hydroxymethyl]aminoethane 
Tween 20 polyoxethylene sorbitane monolaureate 
U units (enzyme activity) 
UDP Uridine diphosphate 
v/v volume/volume relationship 
w/v weight/volume relationship 
α-MEM α-modification of Minimal Essential Medium 
 
Abbreviation 
 
4 
Amino Acids 
 
Abbreviation  Abbreviation Animo acid 
A Ala alanine 
C Cys cysteine 
D Asp aspartic acid 
E Glu glutamic acid 
F Phe phenylalanine 
G Gly glycine 
H His histidine 
I Ile isoleucin 
K Lys lysine 
L Leu leucine 
M Met methionine 
N Asn asparagine 
P Pro proline 
Q Gln glutamine 
R Arg arginine 
S Ser serine 
T Thr threonine 
V Val valine 
W Trp tryptophan 
Y Tyr tyrosine 
 
Abstract 
 
5 
Zusammenfassung 
 
Galectin-1 ist ein β-Galaktosid-spezifisches Lektin der extrazellulären Matrix, 
das an der Regulation verschiedener zellulärer Prozesse wie Zellproliferation, 
Differenzierung und Apoptose beteiligt ist. Das extrazelluläre Auftreten von Galectin-
1 war zunächst eine überraschende Entdeckung, da das Protein kein Signalpeptid 
enthält und somit nicht über ER/Golgi-vermittelten Transport sezerniert werden kann. 
Darüber hinaus ist die Sekretion von Galectin-1 in Gegenwart von Brefeldin A nicht 
gehemmt, so dass ein unkonventioneller Sekretionsweg postuliert wurde. 
 
In der vorliegenden Dissertation wurde ein robustes in vivo Modell zur 
funktionellen Rekonstitution der Galectin-1 Sekretion etabliert. Es wurden mittels 
retroviraler Transduktion stabile Zelllinien generiert, die verschiedene Galectin-1 
Reportermoleküle als GFP Fusionsproteine in Abhängigkeit von der exogenen 
Zugabe von Doxicyclin exprimieren. Da die exportierte Population über β-Galaktosid-
haltige Rezeptoren an Zelloberflächen bindet, konnte die Galectin-1 Sekretionsrate 
über verschiedene Methoden wie Durchflusszytometrie, konfokale Laserscan-
mikroskopie sowie biochemische Zelloberflächenbiotinylierung unter verschiedenen 
experimentellen Bedingungen quantifiziert werden. 
 
Die etablierten Modellsysteme wurden einerseits zur funktionellen Charakteri-
sierung eines in dieser Arbeit identifizierten Galectin-1 Rezeptors genutzt und 
andererseits zur Analyse der molekularen Sortierungsdeterminanten verwendet, die 
Galectin-1 zur entsprechenden Exportmaschinerie dirigieren. Eine systematische 
Mutagenese des offenen Leserasters von Galectin-1 ergab hierbei, dass Mutationen, 
die zu einer Bindungsdefizienz führen, letztlich auch einen Exportdefekt verursachen. 
Komplementär hierzu konnte gezeigt werden, dass Galectin-1 von Zelllinien, die nicht 
zur Expression von β-Galaktosid-haltigen Rezeptoren befähigt sind, nicht exportiert 
wird. Hieraus wurde der Schluss gezogen, dass β-Galaktosid-haltige Zellober-
flächenrezeptoren für den Gesamtprozess der Galectin-1 Sekretion essentiell sind. 
Dieser Befund konnte durch die Expression des mit Galectin-1 entfernt verwandten 
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Proteins CGL-2 aus dem multizellulären Pilz Coprinopsis cinerea bestätigt werden. 
CGL-2 wird von Säugetierzellen unkonventionell exportiert, wobei dieser Prozess von 
der Bindung an β-Galaktosid-haltige Zelloberflächenrezeptoren abhängt. Die 
beschriebenen Arbeiten haben somit gezeigt, dass das primäre Sortierungssignal für 
die unkonventionelle Sekretion von Galectin-1 durch die β-Galaktosid-Bindungsstelle 
definiert ist und haben weitreichende Implikationen für die weitere Analyse der 
Galectin-1 Exportmaschinerie. 
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Abstract 
 
Galectin-1 is a β-galactoside-specific lectin of the extracellular matrix that has 
been implicated in a number of important cellular processes such as the regulation of 
cell proliferation, differentiation and apoptosis. Even though galectin-1 occurs outside 
cells, it does not contain a signal peptide for ER/Golgi-mediated secretion and, 
therefore, unconventional mechanisms of galectin-1 export have been postulated. 
 
In the current thesis, a robust experimental model system has been established 
that allows for a precise quantitation of galectin-1 export from mammalian cells. 
Based on a retroviral transduction system, stable cell lines have been generated 
expressing various galectin reporter molecules as GFP fusion proteins using a 
doxicycline-dependent transactivator. As read out systems, flow cytometry, confocal 
microscopy and a biochemical cell surface biotinylation assay were used since 
exported galectins bind to cell surfaces via β-galactoside-containing counter 
receptors. 
 
This novel experimental system was used for two main purposes, one being the 
functional characterization of a novel galectin-1 counter receptor, the tumor-specific 
antigen CA125 that was identified in this study. A second aspect of the current thesis 
was to define molecular sorting determinants in galectin-1 that direct the protein to its 
unconventional export machinery. A systematic mutational analysis of the galectin-1 
open reading frame was conducted. Additionally, surface residues as well as amino 
acids in galectin-1 conserved across species were exchanged by targeted mutation. 
A major outcome of these studies was that mutations causing a defect in galectin-1 
binding to β-galactosides resulted in a loss of export competence. Intriguingly, when 
expressing the wild-type form of galectin-1 in mutant cells lacking β-galactoside-
containing counter receptors, the protein also failed to get access to its export 
machinery. These findings were taken to mean that a functional interaction between 
galectin-1 and cell surface counter receptors is an obligatory step in the overall 
process of galectin-1 export. Consistently, despite being unrelated with regard to 
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primary structure, a distant galectin relative from the fungus Coprinopsis cinerea, 
CGL-2, was shown to be exported from mammalian cells depending on its ability to 
bind to β-galactosides. Therefore, the work presented in this thesis demonstrates that 
the β-galactoside binding site represents the primary targeting motif for non-classical 
export of galectins defining a galectin export machinery that makes use of β-galacto-
side-containing surface molecules as export receptors for intracellular galectin-1. 
These results have a number of functional implications such as aspects of galectin 
folding during membrane translocation and with regard to the analysis of the 
subcellular site of membrane translocation that is now being investigated based on 
the results described above. 
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1 Introduction 
 
Protein secretion occurs in prokaryotic and eukaryotic cells and involves the 
delivery of secretory products packaged into membrane-bound vesicles to the cell 
exterior. Cells specialized for neurotransmission, enzyme secretion or hormone 
release utilize a highly regulated secretory process. All eukaryotic cells possess an 
endomembrane system that makes up the secretory pathway and endocytic pathway 
(Lee et al., 2004; Rothman and Wieland, 1996). This network consists of a number of 
independent organelles that function sequentially to effect protein secretion to the 
extracellular environment (Keller and Simons, 1997). Each compartment provides a 
specialized surrounding that facilitates various stages in protein biogenesis, 
modification, sorting and secretion (Palade, 1975). Secretory vesicles are transported 
to plasma membrane, where they dock and fuse to release their contents  
(Bonifacino and Glick, 2004). Membrane fusion and secretion are fundamental 
cellular processes regulating ER-Golgi transport, plasma membrane recycling, cell 
division, acid secretion and the release of enzymes, hormones and neurotransmitters 
(Lee et al., 2004; Sudhof, 2004). Therefore it is not surprising that defects in 
secretion and membrane fusion give rise to a number of diseases like diabetes, 
Alzheimer’s, Parkinson’s and acute gastroduodenal diseases (Amara et al., 1992; 
Nagy, 2005; Orci et al., 1997). 
 
1.1 ER/Golgi-mediated protein secretion 
 
 After synthesis of secretory proteins begins on free ribosomes in the cytosol, a 
16- to 30- residue ER signal sequence in the nascent protein directs the ribosome to 
the ER membrane and initiates translocation of the growing polypeptide across the 
ER membrane (Blobel and Dobberstein, 1975a; Blobel and Dobberstein, 1975b; 
Walter et al., 1984). An ER signal sequence typically is located at the N-terminus of 
the protein (Rapoport et al., 1992; Walter, 1992). For most secretory proteins, the 
signal peptide is cleaved off the protein (Blobel and Dobberstein, 1975a; Blobel and 
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Dobberstein, 1975b; Dalbey and Von Heijne, 1992). Since secretory proteins are 
synthesized in association with the ER membrane, a signal-sequence recognition 
mechanism targets them to the ER membrane (Meyer et al., 1982). The two key 
components of this targeting process are the signal-recognition particle (SRP) and its 
receptor located in the ER membrane. SRP is a cytosolic ribonucleoprotein particle 
that transiently binds simultaneously to the ER signal sequence in a nascent protein, 
to the large ribosomal unit, and to the SRP receptor. The SRP receptor is an integral 
membrane protein made up of two subunits: an α subunit and a smaller β subunit 
(Tajima et al., 1986). Once SRP and its receptor have targeted a ribosome 
synthesizing a secretory protein to the ER membrane, the ribosome and the nascent 
chain are rapidly transferred to the translocon, a protein-lined channel within the 
membrane (Rapoport, 1991). During the translation process, the elongating chain 
passes directly from the large ribosomal subunit into the central pore of the trans-
locon (High et al., 1991; Powers and Walter, 1996; Rapoport, 1991). The 60S 
ribosomal subunit is aligned with the pore of the translocon preventing the growing 
chain from being exposed to the cytoplasm and therefore inhibits folding until it 
reaches the ER lumen. Three proteins collectively termed the Sec61 complex were 
found to form the mammalian translocon: Sec61α, an integral membrane protein with 
10 membrane spanning α helices, and two smaller proteins, Sec61β and Sec61γ 
(High et al., 1993; Rapoport, 1992). As the growing polypeptide chain enters the 
lumen of the ER, the signal sequence is cleaved by a signal peptidase, which is a 
transmembrane protein of the ER associated with the translocon (Dalbey and Von 
Heijne, 1992). After the signal sequence has been cleaved, the growing polypeptide 
translocates through the translocon into the ER lumen.  
Soluble and membrane proteins synthesized at the rough ER and translocated 
into the ER are now ready to follow to their final destination via the secretory 
pathway. A single unifying principle governs all protein trafficking in the secretory 
pathway as transport of membrane and soluble proteins from one membrane-
bounded compartment to another is mediated by transport vesicles. Most of the 
newly synthesized proteins in the ER lumen or membrane are incorporated into 
small, 50 nm-diameter transport vesicles. These vesicles either fuse with the cis-
Golgi or with each other to form the membrane stacks known as the cis-Golgi 
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reticulum (network). From the cis-Golgi some proteins, mainly ER localized proteins, 
are retrieved to the ER via a different set of retrograde transport vesicles (Lee et al., 
2004). Importantly, as transport vesicles bud from one membrane and fuse with the 
next, the membrane topology is maintained. 
Two different models of intra-Golgi transport have been discussed in the 
literature (Mironov et al., 2005; Warren and Malhotra, 1998). In the synthesis of 
collagen by fibroblasts, large aggregates of the procollagen precursor often form in 
the lumen of the cis-Golgi. These aggregates are too large to be incorporated into 
small transport vesicles. Newly synthesized procollagen peptides get folded and form 
aggregates in the cis-Golgi where they could subsequently be seen to move as a 
‘wave’ from the cis- through the medial-Golgi cisternae to the trans-Golgi, followed by 
secretion and incorporation into the extracellular matrix. Procollagen aggregates 
could never be detected in small transport vesicles (Mironov et al., 2005). In this 
process called cisternal migration or cisternal progression, a new cis-Golgi stack 
containing its cargo of luminal proteins physically moves from the cis position 
(nearest the ER) to the trans position, successively becoming first a medial-Golgi 
cisterna and finally a trans-Golgi cisterna (Graham and Emr, 1991; Mellman and 
Simons, 1992; Mironov et al., 2005; Rothman and Orci, 1990). In contrast to this 
cisternal progression model a second model exists proposing that transport within the 
Golgi is mediated by vesicles. According to this vesicular transport model, the Golgi 
is a relatively static structure, with its enzymes held in place, while the molecules in 
transit are moved through the cisternae in sequence, carried by transport vesicles 
(Warren and Malhotra, 1998). 
At the molecular level three kinds of transport vesicles have been functionally 
characterized and can be defined by both membrane origin and coat proteins 
(Kirchhausen, 2000; Robinson, 1987). Clathrin-coated vesicles are formed from both 
the plasma membrane and the trans-Golgi network and mediate vesicular trafficking 
within the endosomal membrane system (Schmid, 1997). COPI-coated vesicles and 
COPII-coated vesicles are transport intermediates of the early secretory pathway 
(Barlowe, 1998; Nickel et al., 2002; Rothman and Wieland, 1996; Schekman and 
Orci, 1996). COPII vesicles emerge from the ER in order to export newly synthesized 
secretory proteins towards the Golgi (Barlowe, 1998; Schekman and Orci, 1996). In 
Introduction 
 
12 
contrast, COPI-coated vesicles appear to be involved in both biosynthetic 
(anterograde) and retrograde transport within the Golgi complex (Orci et al., 1997), 
as well as mediating the recycling of proteins from the Golgi to the ER (Cosson and 
Letourneur, 1994; Letourneur et al., 1994; Sonnichsen et al., 1996). All types of 
coated vesicles are formed by polymerization of coat proteins on the cytosolic 
surface of the corresponding donor membrane to form vesicle buds that eventually 
pinch off from the membrane to release a complete vesicle. Shortly after vesicle 
release, the coat is shed exposing proteins required for fusion with the target 
membrane (Lee et al., 2004).  
Small GTP-binding proteins (ARF for COPI and clathrin coated vesicles, 
respectively; SAR1 for COPII-vesicles) belonging to the ras GTPase superfamily 
control polymerization of coat proteins, the initial step in vesicle budding. Both ARF 
and Sar1 are monomeric proteins with an overall structure similar to that of ras (Orci 
et al., 1993; Serafini et al., 1991). After vesicles are released from the donor 
membrane, hydrolysis of GTP-bound to ARF or SAR1 triggers disassembly of the 
vesicle coat (Serafini et al., 1991). The primary mechanism by which the vesicle coat 
selects cargo molecules is by directly binding to specific sequences termed sorting 
signals that typically lie in the cytosolic domain of membrane cargo proteins 
(Goldberg, 2000; Kirchhausen et al., 1997; Lee et al., 2004; Mossessova et al., 
2003). The polymerized coat thus acts as an affinity matrix to cluster selected 
membrane cargo proteins into forming vesicle buds. Soluble proteins within the 
lumen of the parental organelles can in turn be selected by binding to the luminal 
domains of certain membrane cargo proteins (e.g. KDEL signal sequence and KDEL 
receptor) (Lewis and Pelham, 1992a). 
Vesicle budding requires protein coats (Bonifacino and Glick, 2004) and small 
GTPases of the ARF family (Nie et al., 2003), while vesicle targeting and fusion 
depend on SNARE proteins (soluble N-ethylmaleimide-sensitive factor attachment 
protein receptor) (Ungar and Hughson, 2003; Weber et al., 1998), small GTPases of 
the Rab family (Pfeffer, 2001b) and a diverse group of tethering factors (Lee et al., 
2004; Lupashin and Sztul, 2005; Pfeffer, 2001a). The Rab proteins regulate docking 
of vesicles with the correct target membrane. Each Rab appears to bind to a specific 
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Rab effector, typically a long coiled-coil protein associated with the target membrane 
(Goud, 1992; Zerial and Stenmark, 1993).  
The term “tethering factors” describes a group of proteins believed to mediate 
initial, loose ‘tethering’ of vesicles with their targets. This loose interaction is followed 
by a tighter, more stable ‘docking’ interaction involving SNAREs (Pfeffer, 2001a). The 
tethering factors form physical links between the vesicles and the acceptor 
membrane before the engagement of SNAREs. Tethering may provide the initial 
level of recognition that is then amplified by SNARE pairing. Tethering factors can be 
generally divided into a group of coiled-coil proteins and a group of multi-subunits 
complexes (Lupashin and Sztul, 2005; Pfeffer, 2001a).  
Disassembly of the vesicle coat uncovers a vesicle-specific v-SNARE. Likewise, 
each type of target membrane in a cell contains a specific t-SNARE membrane 
protein. After Rab mediated docking of a vesicle on its target membrane, the 
interaction of cognate SNAREs brings the two membranes in close proximity 
resulting in membrane fusion. In this process the v-SNAREs and t-SNAREs on the 
two opposing membranes mediate the short-range docking of the vesicle with the 
target compartment by the formation of the so called trans-SNARE complex (Chen 
and Scheller, 2001; Jahn and Grubmuller, 2002; Jahn and Sudhof, 1999; Rothman, 
2002; Sudhof, 2004). The SNARE motifs are believed to be unstructured before 
complex assembly and become highly organized into a four-helical bundle during 
formation of the trans-SNARE-complex. The trans-SNARE complex directly catalyzes 
the fusion of the two opposing membranes. Therefore, following fusion, the complex 
becomes a cis-SNARE complex in the target compartment (Lee et al., 2004).  
Finally, to be ready for subsequent rounds of transport, the cis-SNARE complex 
needs to be disassembled. This is catalyzed by the combined action of α-SNAP 
(soluble N-ethylmaleimide-sensitive factor attachment protein) and the ATPase NSF 
(N-ethylmaleimide-sensitive factor). Interaction of NSF in a form of a hexamer and 
three α-SNAPs with the cis-SNARE complex leads to the transient formation of a 20 
S complex (Furst et al., 2003; Hohl et al., 1998; Wimmer et al., 2001). ATP hydrolysis 
catalyzed by NSF leads to the disassembly of the 20 S complex as well as the cis-
SNARE complex. The free v-SNARE can then be recycled to the donor compartment 
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by retrograde transport, while the t-SNARE subunits can be re-organized into 
functional t-SNARE for the next round of docking and fusion events. 
 
1.2 Unconventional secretion 
 
As already discussed soluble secretory proteins typically contain N-terminal 
signal peptides that direct them to the translocation apparatus of the endoplasmic 
reticulum (ER) (Rapoport et al., 1996; Walter et al., 1984). Following vesicular 
transport from the ER via the Golgi to the cell surface, luminal proteins are released 
into the extracellular space by fusion of Golgi-derived secretory vesicles with the 
plasma membrane (Mellman and Warren, 2000; Palade, 1975; Rothman and 
Wieland, 1996; Schekman and Orci, 1996). This pathway of protein export from 
eukaryotic cells is known as the classical or ER/Golgi-dependent secretory pathway 
(see 1.1).  
However, about 15 years ago, it was reported that interleukin 1β (IL-1β) and 
Galectin-1 (Gal-1) can be exported from cells in the absence of a functional ER/Golgi 
system (Cooper and Barondes, 1990; Rubartelli et al., 1990). Since then, the list of 
proteins demonstrated to be secreted by unconventional means is steadily growing 
(Nickel, 2003). Fig. 1 gives an overview of cellular, viral proteins and proteins derived 
from parasites that have been shown to be exported by mechanisms independent of 
the classical secretory pathway. Current members of this group of proteins are, for 
example: angiogenic growth factors FGF-1 and -2 (1.2.2) (Florkiewicz et al., 1995; 
Jackson et al., 1992; Mignatti et al., 1992), cytokines such as interleukin 1β and 
thioredoxin (1.2.4) (Rubartelli et al., 1992; Rubartelli et al., 1990; Rubartelli and Sitia, 
1991), lectins of the extracellular matrix such as Gal-1 (1.2.1) (Cho and Cummings, 
1995a; Cho and Cummings, 1995b; Cooper and Barondes, 1990; Mehul and 
Hughes, 1997), viral proteins such as Herpes simplex tegument protein VP22 (Elliott 
and O'Hare, 1997) as well as cell surface proteins such as hydrophilic acylated 
surface protein B (HASPB; 1.2.3) (Denny et al., 2000). 
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The basic observations (Cleves, 1997; Hughes, 1999) that led to the proposal 
of alternative pathways of eukaryotic protein secretion are (i) the lack of conventional 
signal peptides, (ii) the exclusion of these proteins from classical secretory organelles 
such as the ER and the Golgi, (iii) the lack of ER/Golgi-dependent post-translational 
modifications such as N-glycosylation and (iv) resistance of these export processes 
to brefeldin A and monensin, both classical inhibitors of ER/Golgi-dependent protein 
secretion (Lippincott-Schwartz et al., 1989; Misumi et al., 1986; Orci et al., 1991). 
 
 
 
Fig. 1 Cargo proteins and potential export routes of unconventional protein secretion.  
 
Because unconventional secretory proteins are soluble factors synthesized on 
free ribosomes in the cytoplasm, various experimental strategies have been pursued 
in order to exclude unspecific release based on cell death under the experimental 
conditions applied. These experiments included quantitative measurements of the 
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appearance of unrelated cytoplasmic proteins in cellular supernatants (Cleves, 1997; 
Engling et al., 2002; Hughes, 1999) as well as the identification of a CHO mutant cell 
line expressing the unconventional secretory protein HASPB that is deficient in non-
classical export of this protein (Stegmayer et al., 2005).  
Moreover, non-conventional protein secretion of FGF-2 was shown to be 
dependent on both energy (Florkiewicz et al., 1995) and temperature (Schäfer et al., 
2004) and is stimulated or inhibited by various treatments (Cleves, 1997; Hughes, 
1999). Furthermore, Gal-1 secretion was shown to be regulated for example by cell 
differentiation (Cooper and Barondes, 1990; Lutomski et al., 1997). Finally, it was 
described that FGF-2 export is regulated by NF-κB-dependent signaling pathways 
(Wakisaka et al., 2002).  
Based on these observations, it can be concluded that unconventional 
secretory proteins exit eukaryotic cells in a controlled manner mediated by 
proteinaceous machineries. 
 
Four potential mechanisms of unconventional protein export have been 
discussed so far in the literature to mediate translocation of cytosolic factors into the 
extracellular space (Hughes, 1999; Nickel, 2005). Two of these (Fig. 2; mechanism 1 
and 3) involve intracellular vesicles of the endocytic membrane system such as 
secretory lysosomes (Clark and Griffiths, 2003; Stinchcombe et al., 2004) and 
exosomes (Stoorvogel et al., 2002), the latter ones being internal vesicles of 
multivesicular bodies (Stahl and Barbieri, 2002). Under suitable conditions, lysosomal 
contents gain access to the exterior of cells when specialized endocytic structures 
such as secretory lysosomes of T lymphocytes or melanosomes of melanocytes fuse 
with the plasma membrane (Stinchcombe et al., 2004). Similarly, luminal contents of 
endocytic structures can be released into the extracellular space when multivesicular 
bodies fuse with the plasma membrane, a process that results in the release of 
exosomal vesicles along with their cargo molecules (Stoorvogel et al., 2002).  
Two alternative unconventional secretory mechanisms are characterized by a 
direct translocation of cytosolic factors across the plasma membrane using either 
protein conducting channels such as adenosine triphosphate-binding cassette (ABC) 
transporters proposed for FGF-2 secretion (Cleves and Kelly, 1996) (Fig. 2; 
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mechanism 2) or a process called membrane blebbing (Fig. 2; mechanism 4), the 
latter one being characterized by shedding of plasma membrane derived 
microvesicles that are released into the extracellular space (Freyssinet, 2003; Hugel 
et al., 2005; Martinez et al., 2005).  
 
 
 
Fig. 2 Vesicular and non-vesicular pathways potentially involved in unconventional pro-
cesses. 1, export by secretory lysosomes; 2, export mediated by plasma membrane-resident 
transporters; 3, export through the release of exosomes derived from multivesicular bodies; 4, 
export mediated by plasma membrane shedding of microvesicles 
 
1.2.1 Galectins 
 
All 15 members of the galectin protein family are abundant β-galactoside-
specific lectins of the extracellular matrix (Chiariotti et al., 2004; Gray et al., 2004; 
Gray et al., 2005; Perillo et al., 1998). Lectins are defined as carbohydrate-binding 
proteins. They were first discovered more than 100 years ago in plants; they are now 
known to be present throughout nature. For a while after their discovery, animal 
lectins were classified according to the carbohydrate sequence to which they bound 
best. With the advent of molecular cloning a more consistent classification emerged, 
based on amino acid sequence homology and conservation of these lectins. 
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Until the 1990s, all of the animal lectins discovered were found to be naturally 
multivalent, either because of their defined multisubunit structure or by virtue of 
having multiple carbohydrate-binding sites within a single polypeptide (Sharon, 
1993). Indeed, high avidity generated by multivalent binding of low-affinity single sites 
appears to be a common mechanism for optimizing lectin function in nature (Rini, 
1995a), and a traditional definition for a lectin was “a multivalent carbohydrate-
binding protein that is not an antibody”. The first exception to this general rule 
appeared to be the selectins (Crocker and Feizi, 1996; Rosen and Bertozzi, 1994), 
which have only a single CRD site within their extracellular polypeptide domains. The 
same situation applies to the Siglecs (for sialic acid/immunoglobulin superfamily/lec-
tins) (Crocker, 2002). However, evidence is emerging that these molecules become 
functionally multimeric by clustering on cell surfaces (Crocker, 2002; Varki, 1992). 
The galectins are β-galactoside-specific lectins and have been implicated in 
many cellular processes such as regulation of cell growth, cell proliferation, different-
iation and apoptosis (see 1.4). Galectins can act either extracellularly or intra-
cellularly to exert effects on cell growth and apoptosis (Pace et al., 1999; Perillo et 
al., 1998; Perillo et al., 1995; Rabinovich et al., 2002a). The best-characterized 
members of this family are Gal-1 and Gal-3 which are expressed in a wide range of 
vertebrate cell lines and tissues (Cerra et al., 1984; Cho and Cummings, 1995b; 
Cooper and Barondes, 1990; Lutomski et al., 1997; Mehul and Hughes, 1997; Sato 
et al., 1993b; Seelenmeyer et al., 2003).  
 
1.2.1.1 Structure and classification 
 
Members of the galectin family are composed of one or two carbohydrate-
recognition domains (CRD) of approximately 130 amino acids. So far 15 members 
could be identified (Gal-1 to Gal-15). The structures of galectins can be generally 
classified into three categories: 
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1) The prototype galectin (Gal-1, -2, -5, -7, -10, -11, -13, -14, -15), which may 
exist as monomers or homodimers consisting of one carbohydrate 
recognition domain (CRD) per subunit 
2) The chimera type (Gal-3), which contains a non-lectin N-terminal short 
sequence segment followed by 8-12 collagen-like repeats of 9 amino acids 
connected to the C-terminal CRD domain 
3) The tandem-repeat type (galectin-4, -6, -8, -9, -12), composed of two CRD 
domains in a single polypeptide chain connected by a linker peptide 
(Ahmed et al., 1996; Yang et al., 2001). 
 
Gal-1 is a homodimer of two 14-kDa polypeptides. Each subunit consists almost 
exclusively of a carbohydrate recognition domain (CRD) (Barondes et al., 1994). The 
crystal structure of Gal-1 was the first to be determined among galectins (Fig. 3). The 
overall folding of human Gal-1 involves a β-sandwich consisting of two antiparallel β-
sheets of five (F1-F5) and six (S1-S6a/b) strands (Lobsanov et al., 1993), 
respectively. The N- and C-termini of each monomer are positioned at the dimer 
interface and the CRDs are located at the far ends of the same face of the surface, 
which presents a long negatively charged cleft in the cavity. The presence of this cleft 
deserves attention as a site for ionic interactions. The distance between the two 
CRDs is approximately 44 Å (Lopez-Lucendo et al., 2004). 
 
 
 
Fig. 3 Crystal structure of human Gal-1 (Lopez-Lucendo et al., 2004). 
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Similar to interleukin 1β, FGF-1, FGF-2 and HASPB, galectins apparently do not 
contain signal peptides in their primary structure suitable for ER/Golgi-mediated 
secretion (Couraud et al., 1989). Consistently, galectins are synthesized on free 
ribosomes in the cytoplasm (Wilson et al., 1994) and galectin secretion has been 
shown not to be blocked by inhibitors of the ER/Golgi-dependent pathway such as 
brefeldin A and monensin (Hughes, 1999; Lindstedt et al., 1993; Sato et al., 1993b). 
Unlike interkeukin 1β, Gal-1 and Gal-3 do not appear to be packaged into 
intracellular vesicles prior to export (Cooper and Barondes, 1990; Hughes, 1999; 
Mehul and Hughes, 1997; Sato et al., 1993a). Rather, Gal-1 and Gal-3 have been 
shown to accumulate directly underneath the plasma membrane, followed by an 
export mechanism that appears to involve so far the formation of membrane bound 
vesicles that pinch off before being released into the extracellular space (Cooper and 
Barondes, 1990; Hughes, 1999; Mehul and Hughes, 1997; Sato et al., 1993a). This 
potential mechanism also distinguishes galectin export from FGF-1 and FGF-2 
export, as there is no evidence that these proteins are packaged into membrane-
bound vesicles.    
Extracellular galectins are found either bound to the extracellular surface of the 
plasma membrane or as abundant components of the extracellular matrix (Cerra et 
al., 1984; Cho and Cummings, 1995b; Cooper and Barondes, 1990; Lutomski et al., 
1997; Mehul and Hughes, 1997; Sato et al., 1993a; Seelenmeyer et al., 2003). Cell 
surface association of galectins is mediated by both N- and O-linked oligosaccharide 
side chains of glycoproteins bearing terminal β-galactosides (Hughes, 1999; Perillo et 
al., 1998) as well as by β-galactoside-containing glycolipids such as GM1 (Kopitz et 
al., 1998; Perillo et al., 1998). As Gal-1 and Gal-3 can form homodimers (Cho and 
Cummings, 1995b; Giudicelli et al., 1997; Hughes, 1999), it has been proposed that 
extracellular galectins affect their glycosylated cell surface counter receptors by 
inducing conformational changes of their extracellular domains and/or by clustering 
galectin counter receptors based on non-covalent crosslinking of oligosaccharide 
moieties (Perillo et al., 1998). In this way, secreted galectins are thought to affect 
processes such as cell differentiation by cell surface counter receptor-mediated 
signaling (Perillo et al., 1998; Sacchettini et al., 2001). While classical counter 
receptors of, e.g., Gal-1 include laminin (Zhou and Cummings, 1990), fibronectin 
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(Ozeki et al., 1995) and cell-type specific receptors such as T-cell CD43 and CD45 
(Pace et al., 1999), it has been shown that tumor-specific cell surface antigen CA125 
also represents a galectin counter receptor that preferentially binds Gal-1 
(Seelenmeyer et al., 2003). This latter example is of particular interest as it provides 
a potential molecular mechanism for how tumor cells can differentially interact with 
the extracellular matrix, a process crucial for tumor progression (Liu and Rabinovich, 
2005). 
 
1.2.1.2 Gal-1-mediated signaling and biosynthesis of Gal-1 counter 
receptors  
 
Galectins represent a group of proteins that bind β-galactosyl-containing glyco-
conjugates. Galectins are widely distributed throughout the animal kingdom. Certain 
members of the galectin family promote cell-cell adhesion such as Gal-1 (Perillo et 
al., 1998; van den Brule et al., 1995), whereas some have potent biological activities, 
such as the ability to induce apoptosis (Lanteri et al., 2003; Perillo et al., 1995), and 
to induce metabolic changes, such as cellular activation and mitosis (Liu et al., 2002). 
Galectins are soluble proteins that are secreted by a nonclassical pathway and 
require reducing conditions to maintain activity in the absence of ligands (de Waard 
et al., 1976). To fulfill their extracellular function, galectins need d 
To bind to β-galactoside-containing counter receptors. Functional counter 
receptors with regard to galactosylation are obligatory components in order to 
promote cell-cell adhesion, cell-matrix adhesion and to effect cell growth and viability.  
Asparagine-linked glycosylation (N-glycosylation) begins with the assembly of 
the complete dolichol-linked oligosaccharide donor (initial composition Glc3Man9Glc-
NAc2) (Hebert et al., 2005). This process begins on the cytosplasmic face of the ER 
and is finished within the lumen, where the glycan chain is transferred en bloc by 
oligosaccharyltransferase to an Asn residue in the consensus sequence Asn-X-
Ser/Thr. Following translocation into the ER lumen and glycosylation, proteins 
encounter chaperones that facilitate the maturation process (Hebert et al., 2005). The 
initial branched carbohydrate structure is modified and trimmed in the ER, but 5 of 
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the 14 residues are maintained in the structure of all N-linked oligosaccharides on 
secretory and membrane proteins (Kornfeld and Kornfeld, 1985). Further 
modifications and additions of sugar residues occur in the Golgi apparatus, 
depending on the protein (Farquhar, 1981). For example, UDP-galactose is 
specifically transferred by Golgi-resident galactosyltransferases to N-linked 
glycoproteins, which are potential counter receptors for Gal-1. 
The first glycosylation enzyme to be biochemically localized to Golgi 
membranes is galactosyltransferase (GalNAcT) (Fleischer et al., 1969; Morre et al., 
1969). Nearly all eukaryotic GalNAcT (Hennet, 2002) have been shown to be 
membrane-bound proteins (type II transmembrane proteins) with their active sites 
being exposed to the lumen of the Golgi (Carey and Hirschberg, 1981; Creek and 
Morre, 1981; Fleischer, 1981; Schachter et al., 1970). These terminal glycosyltrans-
ferases are biochemically localized to regions of the Golgi distinct from early oligo-
saccharides trimming enzymes (Deutscher et al., 1983; Dunphy et al., 1981; 
Goldberg and Toole, 1983). 
 
The modification of serine or threonine residues on proteins by addition of a 
GalNAc residue results in an O-linked oligosaccharide or O-glycan. O-glycan 
biosynthesis is simpler than oligosaccharide transfer to asparagines in that a lipid-
linked oligosaccharide precursor used to transfer sugars to target proteins is not 
required (Hebert et al., 2005). The initiating event is the addition of the 
monosaccharide GalNAc (from UDP-GalNAc) to serine and threonine residues 
catalyzed by a polypeptide GalNAc transferase (GalNAcT) (Hirschberg and Snider, 
1987).  
Galactose can be activated to UDP-Gal in several ways (Holton, 1996). The first 
is by direct phosphorylation at the C1-position (Gal-1-P), which can react with UTP to 
form UDP-Gal (Gahl, 1997; Holton, 1996). Alternatively, Gal-1-P can be converted to 
UDP-Gal via the uridyl transferase-catalyzed exchange reaction with UDP-Glc. 
Finally, UDP-Gal can be formed from UDP-Glc by the NAD-dependent reaction 
catalyzed by UDP-Gal-4-epimerase (Gahl, 1997). Cytosolic UDP-galactose is trans-
located into the lumen of the Golgi apparatus by a specific UDP-galactose 
transporter localized in the Golgi membrane (Deutscher and Hirschberg, 1986). 
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In contrast to N-glycosylation, a consensus sequence for GalNAc addition to 
polypeptides has not been identified (Hebert et al., 2005; Hennet, 2002). Many O-
glycans are extended into long chains with variable termini that may be similar to the 
termini of N-glycans. However, O-glycans are less branched than most N-glycans 
and are commonly biantennary structures. O-glycosylation can result in the formation 
of mucin-type molecules. Mucins are defined as soluble or membrane-bound glyco-
proteins with a large number of clustered O-glycans. The clustering of O-glycans on 
mucins is in part due to the presence of a large number of serine and threonine 
residues in an uncharged and often proline-rich peptide context. 
 
1.2.2 Pro-angiogenic Growth Factors: FGF-1 and FGF-2 
 
Fibroblast growth factors 1 and 2 (FGF-1 and FGF-2) belong to a large family of 
heparin-binding growth factors that, apart from their mitogenic activity (Burgess and 
Maciag, 1989; Schweigerer et al., 1987), are key activators of tumor-induced 
angiogenesis. In vertebrates, the 22 members of the FGF family range in molecular 
mass from 17 to 34 kDa and are highly conserved in both gene structure and amino 
acid sequence (Ornitz and Itoh, 2001). Most of the different FGF family members 
share 28 highly conserved and six identical amino acid residues. Structural studies 
on FGF-1 and FGF-2 identified 12 antiparallel β-strands in the conserved core region 
of the protein. Two β-strands include several basic amino acid residues that form the 
primary heparin-binding site of FGF-2, which is responsible for the affinity for 
heparan sulfate proteoglycans (Raman et al., 2003).  
Most FGFs (FGF 3-8, 10, 15, 17-19, and 21-23) have amino-terminal signal 
peptides and are secreted from cells by a classical mechanism. A second group, 
mainly FGF 11-14 lack a signal sequence and are thought to remain intracellularly 
(Ornitz and Itoh, 2001). Their function is presently unknown. 
The other growth factors lack a classical sequence, but are nevertheless 
secreted. FGF-9 and FGF-16, which share 73% homology, contain a new N-terminal, 
non-cleaved signal peptide. As FGF-9 and FGF-16 are glycosylated, it is consistent 
that they are secreted via the classical vesicular pathway (Revest et al., 2000). 
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The remaining FGFs (FGF-1, the 18 kDa isoform of FGF-2, and FGF-20), which 
lack a known signal sequence, are exported in an unconventional manner. As FGF-
20 was discovered only recently, its function and secretion mechanism is largely 
unknown (Hajihosseini and Heath, 2002; Jeffers et al., 2001; Kirikoshi et al., 2000).  
 
As illustrated in Fig. 2 it has been proposed for FGF-2 that membrane 
translocation is mediated by plasma membrane-resident transporters. While it was 
first assumed that angiogenic growth factors might be released from mechanically 
injured tissue to promote wound healing (McNeil et al., 1989), a process that requires 
angiogenesis, various lines of evidence suggest that FGF-1 and FGF-2 are exported 
from cultured cells in the absence of appreciable amounts of cell death (Engling et 
al., 2002; Florkiewicz et al., 1995; Jackson et al., 1992; Mignatti et al., 1992; Trudel 
et al., 2000). Like IL-1β (Rubartelli et al., 1990), FGF-1 is increasingly secreted under 
stress conditions such as heat shock treatment (Jackson et al., 1992; Shin et al., 
1996). In contrast, FGF-2 export is not affected under these conditions (Mignatti and 
Rifkin, 1991). While serum starvation has been reported to inhibit export of FGF-2 
(Mignatti et al., 1992), it was found to induce secretion of FGF-1 (Shin et al., 1996).  
Recently it was shown that direct translocation of FGF-2 across the plasma 
membrane does not require protein unfolding (Backhaus et al., 2004). In case of 
classical secretory transport, quality control occurs at the level of the ER in that 
secretory proteins not being folded properly do not have access to transport vesicle-
mediated exit from this compartment but rather are targeted for degradation (Sayeed 
and Ng, 2005; Sitia and Braakman, 2003; Trombetta and Parodi, 2003). Thus, it 
appears quite reasonable that translocation of FGF-2 is in some way coupled to a 
mechanism that ensures secretion only of functional, properly folded FGF-2 
(Backhaus et al., 2004). These considerations imply that FGF-2 might not be 
released in an unfolded state but rather is exported from cells in a functional form 
that has passed quality control measures (Nickel, 2005). 
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1.2.3 Leishmania hydrophilic acylated surface protein B (HASPB) 
 
Another quite remarkable example of nonclassical protein export from 
eukaryotic cells is the mechanism of cell surface expression of Leishmania HASPB 
which is found associated with the outer leaflet of the plasma membrane only in 
infectious stages of the parasite lifecycle (Alce et al., 1999; Flinn et al., 1994; 
McKean et al., 2001; Pimenta et al., 1994). The protein is synthesized on free 
ribosomes in the cytoplasm. HASPB biogenesis starts with cotranslational 
myristoylation of its N-terminus. A second acylation step involves palmitoylation at 
cysteine 5 of the SH4 domain of HASPB (Denny et al., 2000). The HASPB primary 
structure differs from all other unconventional secretory proteins known to date, as it 
contains an N-terminal SH4 domain commonly found in src kinases that is a 
substrate for N-terminal protein acylation (Resh, 2004).  
Mutational analysis revealed that a HASPB construct lacking its 18 N-terminal 
amino acids is localized to the cytoplasm (Denny et al., 2000). The same is true for a 
mutant that retains the N-terminus but lacks the myristoylation site (Denny et al., 
2000). Interestingly, a mutant that lacks the palmitoylation site (C5A), but continues 
to be myristoylated, has been found associated with the cytoplasmic surface of the 
Golgi apparatus (Denny et al., 2000) suggesting that the putative palmitoylacyltrans-
ferase is a resident enzyme of the Golgi apparatus (Denny et al., 2000; Stegmayer et 
al., 2005). Dual acylation of the SH4 domain of HASPB mediates stable membrane 
association of the molecule. Following transient association with the Golgi, HASPB is 
transported to the inner leaflet of the plasma membrane. Based on these 
observations, there are in principle three options how this transport step is mediated: 
(i) HASPB might be transported to the plasma membrane associated with the cyto-
plasmic leaflet of secretory vesicles, (ii) HASPB might be targeted first to endosomal 
structures followed by translocation to the plasma membrane or (iii) HASPB transport 
from the Golgi to the plasma membrane might not rely on transport vesicles. 
Intriguingly, heterologous expression of various HASPB fusion proteins in 
mammalian cells revealed the existence of a machinery that is capable of trans-
locating the protein across the plasma membrane (Denny et al., 2000), demonstra-
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ting a conserved pathway among lower and higher eukaryotes. No endogenous 
mammalian cargo proteins that make use of this type of export system have been 
identified so far. In any case, palmitoylation of HASPB is strictly required for plasma 
membrane targeting as palmitoylation deficient mutants of HASPB are efficiently 
retained at the level of the Golgi (Denny et al., 2000; Stegmayer et al., 2005). The 
final localization of HASPB is characterized by its stable association with the outer 
leaflet of the plasma membrane with the protein moiety being exposed to the 
extracellular space. Therefore, HASPB must translocate across at least one 
membrane during its biogenesis pathway. Recently, it was shown that the HASPB 
membrane translocation is likely to be mediated by a plasma membrane-resident 
transporter (Stegmayer et al., 2005). 
 
1.2.4 Cytokines: Interleukin-1β , Thioredoxin and Macrophage 
Migration Inhibitory Factor 
 
A classical example of an unconventional secretory protein whose export 
mechanism involves intracellular vesicles is IL-1β (Rubartelli et al., 1990). In 1987, 
Dinarello and colleague demonstrated that interleukin 1, a cytokine (Dinarello, 1991; 
Dinarello, 1997) lacking a classical signal peptide for ER/Golgi-mediated protein 
secretion, is exported from activated human monocytes (Auron et al., 1984). Two 
isoforms of interleukin 1 termed 1α and 1β have been described which represent 
proteolytically processed forms derived from two related but distinct precursors 
(Dinarello, 1997). The processing of IL-1α involves myristoylation and, following 
insertion into the plasma membrane, calpain-dependent cleavage that is thought to 
cause release of the mature form of IL-1α into the extracellular space (Kobayashi et 
al., 1990; Watanabe and Kobayashi, 1994). In the case of IL-1β, interleukin 
converting enzyme produces mature IL-1β (Black et al., 1988; Wilson et al., 1994), 
which is then exported (Dinarello, 1991). When homogenates of activated monocytes 
were analyzed by gradient centrifugation and protease protection experiments, an IL-
1β subpopulation could be detected in the lumen of intracellular vesicles (Andrei et 
al., 1999). On the basis of immunolocalization studies employing electron 
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microscopy, these subcellular vesicles have been identified as an endolysosomal 
subcompartment because IL-1β-positive vesicles display the typical morphology of 
endocytic organelles and are positive for cathepsin D and Lamp-1, classical markers 
of late endosomes and lysosomes. However, only a fraction of the total population of 
cathepsin D- and Lamp-1-positive vesicles was also labeled by anti-IL-1β antibodies 
suggesting that this population represent a specialized subspecies of endolysosomes 
(Andrei et al., 1999). Following appropriate stimulation during the onset of 
inflammatory processes, IL-1β-containing vesicles undergo fusion with the plasma 
membrane resulting in the release of IL-1β into the extracellular space (Andrei et al., 
1999; Andrei et al., 2004). Uptake of IL-1β into secretory lysosomes might be 
mediated by a protein-conducting ABC transporter as the overall process of IL-1β 
secretion is sensitive to glyburide, a drug targeted against the ABC1 family of 
membrane transporters (Hamon et al., 1997; Zhou et al., 2002). Other 
unconventional secretory protein such as high mobility group 1 protein (HMGB1) and 
possibly MIF (migration inhibiting factor), an inflammatory cytokine mediating a 
number of immune and inflammatory diseases, e.g. bacterial septic shock, are 
released by secretory lysosomes as well (Bonaldi et al., 2003; Gardella et al., 2002) 
and glyburide also appears to inhibit nonclassical secretion of MIF (Flieger et al., 
2003).  
Another example for unconventionally secreted proteins are thioredoxins, 
ubiquitous intracellular enzymes that catalyze thiol disulfide exchange reactions 
(Holmgren, 1989). Additionally, extracellular populations of thioredoxin have been 
detected that, similar to IL-1β and MIF, follow an ER/Golgi-independent route of 
secretion (Rubartelli et al., 1992; Rubartelli et al., 1995; Rubartelli and Sitia, 1991; 
Sahaf and Rosen, 2000). This observation is consistent with additional physiological 
roles of thioredoxin such as its function as a mitogenic cytokine that requires 
extracellular localization (Pekkari et al., 2001; Pekkari et al., 2000). Secretion of 
thioredoxin appears to be mediated by a pathway distinct from IL-1β as it could 
neither be detected in intracellular vesicles, nor was the secretion process reported 
to be inhibited by reagents that interfere with the function of ABC transporters. 
However, as with IL-1β (Rubartelli et al., 1990), secretion of thioredoxin is inhibited 
my methylamine and stimulated by brefeldin A (Rubartelli et al., 1992).  
Introduction 
 
28 
1.3 Gal-1 receptors in different cell types 
 
As already described galectins are a family of animal lectins defined by two pro-
perties: shared amino acid sequences in their carbohydrate recognition domain, and 
affinity to β-galactosides. A wide variety of biological phenomena are related to 
galectins, i.e. development, differentiation, morphogenesis, tumor metastasis, 
apoptosis, RNA splicing, and immunoregulatory functions. Several Gal-1 receptors 
are discussed such as CD45, CD7, CD43, CD2, CD3, CD4, CD107, CEA, extracel-
lular matrix proteins such as laminin and fibronectin, glycosaminoglycans, integrins, a 
β-lactosamine glycolipid, GM1 ganglioside, Polypeptide HBGp82, glycoprotein 90 K/ 
Mac-2BP and pre-B-cell receptor.  
 
1.3.1 Biological functions of Gal-1 in different cell types 
 
A wide variety of biological phenomena have been shown to be related to Gal-
1, i.e. cell adhesion, proliferation, apoptosis, T-cell receptor counter-stimulation, 
immunomodulatory effects, cell cycle arrest, pre-B cell signaling, RNA splicing and 
promotion of H-Ras membrane anchorage (Kuwabara et al., 2003; Liu et al., 2002) 
(Rabinovich et al., 2002a; Rabinovich et al., 2002b). Gal-1 is involved in cell-cell and 
cell-matrix adhesion, in processes such as tumor invasion and metastasis, 
inflammation, and organ development. Gal-1 binds to poly-N-acetyl-lactosamine 
chains from extracellular cell matrix proteins such as laminin and fibronectin, thereby 
modulating cell adhesion both positively and negatively (Moiseeva et al., 2000; Ozeki 
et al., 1995; van den Brule et al., 1995; Zhou and Cummings, 1990; Zhou and 
Cummings, 1993). Gal-1 also affects the interaction of tumor cells with endothelia 
cells, which is critical in invasion and metastasis. Accumulation of Gal-1 is observed 
at the contact sites between breast tumor cells and the endothelium: Gal-1 localizes 
on tumor cells and Gal-3 preferentially localizes on endothelial cells, suggesting 
different roles of these lectins in adhesion. Increased Gal-1 expression has been 
reported in many types of human cancer such as those arising from the thyroid, 
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endometrium, head and neck, thymus, bladder, pancreas, and colon, and in 
cholangiocarcinoma, and glioma (Danguy et al., 2002; Lahm et al., 2004). 
In the immune system, Gal-1 is expressed in the thymus, spleen, lymph nodes, 
bone marrow, liver, and immune-privileged sites (Perillo et al., 1998). Gal-1 from 
human thymic epithelial cells binds to core 2-O-glycans on immature cortical 
thymocytes and induces cell apoptosis during thymocyte maturation. Immature 
cortical thymocytes bind more Gal-1 than mature medullar thymocytes do (Perillo et 
al., 1997). The apoptotic effect is dose dependent, carbohydrate-specific, and Fas-, 
steroid- and CD3- independent. In addition, Gal-1 expressed on endothelial cells can 
trigger apoptosis of adherent T cells in a carbohydrate-dependent manner (Nguyen 
et al., 2001; Perillo et al., 1995).  
In inflammation, activated macrophages, antigen-stimulated T cells, activated B 
cells, and alloreactive T cells produce high levels of Gal-1 to kill effector T cells after 
immune response. Immune privileged tissues such as the retina, placenta, testis, and 
the ovary overexpress Gal-1, which might ensure the rapid elimination of 
inflammatory T cells by the Gal-1 apoptotic pathway to protect the integrity and 
function of these vulnerable tissues (Rabinovich et al., 2002a; Rabinovich et al., 
2002b). 
Gal-1 also modulates proliferation of normal and malignant cells, depending on 
the cell type: growth inhibition may be observed at high Gal-1 concentrations 
whereas lower concentrations enhance cell proliferation (Adams et al., 1996). In 
human ovary carcinoma cells, low concentration of Gal-1 do not show any effect, but 
higher concentration decreases cell proliferation (van den Brule et al., 2003). Gal-1 
increases serum-induced DNA synthesis in human SMC cultured cells (Moiseeva et 
al., 2000). In rat pulmonary arterial endothelial cells, Gal-1 also promotes proliferation 
(Sanford and Harris-Hooker, 1990). 
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1.3.2 Galectin-1 receptors 
 
1.3.2.1 Extracellular matrix receptors 
 
Laminin, fibronectin, thrombospondin, vitronectin, and glycoaminoglycans Gal-1 
can modulate cell-ECM interactions in different biological systems. Laminin and fibro-
nectin are two ECM receptors proposed as the main receptors for Gal-1 (van den 
Brule et al., 1995; Zhou and Cummings, 1993). 
 
Laminin is a large glycoprotein and a major component of the basement 
membrane in all types of tissues. Many biological phenomena such as cellular 
adhesion, spreading, proliferation, and differentiation involve interaction between 
cells and laminin. It is composed by three chains, the A chain (400 kDa), B1 chain 
(210 kDa), and B2 chain (200 kDa). It shows ASN-linked oligosaccharides containing 
the repeating disaccharide or poly-N-acetyl-lactosamine sequence (Zhou and 
Cummings, 1990). Gal-1 also modulates human melanoma cell adhesion to laminin. 
Local increases or decreases of Gal-1 expression may play a critical role during 
attachment and detachment of cancer cells throughout the cancer progression 
process (van den Brule et al., 1995). 
Tissue fibronectin has also been proposed as an endogenous receptor for Gal-
1 (Ozeki et al., 1995). Fibronectin, laminin, and Gal-1 colocalize in the extracellular 
matrix of placental tissue. 
Other ECM proteins such as thrombospondin and vitronectin, and, to a lower 
extent, osteopontin can also bind to Gal-1 (Moiseeva et al., 2000). It binds to several 
ECM in a dose-dependent and β-galactoside dependent manner; moreover, Gal-1 
interacts with GAG chains from ECM. For example, heparan sulfate and chondroitin 
sulfate reduce the binding of Gal-1 to ECM proteins (Moiseeva et al., 2003). 
Interactions between Gal-1 and chondroitin sulfate proteoglycans have also been 
described (Seelenmeyer et al., 2003). Chondroitin sulfate B contains galactose-like 
residues and shows significant β-galactoside-dependent binding to Gal-1 in the solid 
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phase, compared to chondroitin sulfate A and C and heparan sulfate, which do not 
bind to Gal-1. 
Interaction between Gal-1 and vitronectin seem to depend on the vitronectin 
conformation. Vitronectin exist either as folded inactive monomer or as an unfolded 
multimer able to interact with ECM components. It shows a significant binding to Gal-
1 in the presence of lactose, probably because lactose induces unfolding of 
vitronectin. Moreover, Gal-1 bound to the ECM reduces the incorporation of 
vitronectin and chondroitin sulfate B to the ECM in a β-galactoside dependent 
manner. Thus, ECM bound Gal-1 can decrease incorporation of its receptors into the 
ECM, which suggests a role for Gal-1 in ECM assembly and tissue matrix remodeling 
(Moiseeva et al., 2003).  
 
1.3.2.2 Cell surface receptors 
 
1.3.2.2.1 Integrins 
 
The α7β1 integrin is the predominant laminin-binding integrin on differentiating 
skeletal muscle cells (Song et al., 1993). The expression of the α7 is developmentally 
regulated during skeletal muscle differentiation and has been used to identify cells at 
distinct stages of the myogenic lineage. The addition of purified recombinant Gal-1 to 
myogenic cells plated on laminin inhibits myoblast spreading and fusion suggesting 
that Gal-1 regulates muscle cell interactions with the extracellular matrix (Cooper et 
al., 1991). 
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1.3.2.2.2 CD45  
 
CD45 is a family of integral membrane tyrosine phosphatases expressed on 
cells of hemopoietic origin. Human CD45 molecules described vary in molecular 
weight from 180 to 220 kDa, accounted for by alternative splicing of a single 
precursor mRNA (Streuli et al., 1987). Additional heterogeneity is accounted for by 
differences in glycosylation of the protein backbone (Sato et al., 1993b).  
The role of CD45 in T cell apoptosis mediated by Gal-1 is controversial (Fajka-
Boja et al., 2002), because CD45 expression is not absolutely required for Gal-1 
induced T cell death. Gal-1-induced T cell apoptosis is regulated by expression of 
specific glycosyltransferase enzymes such as core 2 β-1,6-N-acetylglucoseaminyl-
transferase, which creates a core 2 branch on O-glycans allowing the addition of 
lactosamine sequences (Hernandez and Baum, 2002).  
 
1.3.2.2.3 CD43 
 
CD43 has also been identified as a Gal-1 ligand in T cells. Confocal microscopy 
studies have demonstrated that Gal-1 treatment promotes CD45 segregation, 
virtually excluding CD43. To verify apoptosis of cells undergoing receptor redistri-
bution, annexin V binding was evaluated. Annexin V only localized in large patches of 
CD45 on the surface of apoptotic cells treated with Gal-1. Indeed, before galectin 
induction, CD7 colocalized with CD43, and after addition of Gal-1, CD43 and CD7 
were still associated and moved into larger aggregation. These observations indicate 
that CD43 and CD7 may act as a complex during delivery of Gal-1 apoptotic signals 
(Pace et al., 1999; Perillo et al., 1995).  
Altered glycosylation of CD43 and CD45 has been observed in HIV-1-infected 
of T cells: decreased sialylation and increased expression of core 2 O-glycans have 
been demonstrated. Therefore, HIV-1 infection results in accumulation of exposed 
lactosamine residues, oligosaccharides recognized by Gal-1 on CD43 and CD45, 
Introduction 
 
33 
promoting Gal-1 binding, receptor cross linking, and segregation, critical steps in 
triggering apoptosis (Lanteri et al., 2003). 
1.3.2.2.4 CD7 
 
CD7 appears to have immunomodulatory activity, although ligands for CD7 
have been difficult to find (Lanteri et al., 2003). To determine whether CD7 is 
necessary for Gal-1-induced T cell apoptosis, human CD7 has been expressed in a 
CD7- HUT78 T cell line, which is not susceptible to Gal-1-induced apoptosis. CD7 
expression renders HUT78 cells susceptible to Gal-1. Indeed, CD7 is necessary for 
Gal-1-induced T cell apoptosis via a Ca2+-independent pathway. CD7 is present on 
human immature thymocytes and is up-regulated on activated T cells. Therefore, 
CD7+ T cells may bind Gal-1 expressed by stromal or dendritic cells in tissues where 
T cells die, such as the thymus during T cell development or peripheral lymphoid 
organs following an immune response (Pace et al., 2000). 
 
1.3.2.2.5 GM1 Ganglioside 
 
Gal-1 is a major receptor for the carbohydrate portion of ganglioside GM1 
exposed on the surface of cultured human SK-N-MC neuroblastomas cells. When 
cells were exposed to a ganglioside sialidase inhibitor, which prevents the generation 
of GM1 ganglioside, a significant decrease of Gal-1 binding was detected (Kopitz et 
al., 1998). The pentasaccharide of GM1 presents two building blocks, the 
disaccharide Galβ1-3GalNAC and the central trisaccharide Neu5Acα2-3Galβ1-4Glc: 
these two galactose moieties in central and terminal position are potential binding 
sites for Gal-1. Laser photo-chemically-induced dynamic polarization shows that 
GM1 binding to Gal-1 involves interaction between Trp69 and a galactose residue 
(Siebert et al., 2003). 
 
Introduction 
 
34 
1.4 Galectins and apoptosis 
 
Programmed cell death or apoptosis is indispensable for proper development of 
multicellular organisms. Cell death shapes the proliferating mass of cells into tissues 
and shapes tissues into organs (Meyer and Rustin, 2000). In the mature organism, 
cell death plays a critical role in regulating tissue homeostasis. Dysregulation of cell 
death can cause diseases; excess cell death is associated with immunodeficiency 
and neurodegenerative disorder; and diminished cell death is associated with 
autoimmunity and cancer (Thompson, 1995). To maintain the critical balance 
between cell proliferation and cell death, distinct families of proteins that regulate cell 
death have evolved. These include death-inducing ligands, death receptors, and 
intracellular regulators of death pathways. To date, only two families of proteins have 
been described as death-inducing ligands: the tumor necrosis factor (TNF) family and 
the galectin family (Rabinovich et al., 2002a; Zimmermann et al., 2001). TNF ligands 
bind to cognate TNF receptor polypeptides to initiate cell death. 
 
The intracellular machinery responsible for apoptosis seems to be similar in all 
animal cells. This machinery depends on a family of proteases that have a cysteine 
at their active site and cleave their target proteins at specific aspartic acids, therefore 
called caspases, which are synthesized as inactive precursors. Procaspase 
activation can be triggered from outside the cell by the activation of death receptors 
on the cell surface. Lymphocytes can induce apoptosis by producing Fas ligand, 
which binds the receptor Fas on the surface of the target cells. The Bcl-2 family of 
intracellular proteins regulates the activation of procaspases.  
In contrast, pro-apoptotic galectins bind to specific saccharide ligands on cell 
surface glycoprotein to initiate cell death. Similar to the Bcl family, galectins also 
function intracellularly to promote cell survival or cell death (Kuwabara et al., 2003; 
Yang et al., 1996). Galectins are unique among molecules regulating cell viability 
because they act both outside the cell to initiate death signal and inside the cell to 
regulate susceptibility to death. 
 
Introduction 
 
35 
Thymocyte maturation in the thymus is accompanied by changes in the 
sialylation of cells (i.e. immature cells are less sialylated than mature cells). These 
observations led to studies regarding the possibility that maturing thymocytes interact 
with endogenous thymic lectins. Gal-1 can bind to both activated and resting 
thymocytes and that its binding to activated T cells and T cell leukemic cell lines 
induces apoptosis (Baum et al., 1995a) that is controlled by specific surface 
receptors capable of oligomerization an intracellular caspase cascade. Resting T 
cells also bind Gal-1, but do not undergo apoptosis. The mechanism of Gal-1 
induced apoptosis appears to be distinct from that triggered by Fas (Baum et al., 
1995a). The thymocytes receptors for Gal-1 appear to be CD45 and CD43, both of 
which are highly glycosylated membrane glycoproteins. CD45, CD43 and CD7 are 
the three major glycoproteins on the T cell surface that bind galectin (Walzel et al., 
1999), and Gal-1 regulates CD45-induced signaling in burkitt lymohoma B cells. 
Although initial experiments identified CD7 (Pace et al., 2000) and CD45 (Baum et 
al., 1995b; Nguyen et al., 2001) as the major mediator of Gal-1-induced apoptosis in 
T cells, recent work showed that CD45-deficient Jurkat cells exhibits susceptibility to 
Gal-1 (Fajka-Boja et al., 2002). There is also one report showing the involvement of 
the transcription factor AP-1 and Bcl-2 in Gal-1 induced apoptosis (Rabinovich et al., 
2000). When mature T cells were cultured in the presence of Gal-1, AP-1 was 
activated. Treatment of cells before Gal-1 exposure with curcumin, an inhibitor of AP-
1 activation, suppresses apoptosis, suggesting that AP-1 activation is required for 
Gal-1-induced apoptosis. Gal-1 also inhibits the induction of Bcl-2 by the plant lectin 
concanavalin A (Con A).  
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1.5 Aim of this work 
 
Aim of this work was to elucidate the molecular machinery mediating the export 
of Gal-1. Therefore, a novel experimental system was planned to be established in 
order to facilitate studies on the molecular machinery of Gal-1 secretion. A key 
aspect was to reconstitute Gal-1 secretion in living cells based on a read-out method 
that provides a precise and quantitative analysis of this process. A Gal-1-GFP-based 
system was designed to measure total protein expression (GFP-derived fluores-
cence) and secreted Gal-1-GFP (APC-derived cell surface staining) can be 
measured simultaneously. 
Employing a biochemical approach, a search for Gal-1-interacting proteins 
potentially involved in the unconventional secretion process of Gal-1 was conducted. 
Therefore, a GST-Gal-1 affinity matrix was used to identify human proteins that 
interact with Gal-1. A major aim of this thesis was to characterize such factors in 
terms of function and impact on Gal-1 secretion employing the system described 
above. 
In the third part of this thesis the issue of how Gal-1 is recognized by its transport 
machinery was studied. A targeting motif, directing the protein to its translocation 
apparatus has so far not been described. Therefore, a major aim was to generate a 
large collection of Gal-1 mutants carrying single amino acid substitutions. Using the 
experimental systems to be established in the first part of this thesis, it was planned 
to elucidate the molecular determinants directing Gal-1 to its unconventional export 
machinery. 
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2 Material and Methods 
2.1 Material 
2.1.1 Chemicals 
 
Chemicals Manufacturer 
Agar   Becton Dickinson, Le Pont de 
Claix, France 
Agarose electrophoresis grade Invitrogen Ltd., Paisley, UK 
αMEM Biochrom AG, Berlin 
Ammonium chloride Carl Roth GmbH, Karlsruhe 
Ampicillin sodium salt Gerbu Biotechnik GmbH, Gaiberg 
APS (Ammonium peroxo disulfate) Carl Roth GmbH, Karlsruhe 
β-Mercaptoethanol  Merck, Darmstadt 
EZ-Link Sulfo-NHS-SS-Biotin Pierce, Perbio Sciences, Bonn 
Bromphenol Blue Na-salt Serva Electrophoresis GmbH, 
Heidelberg 
BSA (Bovine serum albumine,  
Albumin fraction V) 
Carl Roth GmbH, Karlsruhe 
Calcium chloride dihydrate Applichem, Darmstadt 
Cell dissociation buffer (CDB) Invitrogen, Paisley, UK 
Chloroquine Sigma-Aldrich Chemie GmbH, 
Steinheim 
CL-4B Sepharose (Beads) Amersham Biosciences Pharmacia, 
Uppsala, Sweden 
Clear Nail Protector Wet’n Wild USA, North Arlington, 
USA 
Complete Mini (Protease Inhibitor 
Cocktail Tablets) 
Roche Diagnostics, Mannheim 
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Deoxycholic acid sodium salt Sigma-Aldrich Chemie GmbH, 
Steinheim 
DMEM Biochrom AG, Berlin 
DMSO (Dimethyl sulfoxide) J.T. Baker, Deventer, USA 
DNA ladder (1 kb and 100 bp) New England Biolabs, Frankfurt 
dNTP-Mix Peqlab, Erlangen 
Doxicycline Clontech, Palo Alto, USA 
ECL Western Blotting Detection 
 Reagent  
Amersham Biosciences Pharmacia, 
Uppsala, Sweden 
EDTA (Ethylene diamine tetraacetic 
acid) 
Merck, Darmstadt 
Ethanol pro analysi Riedel-de Haën, Seelze 
FCS (Fetal Calf Serum) PAA Laboratories GmbH, Linz, 
Austria 
Fluoromount G Southern Biotechnologies Association 
Inc., Birmingham, USA 
Glycerol Carl Roth GmbH, Karlsruhe 
Glycine  Applichem, Darmstadt 
Hepes Carl Roth GmbH, Karlsruhe 
Isopropanol Merck, Darmstadt 
Kanamycin sulfate Gerbu Biotechnik GmbH, Gaiberg 
L-Glutamine Biochrom AG, Berlin 
Magnesium chloride hexahydrate Applichem, Darmstadt 
Methanol pro analysi Merck, Darmstadt 
Milk Powder Carl Roth GmbH, Karlsruhe 
Nonidet P40 (NP-40) Roche, Mannheim 
Paraformaldehyde Electron Microscope Sciences, 
Hatfield, UK 
Penicillin/Streptomycin for cell culture Biochrom AG, Berlin 
Ponceau S Serva Electrophoresis GmbH, 
Heidelberg 
Potassium dihydrogen carbonate Carl Roth GmbH, Karlsruhe 
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Potassium hydroxide J.T.Baker, Deventer, USA 
Protein A-Sepharose (Beads) Amersham Biosciences Pharmacia, 
Uppsala, Sweden 
PVDF Membrane Immobilon P Millipore Corporation, Bedford 
PVDF Membrane Immobilon FL Millipore Corporation, Bedford 
QuikChange®Site-Directed Muta- 
genesis Kit 
Stratagene, La Jolla, USA 
Rotiphorese Gel 30 (37.5:1) Carl Roth GmbH, Karlsruhe 
Sodium chloride J.T. Baker, Deventer, USA 
Sodium dodecyl sulfate  Serva Electrophoreis GmbH, 
Heidelberg 
Sodium hydrogen carbonate J.T. Baker, Deventer, USA 
Sodium hydroxide  J.T. Baker, Deventer, USA 
TEMED (N,N,N',N'-tetramethyl- 
ethylenediamine) 
Bio-Rad, München 
Trichloroacetic acid Carl Roth GmbH, Karlsruhe 
Tris Carl Roth GmbH, Karlsruhe 
Trition X-100 Roche, Mannheim 
Trypsin / EDTA for cell culture Biochrom AG, Berlin 
Trypsin Sigma-Aldrich Chemie GmbH, 
Steinheim 
Tryptone Becton Dickinson, Le Pont de 
Claix, France 
Tween 20 (Polyoxyethylene- 
sorbitan monolaurate) 
Carl Roth GmbH, Karlsruhe 
UltraLink immobilized streptavidin (Beads) Pierce, Perbio Sciences, Bonn 
Whatman MM  Whatman AG, Würzburg 
Xylencyanol FF Serva Electrophoresis GmbH, 
Heidelberg 
Yeast Extract Beckton Dickinson, Le Pont de 
Claix, France 
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2.1.2 Technical devices 
 
Technical devices Manufacturer 
Anthos 2001 Microplate Photometer Anthos, Hombrechtikon, 
Switzerland 
Bacterial Incubator Infors HT ITE Infors AG, Einsbach 
Bacterial Shaker Centromat R Braun, Melsungen 
Centrifuge 5415 R Eppendorf, Hamburg 
Centrifuge 5417 R Eppendorf, Hamburg 
Centrifuge Avanti J-25 Beckman Coulter, Krefeld 
Centrifuge Megafuge 1.0 R Kendro, Langenselbold 
Centrifuge Optima TLX Ultracentrifuge Beckman Coulter, Krefeld 
Centrifuge Rotor Sorvall SS-34 Kendro, Langenselbold 
Centrifuge Sorvall Evolution RC Kendro, Langenselbold 
Centrifuge Sorvall RC 6 Kendro, Langenselbold 
Ultracentrifuge Rotor TLA-45 Beckman Coulter, Krefeld 
EmulsiFlex-C5 Avestin Europe GmbH   
Mannheim, Germany 
FACSAria Becton Dickinson, Heidelberg 
FACSVantage Becton Dickinson, Heidelberg 
FACSCalibur Becton Dickinson, Heidelberg 
Gel Doc 2000 Bio-Rad, München 
Incubator Heraeus CO2-Auto-Zero Kendro, Langenselbold 
LKB Ultraspec III Amersham Biosciences, Freiburg 
Microscope Axiovert 40 C Zeiss, Göttingen 
Microscope LSM 510 Meta Confocal Zeiss, Göttingen 
Mini Trans-Blot Cell Bio-Rad, München 
Mini-PROTEAN 3 Electrophoresis 
System 
Bio-Rad, München 
Nanodrop ND-1000 Spectrophotometer Peqlab, Erlangen 
Odyssey Infrared Imaging System LI-COR Biosciences, Bad Homburg 
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PCR Primus Advanced 25 and 96 Peqlab, Erlangen 
pH-Meter 766 Calimatic Knick, Egelsbach 
Power Pack 200 and 300 Bio-Rad, München 
Roto-Shake Genie Scientific Industries, Bohemia, 
USA 
Sonifier Cell Disruptor B 30 Heinemann, Schwäbisch Gmünd 
Sonorex Super RK 103 h Bandelin, Berlin 
SpectraMax Gemini XPS Microplate 
Spectrofluorometer 
Molecular Devices Corporation, 
Orleans,  U.S 
Thermomixer compact and comfort Eppendorf, Hamburg 
Tricorn 5/150 Column Amersham Biosciences, Freiburg 
 
2.1.3 Plasmids  
 
Name Origin 
peGFP-C1 Clontech, Mountain View, USA 
pET-15b-eGFP AG Nickel, BZH, Heidelberg 
pGEX-2T-Gal-1 AG Nickel, BZH, Heidelberg 
pGEX-2T-Gal-3 AG Nickel, BZH, Heidelberg 
pFB-CA125-C-TERM AG Nickel, BZH, Heidelberg 
pIVEX 2.4b Nde CA125-C-TERM AG Nickel, BZH, Heidelberg 
pGEM-T Promega, Madison, USA 
pGEM-T-Gal-1 AG Nickel, BZH, Heidelberg 
pSilencer™ 1.0-U6  Ambion 
pLNCD4 AG Schwappach, ZMBH, Heidelberg 
pRevTRE2 Clontech, Mountain View, USA 
pRevTRE2-GFP AG Nickel, BZH, Heidelberg 
pFB-hrGFP Stratagene, La Jolla, USA 
pVPack-Eco Stratagene, La Jolla, USA 
pVPack-GP Stratagene, La Jolla, USA 
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2.1.4 DNA modifying enzymes 
 
Enzyme Manufacturer 
AmpliTaq Polymerase Perkin Elmer (Roche), Branchburg, USA 
PfuTurbo Polymerase Stratagene, La Jolla, USA 
Age I New England Biolabs, Frankfurt 
Apa I New England Biolabs, Frankfurt 
BamH I New England Biolabs, Frankfurt 
Dpn I New England Biolabs, Frankfurt 
EcoR I New England Biolabs, Frankfurt 
Nde I New England Biolabs, Frankfurt 
Not I New England Biolabs, Frankfurt 
Sma I New England Biolabs, Frankfurt 
Calf Intestinal Phosphatase (CIP) New England Biolabs, Frankfurt 
 
2.1.5 Primers and oligonucleotides 
 
Primers and oligonucleotides were purchased from Thermo Electron Company. 
 
PCR primers for Gal-1, Gal-3 and eGFP: 
 
5'-primer for His6-eGFP (pET-15b/eGFP), NdeI-restriction-site:  
5‘ - CGTTCATATGGTGAGCAAGGGCGAGGAG - 3‘ 
3'-primer for His6-eGFP (pET-15b/eGFP), BamHI-restriction-site: 
5‘ - CGGGATCCTTACTTGTACAGCTCGTCCAT - 3‘ 
 
5'-primer for GST-Gal-3(pGEX-2T-Gal-3), BamHI-restriction-site: 
5‘ - GGAATTCAGCTCTTAGCAGACATTGG - 3‘ 
3'-primer for GST-Gal-3 (pGEX-2T-Gal-3), EcoRI-restriction-site: 
5‘ - GGAATTCTTATATCATGGTATATGAAGC - 3‘ 
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5'-primer for GST-Gal-1 (pGEX-2T-Gal-1), BamHI-restriction-site: 
5‘ - CGGGATCCATGGCTTGTGGTCTGGTCGCC - 3‘ 
3'-primer for GST-Gal-1 (pGEX-2T-Gal-1), SmaI-restriction-site: 
5‘ - TCCCCCGGGTCAGTCAAAGGCCACACATTTG - 3‘ 
 
PCR primers for pFB/CA125-C-TERM: 
 
5'-primer for CA125-C-TERM, BamHI-restriction-site: 
5’-CGGGATCCCGCCACCATGGGGCTGGACATACAGCAGCTT-3’ 
3'-primer for CA125-C-TERM, NotI-restriction-site: 
5’-GACCTGGAGGATCTGCAATGAGCGGCCGCTTTTTTCCTT-3’ 
 
PCR primers for CA125 in vitro translation pIVEX 2.4b Nde CA125-C-TERM 
 
5’-primer for CA125-C-TERM, NotI-restriction-site: 
5’-AAGGAAAAAAGCGGCCGCATGGGGCTGGACATACAGCAGCTT-3’ 
3’-primer for CA125-C-TERM, BamHI-restriction-site: 
5’-CGGGATCCTCATTGCAGATCCTCCAGGTC-3’ 
 
siRNA oligonucleotides directed against CA125-cytoplasmic tail: 
 
Sense:  
5’-GAAGGAAGGAGAATACAACTTCAAGAGAGTTGTATTCTCCTTCCTTCTTTTTT-
3’ 
 
Antisense:  
5’-AATTAAAAAAGAAGGAAGGAGAATACAACTCTCTTGAAGTTGTATTCTC-
CTTCCTTCGGCC-3’ 
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Site-directed mutagenesis primers: 
 
Primer Sequence  Tm 
Gal-1-GFP   
C3A 5’-TGGCGACCAGACCAGCAGCCATGGTGGCG-3’ 
5’-CGCCACCATGGCTGCTGGTCTGGTCGCCA-3’ 
79.3°C 
V6A 5’-GCTTGTGGTCTGGCCGCCAGCAACC-3’ 
5’-GGTTGCTGGCGGCCAGACCACAAGC-3’ 
71.4°C 
A7I 5’-TGGCTTGTGGTCTGGTCATCAGCAACCTGAATCTCAAAC-3’ 
5’-GTTTGAGATTCAGGTTGCTGATGACCAGACCACAAGCCA-3’ 
75.7°C 
N9A 5’-GTCTGGTCGCCAGCGCCCTGAATCTCAAACCTG-3’ 
5’-CAGGTTTGAGATTCAGGGCGCTGGCGACCAGAC-3’ 
76.4°C 
K13A 5’-CCAGCAACCTGAATCTCGCGCCTGGAGAGTGCCTT-3’ 
5’-AAGGCACTCTCCAGGCGCGAGATTCAGGTTGCTGG-3’ 
78.1°C 
P14A 5’-CAACCTGAATCTCAAAGCTGGAGAGTGCCTTCG-3’ 
5’-CGAAGGCACTCTCCAGCTTTGAGATTCAGGTTG-3’ 
70.6°C 
E16A 5’-TCTCAAACCTGGAGCGTGCCTTCGAGTGC-3’ 
5’-GCACTCGAAGGCACGCTCCAGGTTTGAGA-3’ 
71.6°C 
V20A 5’-GTGCCTTCGAGCGCGAGGCGAGG-3’ 
5’-CCTCGCCTCGCGCTCGAAGGCAC-3’ 
71.1°C 
R21A 5’-AGTGCCTTCGAGTGGCAGGCGAGGTGGCT-3’ 
5’-AGCCACCTCGCCTGCCACTCGAAGGCACT-3’ 
74.8°C 
V32A 5’-GCTAAGAGCTTCGCGCTGAACCTGGGC-3’ 
5’-GCCCAGGTTCAGCGCGAAGCTCTTAGC-3’ 
69.7°C 
V32G 5’-GCTAAGAGCTTCGGGCTGAACCTGGGC-3’ 
5’-GCCCAGGTTCAGCCCGAAGCTCTTAGC-3’ 
68.9°C 
V32E 5’-ACGCTAAGAGCTTCGAGCTGAACCTGGGC-3’ 
5’-GCCCAGGTTCAGCTCGAAGCTCTTAGCGT-3’ 
69.3°C 
V32S 5’-TGACGCTAAGAGCTTCTCGCTGAACCTGGGCAAAG-3’ 
5’-CTTTGCCCAGGTTCAGCGAGAAGCTCTTAGCGTCA-3’ 
74.4°C 
V32W 5’-TGACGCTAAGAGCTTCTGGCTGAACCTGGGCAAAG-3’ 
5’-CTTTGCCCAGGTTCAGCCAGAAGCTCTTAGCGTCA-3’ 
74.3°C 
N34A 5’-AGAGCTTCGTGCTGGCCCTGGGCAAAGACAG-3’ 
5’-CTGTCTTTGCCCAGGGCCAGCACGAAGCTCT-3’ 
74.6°C 
L35A 5’-AGCTTCGTGCTGAACGCGGGCAAAGACAGCAAC-3’ 
5’-GTTGCTGTCTTTGCCCGCGTTCAGCACGAAGCT-3’ 
76.6°C 
K37A 5’-GCTGAACCTGGGCGCAGACAGCAACAACCTG-3’ 
5’-CAGGTTGTTGCTGTCTGCGCCCAGGTTCAGC-3’ 
75.0°C 
K37E 5’-GCTGAACCTGGGCGAAGACAGCAACAACC-3’ 
5’-GGTTGTTGCTGTCTTCGCCCAGGTTCAGC-3’ 
70.9°C 
D38E 5’- GTGCTGAACCTGGGCAAAGAGAGCAACAACCTGTGCCTG-3’ 
5’-CAGGCACAGGTTGTTGCTCTCTTTGCCCAGGTTCAGCAC-3’ 
78.4°C 
D38K 5’-GTGCTGAACCTGGGCAAAAAAAGCAACAACCTGTGCCTG-3’ 
5’-CAGGCACAGGTTGTTGCTTTTTTTGCCCAGGTTCAGCAC-3’ 
78.0°C 
N40A 5’-CTGGGCAAAGACAGCGCCAACCTGTGCCTGCAC-3’ 
5’-GTGCAGGCACAGGTTGGCGCTGTCTTTGCCCAG-3’ 
78.9°C 
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N41A 5’-GGCAAAGACAGCAACGCCCTGTGCCTGCACT-3’ 
5’-AGTGCAGGCACAGGGCGTTGCTGTCTTTGCC-3’ 
75.9°C 
L44A 5’-CAGCAACAACCTGTGCGCGCACTTCAACCCTCGC-3’ 
5’-GCGAGGGTTGAAGTGCGCGCACAGGTTGTTGCTG-3’ 
79.8°C 
L44D 5’-GACAGCAACAACCTGTGCGATCACTTCAACCCTCGCTTC-3’ 
5’-GAAGCGAGGGTTGAAGTGATCGCACAGGTTGTTGCTGTC-3’ 
77.6°C 
L44F 5’-CAGCAACAACCTGTGCTTCCACTTCAACCCTCGCT-3’ 
5’-AGCGAGGGTTGAAGTGGAAGCACAGGTTGTTGCTG-3’ 
75.1°C 
L44S 5’-GACAGCAACAACCTGTGCAGTCACTTCAACCCTCGCTTC-3’ 
5’-GAAGCGAGGGTTGAAGTGACTGCACAGGTTGTTGCTGTC-3’ 
76.7°C 
H45A 5’-CAACAACCTGTGCCTGGCCTTCAACCCTCGCTTCAAC-3’ 
5’-GTTGAAGCGAGGGTTGAAGGCCAGGCACAGGTTGTTG-3’ 
78.2°C 
F46A 5’-CAACCTGTGCCTGCACGCAAACCCTCGCTTCAACG-3’ 
5’-CGTTGAAGCGAGGGTTTGCGTGCAGGCACAGGTTG-3’ 
79.9°C 
R49A 5’-CCTGCACTTCAACCCTGCATTCAACGCCCACGGCG-3’ 
5’-CGCCGTGGGCGTTGAATGCAGGGTTGAAGTGCAGG-3’ 
81.9°C 
N51A 5’-CAACCCTCGCTTCGCCGCCCACGGCGA-3’ 
5’-TCGCCGTGGGCGGCGAAGCGAGGGTTG-3’ 
80.4°C 
A52I 5’-CAACCCTCGCTTCAACATCCACGGCGACGCC-3’ 
5’-GGCGTCGCCGTGGATGTTGAAGCGAGGGTTG-3’ 
78.0°C 
H53A 5’-CGCTTCAACGCCGCCGGCGACGCCAAC-3’ 
5’-CGCTTCAACGCCGGCGGCGACGCCAAC-3’ 
80.5°C 
H53E 5’-TCGCTTCAACGCCGAGGGCGACGCCAACA-3’ 
5’-TGTTGGCGTCGCCCTCGGCGTTGAAGCGA-3’ 
79.7°C 
H53G 5’-CGCTTCAACGCCGGCGGCGACGCCAAC-3’ 
5’-GTTGGCGTCGCCGCCGGCGTTGAAGCG-3’ 
80.5°C 
G54A 5’-TCAACGCCCACGCCGACGCCAACAC-3’ 
5’-GTGTTGGCGTCGGCGTGGGCGTTGA-3’ 
74.8°C 
D55A 5’-CGCCCACGGCGCCGCCAACACCA-3’ 
5’-TGGTGTTGGCGGCGCCGTGGGCG-3’ 
78.2°C 
N57A 5’-CACGGCGACGCCGCCACCATCGTGTGCAA-3’ 
5’-TTGCACACGATGGTGGCGGCGTCGCCGTG-3’ 
81.7°C 
V60A 5’-CGCCAACACCATCGCGTGCAACAGCAAGG-3’ 
5’-CCTTGCTGTTGCACGCGATGGTGTTGGCG-3’ 
76.4°C 
C61A 5’-CGCCAACACCATCGTGGCTAACAGCAAGGACGGCG-3’ 
5’-CGCCGTCCTTGCTGTTAGCCACGATGGTGTTGGCG-3’ 
80.7°C 
D65A 5’-CAACAGCAAGGCCGGCGGGGCCT-3’ 
5’-AGGCCCCGCCGGCCTTGCTGTTG-3’ 
73.3°C 
D65K 5’-TGTGCAACAGCAAGAAGGGCGGGGCCTGG-3’ 
5’-CCAGGCCCCGCCCTTCTTGCTGTTGCACA-3’ 
77.3°C 
G66A  5’-GCTTGTGGTCTGGCCGCCAGCAACC-3’ 
5’-CCCAGGCCCCGGCGTCCTTGCTG-3’ 
73.8°C 
G67A 5’-CAAGGACGGCGCGGCCTGGGGGA-3’ 
5’-TCCCCCAGGCCGCGCCGTCCTTG-3’ 
75.8°C 
A68I 5’-AGCAAGGACGGCGGGATTTGGGGGACCGAGCAG-3’ 
5’-CTGCTCGGTCCCCCAAATCCCGCCGTCCTTGCT-3’ 
80.7°C 
W69G 5’-CGGCGGGGCCGGGGGGACCGAGC-3’ 
5’-GCTCGGTCCCCCCGGCCCCGCCG-3’ 
80.2°C 
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G70A 5’-CGGGGCCTGGGCGACCGAGCAGC-3’ 
5’-GCTGCTCGGTCGCCCAGGCCCCG-3’ 
75.7°C 
E72A 5’-CTGGGGGACCGCGCAGCGGGAGG-3’ 
5’-CCTCCCGCTGCGCGGTCCCCCAG-3’ 
75.6°C 
R74A 5’-GGGACCGAGCAGGCGGAGGCTGTCTTTCC-3’ 
5’-GGAAAGACAGCCTCCGCCTGCTCGGTCCC-3’ 
75.2°C 
E75A 5’-CGGGACCGAGCAGCGGGCCGCTGTCTTTCCCTTC-3’ 
5’-GAAGGGAAAGACAGCGGCCCGCTGCTCGGTCCCG-3’ 
82.6°C 
F80A 5’-GGGAGGCTGTCTTTCCCGCCCAGCCTGGAAGTGTTGCAG-3’ 
5’-CTGCAACACTTCCAGGCTGGGCGGGAAAGACAGCCTCCC-3’ 
82.4°C 
F80K 5’-GGGAGGCTGTCTTTCCCAAGCAGCCTGGAAGTGTTGC-3’ 
5’-GCAACACTTCCAGGCTGCTTGGGAAAGACAGCCTCCC-3’ 
78.3°C 
F80S 5’-GAGGCTGTCTTTCCCAGCCAGCCTGGAAGTGTT-3’ 
5’-AACACTTCCAGGCTGGCTGGGAAAGACAGCCTC-3’ 
73.6°C 
P82A 5’-GTCTTTCCCTTCCAGGCTGGAAGTGTTGCAGAG-3’ 
5’-CTCTGCAACACTTCCAGCCTGGAAGGGAAAGAC-3’ 
71.3°C 
S84A 5’-CCTTCCAGCCTGGAGCTGTTGCAGAGGTGTG-3’ 
5’-ACACATTTGATCTTGAAGGCACCGTCAGCTGCC-3’ 
73.2°C 
E87A 5’-CTGGAAGTGTTGCAGCGGTGTGCATCACCTT-3’ 
5’-AAGGTGATGCACACCGCTGCAACACTTCCAG-3’ 
72.5°C 
I90A 5’-AAGTGTTGCAGAGGTGTGCGCCACCTTCGACCAGGCC-3’ 
5’-GGCCTGGTCGAAGGTGGCGCACACCTCTGCAACACTT-3’ 
81.0°C 
F92A 5’-GGTGTGCATCACCGCCGACCAGGCCAACC-3’ 
5’-GGTTGGCCTGGTCGGCGGTGATGCACACC-3’ 
77.9°C 
A95I  5’-CATCACCTTCGACCAGATCAACCTGACCGTCAAGC-3’ 
5’-GCTTGACGGTCAGGTTGATCTGGTCGAAGGTGATG-3’ 
74.3°C 
D103A 5’-CCGTCAAGCTGCCAGCTGGATACGAATTCAAGT-3’ 
5’-ACTTGAATTCGTATCCAGCTGGCAGCTTGACGG-3’ 
71.9°C 
G104A 5’-CTGACCGTCAAGCTGCCAGATGCCTACGAATTCAAGTTCC-3’ 
5’-GGAACTTGAATTCGTAGGCATCTGGCAGCTTGACGGTCAG-3’ 
77.0°C 
E106A 5’-CTGCCAGATGGATACGCATTCAAGTTCCCCAAC-3’ 
5’-GTTGGGGAACTTGAATGCGTATCCATCTGGCAG-3’ 
71.9°C 
F109A 5’-ATGGATACGAATTCAAGGCCCCCAACCGCCTCAAC-3’ 
5’-GTTGAGGCGGTTGGGGGCCTTGAATTCGTATCCAT-3’ 
76.3°C 
R112A 5’-ATTCAAGTTCCCCAACGCCCTCAACCTGGAGGCCATC-3’ 
5’-GATGGCCTCCAGGTTGAGGGCGTTGGGGAACTTGAAT-3’ 
79.0°C 
R112H 5’-CAAGTTCCCCAACCACCTCAACCTGGAGG-3’ 
5’-CCTCCAGGTTGAGGTGGTTGGGGAACTTG-3’ 
69.9°C 
N114A 5’-CCCAACCGCCTCGCCCTGGAGGCCATC-3’ 
5’-GATGGCCTCCAGGGCGAGGCGGTTGGG-3’ 
77.3°C 
E116A 5’-CGCCTCAACCTGGCGGCCATCAACTACAT-3’ 
5’-ATGTAGTTGATGGCCGCCAGGTTGAGGCG-3’ 
66.7°C 
A117I 5’-CAACCTGGAGATAATCAACTACATGGCAGCTGAC-3’ 
5’-GTCAGCTGCCATGTAGTTGATTATCTCCAGGTTG-3’ 
67.4°C 
I118A 5’-CAACCTGGAGGCCGCCAACTACATGGCAGCT-3’ 
5’-AGCTGCCATGTAGTTGGCGGCCTCCAGGTTG-3’ 
74.8°C 
N119E 5’-CCTGGAGGCCATCGAGTACATGGCAGCTGAC-3’ 
5’-GTCAGCTGCCATGTACTCGATGGCCTCCAGG-3’ 
72.9°C 
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N119K 5’-CCTGGAGGCCATCAAGTACATGGCAGCTG-3’ 
5’-CAGCTGCCATGTACTTGATGGCCTCCAGG-3’ 
70.0°C 
N119W 5’-CAACCTGGAGGCCATCTGGTACATGGCAGCTGACG-3’ 
5’-CGTCAGCTGCCATGTACCAGATGGCCTCCAGGTTG-3’ 
77.1°C 
Y120A 5’-CCTGGAGGCCATCAACGCAATGGCAGCTGACGGTG-3’ 
5’-CACCGTCAGCTGCCATTGCGTTGATGGCCTCCAGG-3’ 
81.2°C 
Y120D 5’-CTGGAGGCCATCAACGATATGGCAGCTGACGGT-3’ 
5’-ACCGTCAGCTGCCATATCGTTGATGGCCTCCAG-3’ 
75.2°C 
M121A 5’-GAGGCCATCAACTACGCGGCAGCTGACGGTG-3’ 
5’-CACCGTCAGCTGCCGCGTAGTTGATGGCCTC-3’ 
76.1°C 
A122I 5’-GAGGCCATCAACTACATGATAGCTGACGGTGACTTCAAG-3’ 
5’-CTTGAAGTCACCGTCAGCTATCATGTAGTTGATGGCCTC-3’ 
72.2°C 
D126A 5’-GGCAGCTGACGGTGCCTTCAAGATCAAATGTGT-3’ 
5’-ACACATTTGATCTTGAAGGCACCGTCAGCTGCC-3’ 
72.8°C 
F127A 5’-GCAGCTGACGGTGACGCCAAGATCAAATGTGTGGC-3’ 
5’-GCCACACATTTGATCTTGGCGTCACCGTCAGCTGC-3’ 
77.9°C 
F127D 5’-GCAGCTGACGGTGACGACAAGATCAAATGTGTGGC-3’ 
5’-GCCACACATTTGATCTTGTCGTCACCGTCAGCTGC-3’ 
75.6°C 
I129R 5’-GCTGACGGTGACTTCAAGAGGAAATGTGTGGCCTTTGAC-3’ 
5’-GTCAAAGGCCACACATTTCCTCTTGAAGTCACCGTCAGC-3’ 
74.6°C 
K130A 5’-ACGGTGACTTCAAGATCGCATGTGTGGCCTTTGACTG-3’ 
5’-CAGTCAAAGGCCACACATGCGATCTTGAAGTCACCGT-3’ 
76.0°C 
V132A 5’-CTTCAAGATCAAATGTGCGGCCTTTGACTCACCG-3’ 
5’-CGGTGAGTCAAAGGCCGCACATTTGATCTTGAAG-3’ 
73.3°C 
V132E 5’-ACTTCAAGATCAAATGTGAGGCCTTTGACTCACCG-3’ 
5’-CGGTGAGTCAAAGGCCTCACATTTGATCTTGAAGT-3’ 
70.5°C 
V132R 5’-GTGACTTCAAGATCAAATGTAGGGCCTTTGACTCACCGG-3’ 
5’-CCGGTGAGTCAAAGGCCCTACATTTGATCTTGAAGTCAC-3’ 
73.7°C 
F134E 5’-AGATCAAATGTGTGGCCGAGGACTCACCGGTCGGC-3’ 
5’-GCCGACCGGTGAGTCCTCGGCCACACATTTGATCT-3’ 
78.6°C 
F134R 5’-GATCAAATGTGTGGCCCGTGACTCACCGGTCGG-3’ 
5’-CCGACCGGTGAGTCACGGGCCACACATTTGATC-3’ 
77.5°C 
GFP-CGL-2   
W72G 5’-GACGGCGGGGCCGGTGGGACCGAGCAGC-3’ 
5’-GCTGCTCGGTCCCACCGGCCCCGCCGTC-3’ 
80.2°C 
Control Primers   
primer Gal-1 forw. 5’-CGGGATCCCGCCACCATGGCTTGTGGTCTGGTCGCC-3’ 84.9°C 
primer Gal-1 revers. 5’-GCCGACCGGTGAGTCAAAGGCCACACATTTGATCTTG-3’ 77.6°C 
 
Table 1 Site-directed mutagenesis primers 
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Truncations primer: 
 
Primer Sequence 
Gal-1-GFP  
∆N5 5’-CGGGATCCCGCCACCATGGTCGCCAGCAACCTGAATCTCAAA-3’ 
∆N10 5’-CGGGATCCCGCCACCATGGAGAATCTCAAACCTGGAGAGTGCCTTCG-3’ 
∆N20 5’-CGGGATCCCGCCACCATGGGACGAGGCGAGGTGGCTCCTGACG-3’ 
∆C4 5’-TTTTCCTTTTGCGGCCGCCTAACATTTGATCTTGAAGTCACCGTCAG-3 
∆C9 5’-TTTTCCTTTTGCGGCCGCCTAGTCACCGTCAGCTGCCATGTAGT-3 
∆C20 5’-TTTTCCTTTTGCGGCCGCCTACAGGTTGAGGCGGTTGGGGAAC-3 
∆C30 5’-TTTTCCTTTTGCGGCCGCCTAGTATCCATCTGGCAGCTTGACGG-3 
∆C40 5’-TTTTCCTTTTGCGGCCGCCTAGGCCTGGTCGAAGGTGATGCAC-3 
∆C50 5’-TTTTCCTTTTGCGGCCGCCTAAACACTTCCAGGCTGGAAGGGAAAG-3 
Reverse primer for ∆N truncations 5’-GCCGACCGGTGAGTCAAAGGCCACACATTTGATCTTG-3’ 
Forward primer for ∆C truncations 5’-GACTGGTGTACAAGATGGCTTGTGGTCTGGTCGCCAG-3 
 
Table 2 Truncation primers 
 
2.1.6 Bacteria and bacterial media 
 
For transformation and plasmid amplification competent DH5α cells (Invitrogen) 
or XL1-Blue supercompetent cells (Stratagene) were used. For transformation and 
protein expression BL21 pLysS (DE3) cells were used. They were grown in LB 
medium (Luria Bertani medium) or on LB agar plates supplied with ampicillin or kana-
mycin in a final concentration of 100 µg/ml to select for successfully transformed cells 
carrying plasmids containing a resistance gene. 
 
Bacteria:  subcloning efficiency DH5α competent cells, Genotype:  
  F- φ80dlacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rk-, 
 mk+) phoA supE44 λ- thi-1 gyrA96 relA1 
 
   XL1-Blue supercompetent cells, Genotype:  
 recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB 
 lacIqZΔM15 Tn10 (Tetr)]. 
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 BL21 pLysS (DE3) competent cells, Genotype: 
 F- ompT hsdSB(rB-mB-) gal dcm (DE3) 
 
LB medium:  0.5% (v/w) NaCl 
    1% (w/v)  Tryptone 
    0.5% (w/v) Yeast extract 
    
LB agar plates:  0.5% (w/v) NaCl 
    1% (w/v)  Tryptone 
    0.5% (w/v) Yeast extract 
    1.6% (w/v) Agar 
 
SOC-Medium:   10 mM   NaCl  
 2% (w/v)   Tryptone 
 0.5% (w/v)  Yeast extract 
 2.5 mM   KCl 
 10 mM   MgCl2 
 20 mM   MgSO4 
 20 mM   Glucose 
 
2.1.7 Eukaryotic cell lines 
 
The cell line HEK 293T (Human Embryonic Kidney cells) was used as a host to 
produce retroviral particles carrying the various reporter constructs.  
S-HeLa cells were used as a source for human proteins applied to interaction studies 
with human Gal-1. 
HeLa and CHO cells (Chinese Hamster Ovary cells) were target cell lines for 
retroviral transduction. They were stably transduced with cDNA constructs and used 
for the expression of reporter molecules to function as a eukaryotic in vivo system to 
investigate proteins in a living cell environment.  
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Eukaryotic cell lines:  HEK 293Tcells (ATCC CRL-11268) 
     S-HeLa cells (ATCC CCL-2.2) 
     HeLa cells (ATCC CCL-2.1) 
     CHO cells (ECACC 85050302) 
2.1.8 Eukaryotic cell culture media 
 
α Modification of the Minimal Essential Medium (αMEM) 
 
The α-modification of the Minimal Essential Medium (Biochrom AG) was used 
to cultivate CHO cells. Dry medium was dissolved in 5 l ddH2O, and 10 g of sodium 
hydrogencarbonate were added to adjust the pH to 7.4, which was checked 
continuously. The prepared medium was sterile filtered into autoclaved bottles and 
stored at 4°C. Before addition to cells the medium was supplemented with 10% (v/v) 
fetal calf serum (FCS), 100 µg/ml Streptomycin/Penicillin and, if stored longer than 6 
weeks, 2 mM L-Glutamine. 
 
Dulbecco’s Modified Eagle Medium (DMEM) 
 
Dulbecco’s Modified Eagle Medium (Biochrom AG) was used to cultivate HEK 
293T and HeLa cells. Dry medium was dissolved in 5 l ddH2O and 10 g of sodium 
hydrogencarbonate were added to adjust the pH to 7.4. The prepared medium was 
sterile filtered into autoclaved bottles and stored at 4°C. Before addition to cells 10% 
(v/v) FCS, 100 µg/ml Streptomycin/Penicillin and, if stored longer than 6 weeks, 2 
mM L-Glutamine were supplemented. 
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2.1.9 Primary antibodies 
 
Anti-GFP or anti-Gal-1 antibodies were affinity-purified by incubation of the cor-
responding serum with His6-eGFP or GST-Gal-1 coupled Epoxy-Sepharose beads 
(Amershan).  
Anti-Gal-1 antibodies and anti-GFP antibodies were eluted from the corre-
sponding affinity matrix under acidic and basic conditions according to standard 
procedures. 
To detect endogenous Gal-1 affintiy-purified anti-Gal-1 antibodies (Pineda Anti-
bodies, acidic elution) were used. They were applied in a 1:100 dilution for Western 
blot and FACS analysis and in a 1:50 dilution for confocal microscopy. 
To detect GFP-containing reporter constructs affinity-purified anti-GFP 
antibodies (Pineda Antibodies, acidic elution) were used (Engling et al., 2002). They 
were applied in a 1:200 dilution for Western blot and FACS analysis and in a 1:50 
dilution for confocal microscopy. 
When performing immunoprecipitation experiments 20 µl of affinity-purified anti-
GFP antibodies (Pineda Antibodies, basic elution, (Engling et al., 2002)) were 
coupled to 20 µl Protein A sepharose: CL4B beads pro reaction. 
The mAb anti-CA125 antibody OC125 was purchased from Zymed and was 
applied in a 1:200 dilution for Western blot analysis (Lloyd and Yin, 2001). 
The polyclonal anti-CA125-C-TERM1-356 antiserum was applied in a 1:200 
dilution for Western blot analysis (Seelenmeyer et al., 2003). 
 
2.1.10 Secondary antibodies 
 
Secondary antibodies for Western blot analysis were goat anti-rabbit IgG HRP-
coupled antibodies (Bio-Rad; 1:5,000), goat anti-mouse IgG HRP-coupled antibodies 
(Bio-Rad; 1:5,000), monoclonal mouse anti-rabbit IgG clone RG-16 HRP-coupled 
(Sigma-Aldrich; 1:3,000), goat anti-rabbit IgG Alexa 680-coupled antibodies 
(Molecular Probes; 1:10,000) and goat anti-mouse IgG Alexa 680-coupled antibodies 
(Molecular Probes; 1:10,000). 
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Secondary antibodies for FACS analysis were goat anti-rabbit IgG and goat 
anti-mouse IgG antibodies, both conjugated with Allophycocyanin (APC) (Molecular 
Probes). They were used in a 1:750 dilution. 
Secondary antibodies for confocal microscopy were goat anti-rabbit or goat 
anti-mouse IgG Alexa 546-coupled antibodies (Molecular Probes). They were applied 
in a 1:750 dilution. 
 
2.2 Molecular biological methods 
 
2.2.1 Bacterial transformation 
 
To transform DH5α cells, 1 µl of plasmid DNA (1-10 ng DNA) or 3 µl of a 
ligation reaction were added to 30 µl bacteria suspension and incubated on ice for 30 
min followed by a heat shock of 20 s at 37°C and an additional incubation period of 2 
min on ice. After that 1 ml LB medium without ampicillin was added followed by 
incubation at 37°C for 1 h under constant shaking (300 rpm).  
To transform XL1-Blue cells, 1 µl of plasmid DNA (1-10 ng DNA) or 5 µl of a 
ligation reaction were added to 50 µl bacteria suspension and incubated on ice for 30 
min followed by a heat shock of 45 s at 42°C and an additional incubation period of 2 
min on ice. After that 1 ml LB medium without ampicillin was added followed by 
incubation at 37°C for 1 h under constant shaking (300 rpm).  
To transform BL21 pLysS (DE3) cells 1 µl of plasmid DNA (1-10 ng) was added 
to 20 µl bacteria suspension and incubated on ice for 5 min followed by heat shock of 
30 s at 42°C and an additional incubation period of 2 min on ice. After that 80 µl SOC 
medium without antibiotics were added followed by incubation at 37°C for 1 h under 
constant shaking (300 rpm).  
After transformation bacteria were spread on LB plates supplemented with 100 
µg/ml ampicillin or kanamycin and incubated at 37°C for 12 to 16 h or used to 
inoculate liquid cultures of LB medium supplemented with the respective antibiotics, 
which were grown at 37°C under constant shaking (180 rpm) for 12 to 16 h. 
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2.2.2 Selection and amplification of plasmids 
 
If bacteria were grown on agar plates in correct density they form colonies each 
originating from a single bacterium. To obtain genetically identical plasmids, bacteria 
from one colony were transferred to 5-10 ml LB medium culture using a 20 µl pipet 
tip. The liquid cultures containing the respective antibiotic to select for bacteria 
carrying plasmids containing a resistance gene were incubated at 37°C overnight 
under constant shaking (180 rpm). 
 
2.2.3 Plasmid preparation 
 
Plasmids were prepared from overnight LB medium cultures of transformed 
bacteria by the application of Qiagen or Macherey Nagel DNA purification kits. The 
kit used was dependent on the volume of the overnight culture. 
 
Volume of bacterial culture Qiagen Kit Macherey Nagel Kit 
5 - 10 ml QIAprep Spin Miniprep Kit Nucleospin Plasmid 
20 – 150 ml QIAGEN Plasmid Midi Kit Nucleobond-PC 100 
More than 150 ml QIAGEN Plasmid Maxi Kit Nucleobond-PC 500 
 
Purification was performed following the manufacturer’s manual employing 
alkaline lysis and binding of DNA to silica membranes or anion-exchange resins, 
respectively. Elution of the DNA was performed using appropriate volumes of ddH2O. 
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2.2.4 Determination of DNA concentration 
 
The concentration of a DNA solution was determined photometrically by 
measuring the absorption at 260 nm wavelength. The measurement was either 
performed in a photometer with a diluted DNA solution using a quarz cuvette with a 
thickness of 10 mm or by directly measuring 1 µl of the DNA solution in a Nanodrop 
photometer. The concentration of double stranded DNA was calculated based on the 
fact that an optical density (OD) of 1 corresponds to a concentration of 50 µg/ml. 
 To determine contamination the OD at 280 nm was measured additionally. The 
ratio OD260/OD280 represents the grade of purity since pure DNA shows a value 
between 1.8 and 2.0. Values above 2.0 show contaminations with RNA, values below 
1.8 contaminations with protein. 
 
2.2.5 Agarose gel electrophoresis 
 
 To separate mixtures of DNA molecules by size agarose gel electrophoresis 
was used. Separation is achieved by loading the negatively charged DNA molecules 
on a gel matrix with a defined pore size and subjecting them to an electric field where 
they migrate to the anode. The migration speed depends on the size of the DNA 
molecules and is limited by the pore size of the gel, which is defined by the amount of 
agarose used. 
 Agarose gels were prepared by heating 1% agarose (w/v) in TAE buffer. After 
the agarose was dissolved ethidiumbromide in a final concentration of 0.5 µg/ml was 
added. The gel was poured into an agarose gel-casting chamber and a plastic comb 
was inserted which forms the loading wells. After hardening the gel can be stored at 
4°C until use. 
 To perform electrophoresis the gel was transferred into an agarose gel running 
chamber and TAE was added until the gel was completely covered with liquid. 
Samples containing DNA sample buffer in a 1:5 dilution were loaded on the gel and 
electrophoresis was performed at 100 V until sufficient separation was reached 
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visualized by the migration behaviour of the blue bromphenol marker front. Agarose 
gels were documented using the Gel Doc 2000 imaging system (Bio-Rad). 
 
TAE buffer (50x):   242 g  Tris 
      57.1 ml  Glacial acidic acid 
      100 ml  0.5 M EDTA, pH 8 
      ad 1 l   ddH2O 
 
DNA sample buffer (5x):  0.25% (w/v) Bromphenol Blue  
      0.25% (w/v) Xylencyanol FF  
      30% (w/v)  Glycerol 
 
2.2.6 DNA marker 
 
 As a size standard two premixed DNA ladders were used, the 1 kb DNA ladder 
and the 100 bp DNA ladder (New England Biolabs). They contain DNA fragments of 
defined sizes ranging from 100 to 1,500 bp (100 bp ladder) to analyze smaller DNA 
fragments or from 500 to 10,000 bp (1 kb ladder) to analyze large inserts and 
vectors. The markers were applied by loading 10 µl of a stock solution containing 
0.05 µg/µl DNA in DNA sample buffer. Since each band of the marker contains a 
defined amount of DNA, the marker can be used to approximate the mass of DNA of 
an unknown sample by comparing band intensities visually.  
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2.2.7 Site-directed mutagenesis 
 
 The QuikChange site-directed mutagenesis kit (stratagene) was used to insert 
point mutations, switch amino acids, and delete or insert single or multiple amino 
acids. The site-directed mutagenesis method was performed using PfuTurbo DNA 
polymerase and a temperature cycler. PfuTurbo DNA polymerase replicates both 
plasmid strands with high fidelity and without displacing the mutant oligonucleotide 
primers. The basic procedure utilizes a supercoiled double-stranded DNA (dsDNA) 
vector with the insert of interest (pGEM-T/Gal-1 or CGL-2; 3500 bp) and two 
synthetic oligonucleotide primers (see Table 1) containing the desired mutation. 
Stratagene has developed a web-based software program to design optimal 
mutagenic primers for use with the QuikChange site directed mutagenesis kit:  
 
http://labtools.stratagene.com/QC 
 
 The control and sample reaction was prepared as indicated below. The 
oligonucleotide primers were extended during temperature cycling (see below) by 
PfuTurbo DNA polymerase. Following temperature cycling, the product was treated 
with 1 µl Dpn I (10 U/µl) for 1 h at 37°C. The Dpn I endonuclease (target sequence: 
5’-Gm6ATC-3’) is specific for methylated DNA and was used to digest the parental 
DNA template derived from methylase positive E.coli strainds and to select for 
mutation containing newly synthesized DNA. The vector DNA containing the desired 
mutations was then transformed into DH5α or XL1-Blue competent cells according to 
standard procedure (2.2.1). The isolated DNA was sequenced and the correctly 
mutagenized insert was digested with BamH I and Age I, purified and ligated with a 
retroviral Vector (pRevTRE2/GFP). 
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Control reaction: 
 
5 µl of 10x reaction buffer 
2 µl (10 ng) dsDNA template pGEM-T/gal-1 or CGL-2 
1 µl (125 ng) oligonucleotide primer Gal-1 forw. 
1 µl (125 ng) oligonucleotide primer Gal-1 revers. 
1 µl dNTP mix 
40 µl ddH2O 
1 µl PfuTurbo DNA Polymerase (2.5 U/µl) 
 
Sample reaction: 
 
5 µl 10x reaction buffer 
2 µl (10 ng) dsDNA template pGEM-T/gal-1 or CGL-2 
1 µl (125 ng) oligonucleotide primer # 1 (sense) 
1 µl (125 ng) oligonucleotide primer # 2 (antisense) 
1 µl dNTP mix 
40 µl ddH2O 
1 µl PfuTurbo DNA Polymerase (2.5 U/µl) 
 
Cycling parameters: 
 
Denaturation  30 s, 95°C   
 
Amplification  30 sec, 95°C   Denaturation 
(16 cycles)  1 min, 55°C   Hybridization    
    4 min, 68°C   Elongation 
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2.2.8 Polymerase chain reaction 
 
 To amplify a gene or DNA fragment the polymerase chain reaction (PCR) was 
used (Lawyer et al., 1989; Saiki et al., 1988). During PCR a DNA template defined by 
a forward and reverse primer is amplified in high amounts and can be used for further 
cloning to generate desired reporter constructs. PCRs were performed with the 
enzyme AmpliTaq polymerase (Perkin Elmer) which generate adenosine overhangs 
at the 3’ ends. This was important regarding the use of the pGEM-T vector system for 
further cloning since this vector contains thymidine overhangs at its 3’ ends for 
simplified ligation of PCR products. The following reaction mix was used for PCRs. 
 
Sample reaction: 
 
10 µl 10x reaction buffer 
2 µl (10 ng) dsDNA template 
1 µl (25 pmol) oligonucleotide forward primer  
1 µl (25 pmol) oligonucleotide reverse primer   
10 µl (10 mM) dNTP mix 
5.9 µl (25 mM) MgCl2 
69.1 µl ddH2O 
1 µl of AmpliTaq DNA Polymerase (2.5 U/µl) 
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 The reaction was performed employing a Primus Advance Thermocycler 
(PeqLab). The following program was used to amplify DNA. 
 
Cycling parameters: 
 
Denaturation  2 min, 95°C    
 
Amplification  45 sec, 94°C    Denaturation 
(30 cycles)  1 min, T<Tm of primers  Hybridization   
    1 min, 72°C    Elongation 
 
Elongation  10 min, 72°C    
 
Store   ∞, 4°C 
 
 The annealing temperature was chosen depending on the melting temperatures 
(Tm) of the used primers after subtracting 5°C from the lower one (T = Tm – 5°C). The 
melting temperature for each individual primer was calculated according to the 
following equation. 
 
  
! 
Tm = 81.5 +16.6" log Na
+[ ] + 41"% GC#
675
N
 
 
  
! 
Na
+[ ] = 0.05 M 
  
! 
% GC = GC content of annealing sequence 
  
! 
N = number of annealing bases 
 
 When problematic primers were used which resulted in very low yields or no 
amplification, up to 10% DMSO (dimethyl sulfoxide) were added to the reaction mix. 
DMSO reduces secondary structures like loops or hairpins and the primers can 
anneal more easily at the template. A disadvantage of DMSO is that mutations and 
mispairing of bases occur more frequently. When using DMSO it was of great 
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importance to verify obtained PCR products by sequencing before using them for 
further cloning. 
 
2.2.9 PCR purification 
 
 To purify PCR products and remove primers and reaction mix components PCR 
samples were processed using a PCR purification kit (QiaQuick PCR purification kit, 
Qiagen). The DNA was bound to a silica membrane under high salt conditions and 
eluted after washing with an appropriate volume of ddH2O. 
 
2.2.10 Gel extraction of DNA fragments 
 
 To purify desired DNA fragments from a restriction digest the reaction mix was 
separated on a 1% agarose gel. The bands were transiently visualized with a UV 
lamp (366 nm) and cut out of the gel with a sharp blade. To purify the DNA from the 
agarose gel the samples were processed using a gel extraction kit (Qiagen). The 
agarose was melted in a specific buffer and DNA was bound to a silica membrane 
under high salt conditions. Elution was performed after a washing step in an 
appropriate volume of ddH2O. 
 
2.2.11 Restriction digests 
 
 Restriction enzymes were purchased from New England Biolab. Restriction 
digests were performed according to the manufacturer’s manual. An optimized buffer 
system consisting of buffer 1 to 4 from which one is optimal for a specific enzyme 
was used. Additionally unique buffers for certain enzymes are available. In the case 
of a double digest a buffer was chosen which provides the highest cleavage 
efficiency for both enzymes or the digest was performed sequentially with a DNA 
purification step in between (2.2.9). Depending on the enzyme and the quality of the 
DNA 1 to 5 U/µg DNA were used in a restriction digest incubated 2 to 4 h at 37°C. 
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2.2.12 DNA dephosphorylation 
 
 To dephosphorylate linearized vectors at the 5’-end after restriction digests in 
order to prevent self-ligation, Calf Intestinal Phosphatase (CIP, New England 
Biolabs) was added to the reaction mix in a concentration of 1 U/µg DNA for 30 min 
at 37°C. The enzyme was heat inactivated by incubation at 70°C for 10 min. 
 
2.2.13 Ligation of DNA fragments 
 
 In order to ligate PCR products or other DNA fragments to each other or into 
linearized vectors a ligation kit was used (Takara Bio Inc.). The ligation partners were 
digested with the same restriction enzymes to provide compatible ends. Following 
the manual, 50 ng of vector (or the longer DNA fragment) were used. The amount of 
insert (or the shorter DNA fragment) was calculated according to the following 
equation. 
 
  
! 
amount vector ng[ ] "number of basepairs insert bp[ ]
number of basepairs vector bp[ ]
= amount insert ng[ ]
 
 The DNA solutions and 5 µl of Takara Solution 1, which contains the T4 DNA 
ligase and an optimized buffer in a 2-fold concentration, were mixed and ddH2O was 
added to a total volume of 10 µl. The reaction was incubated for 3 h at 37°C or for at 
least 16 h at 4°C. After the incubation period the enzyme was heat inactivated by 
incubation at 70°C for 10 min. 
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2.2.14 DNA sequencing 
 
 Cloned inserts or cDNA constructs in different plasmids were sequenced in 
order to rule out mutations and to verify the correct sequence. Therefore, plasmid 
samples and primers were sent to commercial sequencing companies (Seqlab, 
Göttingen or GATC, Konstanz). Obtained sequences were analyzed using the 
Lasergene software suite (Lasergene, DNAStar) or the ‘align 2 sequences’ function 
of the BLAST project: 
  
http://www.ncbi.nlm.nih.gov/blast/bl2seq/wblast2.cgi 
 
2.2.15 Short interfering RNAs in mammalian cells 
 
 Most eukaryotes possess a cellular defense system protecting their genomes 
against invading foreign genetic elements. Dicer RNase III rapidly processes dsRNA 
to small dsRNA fragments of distinct size and structure, the small interfering RNAs, 
which direct the sequence-specific degradation of the single-stranded mRNAs of the 
invading genes. In several organisms, introduction of double-stranded RNA has been 
proven to be a powerful tool to suppress gene expression. 
 For silencing genes specifically, siRNA target sites are typically chosen by 
scanning the mRNA sequence of interest for AA dinucleotides, recording the 19 
nucleotides downstream of the AA, and then comparing the potential siRNA target 
sequences with an appropriate genome database to eliminate any sequences with 
significant homology to other genes. To facilitate this procedure a “siRNA Target 
Finder and Design Tool” provided by Ambion was used: 
 
http://www.ambion.com/techlib/misc/siRNA_finder.html 
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 Subsequently two complementary DNA oligonucleotides corresponding to the 
selected target sequence were synthesized (Thermo Electron).  
 The two oligonucleotides were mixed, heated at 90°C for 3 min and annealed at 
37°C for 1 h. The annealed siRNA insert was used directly in a ligation reaction with 
a vector called pSilencer™ 1.0-U6 (Ambion) linearized with EcoR I and Apa I. 
pSilencer™ 1.0-U6 Expression Vector was designed for plasmid-based siRNA 
experiments. 
 To enable retroviral transduction the generated vector was digested with BamHI 
and the resulting insert was ligated into the retroviral vector pLNCD4 digested with 
the same enzyme. HeLamt cells were transduced with this contruct as described in 
2.3.4 by retroviral transduction of the generated retroviral vector. The vector pLNCD4 
alone was used as a control. Successfully transduced target cells were sorted using 
cell surface localized CD4 as a marker.  
 
Annealing buffer: 100 mM  Potassium acetate 
    30 mM  HEPES-KOH pH 7.4 
    2 mM   Magnesium acetate 
 
2.3 Eukaryotic cell culture techniques 
 
2.3.1 Maintaining cell lines 
 
 Adherent cell lines were grown on culture dishes in their respective culture 
medium at 37°C with 5% CO2. The cells were splitted dependent on confluency every 
3 to 5 days by washing with PBS and addition of 0.125% (w/v) Trypsin/EDTA in PBS. 
After 1 min incubation the trypsin solution was removed and the cells were 
resuspended in the appropriate volume of medium used for the culture dish. The 
cells were then seeded in the desired dilution on new culture dishes prepared with 
fresh medium. 
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PBS (Phosphate buffer saline):  140 mM    NaCl 
       2.7 mM   KCl 
       10 mM    Na2HPO4 
       1.8 mM    KH2PO4 
 
Trypsin/EDTA:     0.5 mM    EDTA  
       0.125% (w/v)  Trypsin  
           PBS 
 
2.3.2 Freezing of eukaryotic cells 
 
 To prepare frozen stocks for long-term storage cells grown to about 100% 
confluency were washed once with PBS and trypsinized. Then the cells were 
resuspended in normal growth medium, transferred to a 15 ml tube and collected by 
centrifugation (200 gav, 5 min, 4°C). The pellet was carefully resuspended in 2 ml 
freeze medium and transferred to 1.8 ml cryo-vials (Greiner). An alternative 
procedure is to resuspend the cells directly in freeze medium after trypsinization. The 
cryo-vials were frozen at -80°C in special cryo-boxes which ensure a temperature 
decrease of 1°C per minute. For long-term storage the frozen cryo-vials were 
transferred to liquid nitrogen cell storage tanks. 
 
Freeze Medium: 20% (v/v)  FCS  
    10% (v/v)   DMSO  
    100 µg/ml  Streptomycin/Penicillin 
       αMEM or DMEM 
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2.3.3 Thawing of eukaryotic cells 
 
 To unfreeze cells the cryo-vial was removed from liquid nitrogen and immedi-
ately thawed in a water bath at 37°C. The content was transferred to 20 ml fresh, pre-
warmed culture medium in a 50 ml tube and the cells were sedimented by 
centrifugation (200 gav, 5 min, 4°C). To remove DMSO the medium was discarded 
and the cell pellet was resupended in fresh culture medium. The cells were then 
seeded on culture dishes of the same size they were taken from to prepare the 
frozen stocks and incubated at 37°C with 5% CO2. 
 
2.3.4 Viral transduction 
 
 To stably integrate reporter genes into the genome of target cells and finally 
generate genetically modified reporter cell lines, a MBS Mammalian Transfection Kit 
(Stratagene) was used according to the instructions of the manufacturer’s manual. 
The procedure takes 5 days and consists of preparation of plasmids coding for virus 
components and the reporter gene, production of retroviral particles using HEK 293T 
as host cells, harvesting of the retroviral particles and infection of target cells. 
 The target cell lines were CHOMCAT-TAM2 (Engling et al., 2002) and HeLaMCAT-
TAM2 (Seelenmeyer et al., 2003) expressing the murine cationic transporter MCAT-1 
(Albritton et al., 1989; Davey et al., 1997) on the cell surface which is recognized by 
the virus and mediates docking and uptake. Additionally, the doxicycline-sensitive 
transactivator rtTA2-M2 (Urlinger et al., 2000) is constitutively expressed and allows 
production of reporter proteins in a doxicycline-dependent manner. 
 The reporter construct cDNAs were cloned either into the pRevTRE2, pLNCD4 
or the pFB vector (2.2.13). pRevTRE2 is a expression vector which allows 
doxicycline-dependent protein synthesis due to a doxicycline transactivator 
responsive element mediating mRNA formation. The pLNCD4 and pFB vectors 
promote constitutive expression of the reporter construct. As a control GFP in the 
pFB vector was used which was constitutively expressed after successful 
transduction. The plasmid containing the reporter construct was mixed with two other 
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plasmids, pVPack-GP and pVPack-Eco, encoding the viral gag-pol elements (GP) 
and the viral envelope protein (Eco). 
 
 On Day 1 the corresponding DNA mixture was precipitated using 1 ml 100% 
(v/v) ethanol and 0.1 x volume 3 M sodium acetate. After incubation at -80°C for 30 
minutes, the DNA pellet was collected by centrifugation at 12,000 gav for 10 minutes. 
After discarding the supernatant 1 ml 70% (v/v) ethanol was added. After centri-
fugation (12,000 gav, 4°C, 5 min) the supernatant was discarded and the wet pellet 
was stored at 4°C overnight. The virus producing HEK 293T cells were seeded on 
freshly prepared culture dishes to be used for transfection the next day. On day 2 
HEK 293T cells were transfected with the three plasmids prepared the day before 
according to the manual of the MBS mammalian transfection kit and incubated for 72 
h at 37°C to produce retroviral particles. On day 4 the CHOMCAT-TAM2 or HeLaMCAT-TAM2 
cells were seeded on culture dishes in the desired dilution to be used for transduction 
24 h later. On day 5 the virus particle containing medium was harvested from trans-
fected HEK 293T cells and passed through a sterile filter. Subsequently, this medium 
was transferred to the target cells and transduction occurred by virus mediated gene 
transfer leading to stable integration of the reporter construct cDNA into genome of 
the target cell. Normal growth medium was added and the cells were incubated for 
two days with the retroviral particles. The cells were further analyzed using flow 
cytometry and transduction efficiency was measured by counting GFP positive cells 
transduced with pFB-hrGFP. 
 
Vectors:  pVPack-GP  (Stratagene) 
 pVPack-Eco   (Stratagene) 
   pFB-hrGFP  (Clontech) derived from Moloney Murine  
       Leukemia Virus (MMLV) 
   pRevTRE2  (Clontech) derived from MMLV, contains tet-
       response element (TRE) 
 
Material and Methods 
 
67 
2.3.5 Addition of doxicycline 
 
 Doxicycline (Clontech) was added to the culture medium of different reporter 
cell lines, to induce protein expression by the tetracycline/doxicycline-responsive 
element for 48 h. A stock solution of 1 mg/ml in PBS was diluted 1:1,000 directly into 
the culture medium to reach a final concentration of 1 µg/ml.  
 
2.4 Biochemical methods 
 
2.4.1 Recombinant proteins 
 
 GST-Gal-1, GST-Gal-3 fusion constructs was cloned using the vector pGEX-2T 
(Amershan) and His6-eGFP were cloned using pET-15b (Novagen). Appropriate PCR 
products were generated using the IMAGE clones 2666528 and 2419761 as a 
source for the ORFs of human Gal-1 and Gal-3. The plasmids were transformed into 
BL21 (DE3) cells (Invitrogen) (2.2.1) and the corresponding proteins were expressed 
in an ITPG inducible manner. Therefore a small amount of LB medium containing 
ampicillin was inoculated with transformed bacteria (Pre-culture; overnight; 37°C; 
constant shaking 300 rpm). The expression of the corresponding protein was induced 
by adding IPTG  (0.5 mM) to the main-culture for 3 h at 37°C (  
! 
OD
600
"  0.6). Protein 
purification was achieved by affinity chromatography using GSH sepharose 
(Amershan) and Ni-NTA-agarose according to standard procedure.  
 A N-terminal fragment of CA125-C-TERM (defined by the NCBI clone 
AK024365) that corresponds to amino acids 1-356 (CA125-C-Term1-356) was cloned 
into pIVEX 2.4b Nde (Roche) in order to express a His6-tagged protein in vitro 
employing the Rapid Translation System RTS 100 (Rapid Translation System RTS 
100 E.coli HY kit Cat. No. 3 186 148, Roche) according to manufacturer’s manual.  
 Homogenous preparations of GST-Gal-1, His6-eGFP and His6-CA125-C-
TERM1-356, respectively, were used to generate polyclonal antisera in rabbits. Anti-
Gal-1 antibodies were affinity-purified from the corresponding rabbit serum in two 
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steps: the serum was first incubated with GST-coupled beads to remove anti-GST-
antibodies, followed by affinity purification of anti-Gal-1 antibodies on GST-Gal-1 
coupled beads. 
 
2.4.2 Preparation of cell lysates 
 
 Both wild-type and mutant forms of Gal-1-GFP and CGL-2-GFP fusion proteins 
were expressed in CHO cells by cultivating the cells in the presence of doxicycline (1 
µg/ml) for 48 h at 37°C. Following detachment of cells from the culture dishes using 
PBS, 0.5 mM EDTA pH 8.0 (10 min, 37°C), cells were sedimented (200 gav, 4°C, 5 
min) and solubilized in PBS/TX-100 (1% (w/v)). Membranes were removed in two 
steps by centrifugation at 13,000 gav (10 min, 4°C) and 100,000 gav (1 h, 4°C). The 
supernatant was analyzed for the amounts of GFP fusion proteins based on GFP 
fluorescence as measured with a fluorescence plate reader (Molecular Devices 
SpectraMax Gemini XS). 
 
2.4.3 Preparation of cell-free supernatants 
 
 CHO cells expressing GFP fusion proteins in a doxicycline-dependent manner 
were incubated in the presence of the antibiotic for 48 h at 37°C. The expressing 
cells were washed with PBS and detached by adding PBS, 0.5 mM EDTA. After 
incubation for 10 min at 37°C cells were harvested (200 gav, 4°C, 5 min) and 
resuspended in PBS. Cell-free supernatants were prepared by homogenization com-
bining freeze-thaw-cycles with sonication. Membranes were removed in two steps by 
centrifugation at 13,000 gav (10 min, 4°C) and 100,000 gav (1 h, 4°C). The resulting 
supernatant was analyzed for the amounts of GFP fusion proteins based on GFP 
fluorescence as measured with a fluorescence plate reader (Molecular Devices 
SpectraMax Gemini XS). 
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2.4.4 Determination of protein concentration based on GFP fluo-
rescence 
 
 The concentration of a GFP fusion protein was determined employing a 
fluorescence plate reader (Molecular Devices SpectraMax Gemini XS). 
 30 µl of an unknown protein sample were transferred to a 96-well plate. The 
GFP fluorescence was determined by measuring fluorescence at 530 nm after 
excitation at 485 nm wavelength. Recombinant eGFP protein with a known protein 
concentration was used to calculate the protein amount in the unknown sample. 
 
2.4.5 Sample preparation for SDS polyacrylamide gel electro-
phoresis 
 
 Samples were mixed with SDS sample buffer in a ratio of 3:1 followed by an 
incubation at 95°C for 5 min. Before loading the samples onto the gel a centrifugation 
step was performed (5,000 gav, 4°C, 1 min) to collect all liquid at the bottom of the 
reaction tube or in case of cell lysates directly prepared in SDS sample buffer to 
sediment insoluble DNA aggregates (16,000 gav, 4°C, 10 min). In the latter case only 
the supernatant was used. 
 
SDS sample buffer (4x): 200 mM  Tris-HCl, pH 6.8 
     25% (w/v)  Glycerol  
     2% (w/v)  SDS  
     0.2% (w/v) Bromphenol Blue  
     0.7 M  β-Mercaptoethanol 
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2.4.6 SDS polyacrylamide gel electrophoresis 
 
 To separate SDS denatured proteins according to their size SDS 
polyacrylamide gel electrophoresis was performed as described (Laemmli et al., 
1970) using the Mini PROTEAN III Electrophoresis System (Bio-Rad). 
 Gels with dimensions of 80 x 73 mm and a thickness of 0.75 mm were casted 
between to glass plates of the respective size by first pouring the freshly prepared 
separating gel solution containing 13% acrylamide into the gel cassette fixed in a 
casting frame. Unpolymerized separating gel solution was overlayed with isopropanol 
to achieve an even surface. After polymerization the isopropanol was poured off and 
remains were removed with whatman filter paper. Then unpolymerized stacking gel 
solution was poured into the gel cassette and a plastic comb was inserted from the 
top, which forms the loading wells in the stacking gel. After polymerization the gels 
were stored at 4°C for up to 3 weeks or used directly. 
 To perform electrophoresis the gel was placed into the electrode assembly 
inside a clamping frame in the tank of the PROTEAN III system. Electrophoresis 
running buffer was added to the inner and outer chamber of the tank and the comb 
was carefully removed from the stacking gel. Samples were loaded by carefully 
pipetting into the wells of the stacking gel using extra-long loading pipet tips. 
Electrophoretic separation was performed at 200 V until the Bromphenol Blue front of 
the SDS sample buffer reached the end of the separating gel. 
 
Separating Gel Solution:  13% Gel 
      1.68 ml  ddH2O 
      1.25 ml  1.5 M Tris-HCl, pH 8.8 
      50 µl   10% (w/v) SDS  
      2 ml   30% (w/v) Acrylamide/Bis  
      25 µl   10% (w/v) APS  
      2.5 µl  TEMED 
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Stacking Gel Solution:  4.8% Gel 
      1.53 ml  ddH2O 
      0.625 ml  0.5 M Tris-HCl, pH 6.8 
      25 µl   10% (w/v) SDS  
      335 µl  30% (w/v) Acrylamide/Bis  
      12.5 µl  10 % (w/v) APS  
      2.5 µl  TEMED 
 
Electrophoresis running buffer: 25 mM  Tris-HCl, pH 8.3 
      192 mM  Glycine 
      0.1%  SDS  
 
 Alternatively Novex NuPAGE 10% Bis-Tris-HCl polyacrylamide-gels (pH 6.4) 
were employed using standard procedure. To separate proteins under reducing 
conditions 0.5 ml Antioxidant was added to the MES running buffer into the inner 
chamber of the XCEll II™ mini-cell apparatus. The run was performed at a 200 V for 
approximately 35 min.  
 
MES running buffer:   1 M    MES  
(20 x)      1 M    Tris Base 
      69.3 mM   SDS 
      20.5 mM   EDTA 
  
2.4.7 SDS-PAGE protein molecular weight standards 
 
 As protein molecular weight standards either peqGOLD Protein-Marker I 
(Peqlab) or Odyssey Protein Molecular Weight Marker (LICOR) were used. The 
peqGold marker, ranging from 14 to 116 kDa, was used when analyzing the gel by 
Western blot using the ECL detection method. The Odyssey marker, ranging from 10 
to 250 kDa, was applied when performing the analysis in an Odyssey infrared 
imaging system since the marker proteins were prestained with Coomassie and can 
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therefore be visualized by this system. Markers were applied by loading 1 to 5 µl of 
the premixed solutions onto the SDS-Gel. 
 
2.4.8 Western blot analysis 
 
 To transfer proteins separated by SDS-PAGE to a polyvinylidene fluoride 
(PVDF) membrane for further analysis (Towbin et al., 1979), a wet blot transfer 
device was used (Mini Trans-Blot Cell, Bio-Rad). A PVDF membrane and two pieces 
of filter paper (Whatman 3MM, Whatman AG) were cut to the size of the separating 
gel. The PVDF membrane was activated by incubation in 100% methanol for 1 min. 
The membrane, filter paper, two sponges and a sandwich-blotting cassette were 
equilibrated in blotting buffer. The parts were assembled as depicted in the following 
figure avoiding air bubbles between the layers. 
 
anode (+) 
 
Sponge 
Filter paper 
PVDF membrane 
SDS-Gel 
Filter paper 
Sponge 
 
cathode (-) 
 
Fig. 4 Schematic overview: Assembly of a Western blot sandwich cassette. 
 
 The assembled blotting cassette was inserted into the transfer tank, an ice 
block for cooling was added and the tank was filled with blotting buffer. Protein 
transfer was performed at 100 V for 1 h under constant stirring. 
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Blotting buffer:  192 mM   Glycine 
    25 mM   Tris, pH 8.4 
    20% (v/v)  MetOH  
 
2.4.9 Immunochemical protein detection using the ECL system 
 
 Western blotting was performed as described above using Immobilon-P PVDF 
membrane (Millipore Corporation). The membrane was incubated in blocking buffer 
for 1 h at room temperature or at 4°C overnight on a shaker. Following blocking the 
membrane was rinsed with PBS-T and incubated with primary antibodies directed 
against the protein of interest in the desired dilution for 1 h at room temperature on a 
shaker. Three washing steps for 5 min with PBS-T were applied and the membrane 
was incubated with secondary goat anti-rabbit IgG or goat anti-mouse IgG antibodies 
coupled to HRP in a 1:5,000 dilution. If samples derived from an immunoprecipitation 
experiment were analyzed monoclonal anti-rabbit IgG clone RG-16 HRP-coupled 
antibodies in a 1:3,000 dilution were used to detect only native antibodies excluding 
those derived from the IP procedure. After three times washing for 5 min with PBS-T 
on a shaker, visualization was performed using the enhanced chemiluminescence 
system (ECL, Amersham Pharmacia). The membrane was incubated with the ECL 
solution for 1 min at room temperature and chemiluminescence was detected using 
medical x-ray films (Super RX Medical X ray film, Fuji). 
 
Blocking buffer:    5% (w/v)  Milk powder  
         PBS-T 
 
Primary antibody buffer:  3% (w/v)  BSA  
      0.02% (w/v) Sodium azide    
         PBS-T 
 
Secondary antibody buffer: 3% (w/v)  Milk powder  
         PBS-T 
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2.4.10 Immunochemical protein detection using the LICOR system 
 
 Western blotting was performed as described above using Immobilon-FL PVDF 
membrane (Millipore Corporation) optimized for fluorescence detection. The mem-
brane was incubated in blocking buffer for 1 h at room temperature on a shaker. 
Following blocking the membrane was rinsed two times for 5 min with PBS-T and 
incubated with primary antibodies directed against the protein of interest in the 
desired dilution for 1 h at room temperature on a shaker. Four washing steps for 5 
min with PBS-T were applied followed by incubation with secondary goat anti-rabbit 
IgG or goat anti-mouse IgG antibodies coupled to the fluorophor Alexa 680 diluted 
1:10,000 for 30 min at room temperature under constant shaking in the dark. Finally 
the membrane was washed four times for 5 min with PBS-T on a shaker and once 
with PBS without Tween 20. Visualization was performed using the Odyssey infrared 
imaging system. 
 
Blocking buffer:    5% (w/v)   Milk powder  
          PBS 
 
Primary antibody buffer:  3% (w/v)   BSA  
      0.02% (w/v)  Sodium azide  
      0.1% (w/v)  Tween 20  
          PBS 
 
Secondary antibody buffer: 3% (w/v)   Milk powder  
      0.01%(w/v)  SDS  
      0.1% (w/v)  Tween 20  
          PBS 
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2.4.11 Gal-1 affinity matrix and binding experiments employing 
subcellular fractions of S-HeLa cells 
 
 To perform affinity purification of Gal-1-interacting proteins, GST-Gal-1 and 
GST-Gal-3 fusion proteins, as well as GST as a control, were expressed in E.coli 
BL21 (DE3)) cells. Cells were resuspended in homogenization buffer, followed by cell 
breakage using an EmulsiFlex 5 (Avestin) cell disruptor. A 100,000 gav supernatant 
was prepared and incubated with an appropriate amount of glutathione beads for 2 
hours at 4°C on a rotating wheel. Following extensive washing using homogenization 
buffer, 250 µl of beads were used per binding experiment. 
 S-HeLa cells were cultured in spinner flasks according to standard procedure. 
Typically, cultures were grown to a density of about 6-7x105 cells per ml. Cells were 
collected by centrifugation (200 gav, 4°C, 10 min) and resuspended in HeLa-
homogenization buffer at 1 g cells per ml. 
 
 Following cell breakage using a Balch homogenizer, the homogenate was 
sequentially centrifuged twice at 1,000 gav and twice at 3,500 gav. The resulting 
supernatant was subjected to centrifugation at 100,000 gav. Following separation of 
supernatant and sediment, the soluble fraction was diluted with PBS to achieve a 
final protein concentration of about 0.25 mg/ml. Typically, when starting with 5 g 
cells, the soluble fraction was adjusted to a final volume of 50 ml. The corresponding 
sediment was resuspended in 50 ml Resuspension buffer (membrane). Per 
experimental condition, 25 ml of the soluble or the membrane fraction were incubated 
with 250 µl of GSH beads coupled to GST-Gal-1, GST-Gal-3 or GST. Bound proteins 
were eluted sequentially with 100 mM lactose and 25 mM glutathione diluted in the 
corresponding buffers. 
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Homogenization buffer:   1 mM   DTT 
       0.1% (w/v)  Triton X-100 
       10% (w/v)  Glycerol 
       5 mM   Pprotease inhibitor tabs 
          PBS  
 
HeLa-homogenization buffer:  25mM   Tris pH 7.5 
       130 mM   KCl 
       5 mM   Protease inhibitor tabs 
 
Resuspension buffer (membrane): 1 mM   DTT 
       1% (w/v)  NP-40 
       5 mM   Protease inhibitor tabs 
          PBS 
 
2.4.12 Protein identification employing MALDI-Tof mass spectro-
metry 
 
 In order to identify proteins eluted from the Gal-1 affinity matrix, the eluates 
were separated on 10% Novex Bis-Tris gels (Invitrogen) followed by protein staining 
using the SilverQuest system (Invitrogen). After excision of gel pieces containing the 
individual proteins, in-gel trypsin digestion allowed extraction of tryptic peptides. 
Proteins were identified based on the masses of the peptides obtained in this way by 
employing MALDI-Tof mass spectrometry (Seelenmeyer et al., 2003). 
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2.4.13 Biotinylation of cell surface proteins 
 
 To analyze exported, cell surface bound material a biotinylation assay was 
performed as described (Seelenmeyer et al., 2005). A membrane impermeable 
biotinylation reagent that binds covalently to all free ε-amino groups of lysines 
present in surface associated proteins was added to the cells. Following lysis the 
biotinylated proteins were separated by incubation with streptavidin beads and the 
amounts of biotinylated and non-biotinylated proteins could be compared resembling 
the ratio of exported to non-exported reporter protein. 
 Galectin-GFP-fusion protein were expressed in the corresponding CHO cell 
lines by cultivation in the presence of doxicycline (1 µg/ml) for 48 h at 37°C (6-well 
plate; 70% confluency). The medium was removed and the cells were washed once 
with PBS. Medium and PBS wash were combined and subjected to 
immunoprecipitation using affinity-purified anti-GFP antibodies coupled to Protein A 
Sepharose (2.4.14). 
 After washing with cold PBS Ca2+/Mg2+ cells were treated with a membrane-
impermeable biotinylation reagent (EZ-Link Sulfo-NHS-SS-Biotin; Pierce; 0.5 mg/ml 
Biotin/Incubation buffer; 4°C, 30 min). To quench unbound biotinylation reagent cells 
were washed once with quenching buffer followed by an incubation with 500 µl 
quenching buffer for 20 min at 4°C. Then cells were washed two times with PBS and 
200 µl lysis buffer were added per well. The cells were incubated 10 min at 37°C with 
lysis buffer and subsequently scraped off the cell culture plates using a rubber 
policeman. The cell solution was homogenized by pipetting and transfrerred to an 
eppendorf tube on ice. To complete lysis the samples were subjected to sonication in 
a water bath for 3 min and incubated for 15 min at room temperature being vortexed 
every 5 min. To remove insoluble material a centrifugation step (18,000 gav, 10 min, 
4°C) was performed and 10 µl of the supernatant were saved to function as an input 
sample for later analysis. The remaining lysate was added to 40 µl packed 
streptavidin beads equilibrated with lysis buffer and incubated for 1 h at room 
temperature under constant rotation to allow binding of biotinylated proteins to the 
streptavidin moiety. After the incubation the beads were washed two times with 
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washing buffer 1 and two times with washing buffer 2. Sedimentation of the beads 
was performed by centrifugation (3,000 gav, 4°C, 1 min). After the last washing step 
the supernatant was carefully discarded and bound material was eluted by incubation 
with SDS sample buffer for 5 min at 95°C. Subsequently the samples were analyzed 
by SDS-PAGE and Western blotting. 
 
PBS Ca2+/Mg2+:  1 mM  MgCl2 
     0.1 mM  CaCl2 
        PBS 
 
Incubation buffer:  150 mM   MgCl2 
     10 mM  Triethanolamine, pH 9 
     2 mM  CaCl2 
 
Quenching buffer :  100 mM  Glycine 
        PBS Ca2+/Mg2+ 
 
Lysis buffer:   62.5 mM  EDTA 
     50 mM  Tris-HCl, pH 7.5 
     0.4% (w/v) Deoxycholate  
        Protease Inhibitor tablet (1/10 ml) 
 
Washing buffer 1:  62.5 mM  EDTA 
     50 mM  Tris-HCl, pH 7.5 
     0.4% (w/v) Deoxycholate  
     1% (w/v)  NP-40 
     0.5 M  NaCl 
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Washing buffer 2:  62.5 mM  EDTA 
     50 mM  Tris-HCl, pH 7.5 
     0.4% (w/v) Deoxycholate 
     0.1% (w/v) NP-40 
     0.5 M  NaCl 
 
2.4.14 Immunoprecipitation of proteins 
 
 To immunoprecipitate GFP containing reporter molecules a mixture of Protein 
A-Sepahrose beads, CL-4B beads (Amersham Pharmacia) and 20% ethanol (1:1:2) 
was prepared and 40 µl slurry, corresponding to 20 µl pure beads, per sample were 
used. The beads were washed three times with IP-Buffer 1. Sedimentation was 
performed at 800 gav, 3 min, 4°C. To couple affinity-purified anti-GFP antibodies to 
the beads, they were incubated with 20 µl anti-GFP antibodies (basic elution) in 180 
µl Buffer 1 overnight at 4°C on a rotation wheel. Following the coupling procedure the 
beads were washed three times using IP-buffer 1. After sedimentation and removal 
of the buffer the sample consisting of 1 ml culture medium obtained from the 
respective reporter cell line grown on 6-well plates and 500 µl PBS obtained from 
washing the cells (see 2.4.13) were added to the beads followed by an 2 to 4 h 
incubation at 4°C. After the incubation with the medium sample the beads were 
washed three times with IP-buffer 1 and once with IP-buffer 2. Bound material was 
eluted by addition of SDS sample buffer and incubation at 95°C for 5 min. 
 
IP-buffer 1:  25 mM   Tris-HCl, pH 7,4 
    150 mM  NaCl 
    1 mM   EDTA 
    0.5% (w/v) NP-40 
 
IP-buffer 2:  25 mM   Tris-HCl, pH 7,4 
    150 mM  NaCl 
    1 mM   EDTA 
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2.4.15 Galectin binding to lactose-coupled beads 
 
 Detergent lysates of galectin-GFP expressing CHO cells were generated (2.4.2) 
and a sample was saved to function as input fraction. Following equilibration of 
lactose-coupled beads with PBS/TX-100 (1% (w/v) normalized amounts (50 GFP 
units corresponding to about 0.5 µg GFP) were incubated with 40 µl lactose-coupled 
beads (Sigma) for 1 h at 4°C to allow binding. After centrifugation (3000 gav, 1 min, 
4°C) a sample of the flow-through was saved for further analysis. After washing with 
PBS/TX-100 (1% (w/v)) bound proteins were eluted by adding SDS sample buffer. 
Comparable amounts of input (5%), flow-through (5%) and bound fraction (5%) were 
analyzed by Western blotting using affinity-purified anti-GFP antibodies (2.4.8). 
 
2.4.16 Galectin binding to the cell surface of CHO cells 
 
 Cell-free supernatants of galectin-GFP expressing CHO cells (2.4.3) were ana-
lyzed for the amounts of GFP fusion protein (2.4.4). CHO cells not expressing the 
GFP reporter molecule were detached from cell culture dishes. Following washing 
with 250 mM lactose/PBS normalized amounts (150 GFP units corresponding to 
about 1.5 µg GFP) of the cell-free supernatants were incubated with CHO cells to 
allow binding to the cell surface (1 h, 4°C). Following treatment with affinity-purified 
anti-GFP antibodies and APC-conjugated secondary antibodies, cell surface binding 
was quantified by flow cytometry. 
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2.4.17 Stability analysis of Galectin-GFP fusion proteins in con-
ditioned media derived from CHO cells 
 
 Cell-free supernatant of both wild–type and mutant forms of Gal-1-GFP and 
CGL-2-GFP fusion proteins, as well as GFP as a control, were prepared (2.4.3). 
Normalized amounts (50 GFP units corresponding to about 0.5 µg GFP, Molecular 
Devices SpectraMax Gemini XS) were diluted 1:10 in conditioned medium derived 
from CHO cells. Samples were then either directly subjected to immunoprecipitation 
employing anti-GFP antibodies, incubated for 48 h at 4°C followed by 
immunoprecipitation (2.4.14) or incubated for 48 h at 37°C followed by immuno-
precipitation (2.4.14). In each case, bound material was eluted with SDS sample 
buffer. The samples were then analyzed by SDS Page and Western blotting using 
affinity-purified anti-GFP antibodies and anti-rabbit secondary antibodies (clone RG-
16, see above) coupled to HRP (ECL detection). 
 
2.5 Flow cytometry 
 
2.5.1 Sample preparation for FACS analysis  
 
 To analyze GFP fluorescence and exported reporter proteins by specific anti-
body cell surface staining, cells were processed according to the following protocol 
and analyzed via FACS. 
 Cells were grown on 6-well plates to a confluency of about 70% in the absence 
or presence of doxicycline (1 µg/ml) to obtain samples from cells expressing reporter 
constructs and negative controls for direct comparison. After removal of the growth 
medium the cells were washed with 500 µl PBS and 500 µl Cell Dissociation Buffer 
(CDB, Invitrogen) or PBS/EDTA were added. The cells were incubated for 10 min at 
37°C and detached by resuspension. After transfer to an Eppendorf tube on ice a 
centrifugation step was applied (200 gav, 4°C, 5 min) and the supernatant was 
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discarded. The pellet was carefully resuspended in 300 µl αMEM containing the 
primary antibody in the desired dilution. After an incubation period of 1 h at 4°C under 
constant rotation, the cells were sedimented again and the pellet was washed once 
with αMEM without antibody. Then secondary antibodies coupled to the fluorophor 
Allophycocyanin were added in a 1:750 dilution in αMEM and cells were incubated 
for 30 min as described above. To remove secondary antibodies cells were washed 
once with αMEM and the pellet was resuspended in 500 µl sorting medium con-
taining propidium iodide in a final concentration of 1 µg/ml to stain dead cells. The 
samples were subsequently measured using a FACSCalibur flow cytometer. 
 
PBS/EDTA:   0.5 mM  EDTA 
        PBS 
 
Primary antibodies:  αMEM/FCS (10% (v/v)) 
 
Affinity-purified anti-GFP anibodies (acidic elution) 1:200 
Affinity-purified anti-Gal-1 antibodies (acidic elution) 1:200 
Polyclonal anti-CA125 antibodies (1:50) 
Monoclonal anti-CA125 (OC125) antibodies (1:200) 
 
Secondary antibodies: αMEM/FCS (10% (v/v)) 
 
goat anti-rabbit IgG APC-coupled antibodies 1:750 
goat anti-mouse IgG APC-coupled antibodies 1:750 
 
Sorting Medium:  5% (v/v)  CDB 
     0.2% (v/v)  FCS 
        αMEM without FCS 
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2.5.2 Plate labelling technique 
 
 To prepare cells for FACS analysis using the plate labelling technique the cells 
were grown on 6-well plates to a confluency of about 70% in the absence or 
presence of doxicycline (1 µg/ml). Following washing with 500 µl PBS primary 
antibodies in the desired dilution were added in 600 µl αMEM and the plates were 
incubated for 1 h at 4°C under constant shaking. Cells were subsequently washed 
three times with 500 µl PBS and secondary antibodies were added in the desired 
dilution in 600 µl αMEM. The samples were incubated for 30 min at 4°C under 
constant shaking followed by three times washing with 500 µl PBS. The cells were 
detached by addition of 200 µl PBS/EDTA followed by an incubation period of 10 min 
at 37°C. The samples were resuspended and transferred to an Eppendorf tube 
containing 500 µl αMEM without FCS and propidium iodide in a dilution that results in 
final concentration of 1 µg/ml after addition of 200 µl cell suspension. GFP-derived 
and APC-derived fluorescence were measured simultaneously on a FACSCalibur 
two-laser system without the need of channel compensation.  
 
Primary antibodies:   αMEM/FCS (10% (v/v)) 
 
Affinity-purified rabbit anti-GFP anibodies (acidic elution) 
1:200 
Affinity-purified anti-Gal-1 antibodies (acidic elution) 1:200 
Polyclonal anti CA125 antibodies (1:50) 
Monoclonal anti-CA125 (OC125) antibodies (1:200) 
 
Secondary antibodies: αMEM/FCS (10% (v/v)) 
 
Goat anti-rabbit IgG Allophycocyanin-coupled antibodies 
(1:750) 
Goat anti-mouse IgG Allophycocyanin-coupled antibodies 
(1:750) 
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Sorting Medium:  5% (v/v)  CDB  
     0.2% (v/v)  FCS 
        αMEM without FCS 
 
2.5.3 FACS sorting 
 
 FACS based sorting was performed in collaboration with Dr. Blanche 
Schwappach from the Center of Molecular Biology Heidelberg (ZMBH). Cells induced 
by addition of doxicycline for 48 h or grown after a sort in the absence of doxicycline 
for 7 days were detached from culture dishes using sterile CDB (Invitrogen) after 
washing once with PBS. The resulting suspension was added to 5 ml cell culture 
medium. After sedimention at 200 gav, 4°C, 5 min the supernatant was removed and 
the pellet was carefully resuspended in sorting medium. The cells were filtered using 
cell strainer caps (Becton Dickinson) into 5 ml round bottom FACS tubes (Becton 
Dickinson) and propidium iodide in a final concentration of 1 µg/ml was added. 
Subsequently, cells were sorted using a FACSVantage or FACSAria sorting device 
for pools of 50.000 or 100.000 cells in 6-well plates or as single cells to generate 
clonal cell lines in 96-well plates. 
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2.6 Confocal microscopy 
 
2.6.1 Sample preparation for confocal microscopy 
 
 For confocal microscopy cells were grown on glass coverslips to about 70% 
confluency in 24-well plates. Following two times washing with PBS on ice 200 µl 
PFA in PBS per well were added (3% (w/v)) and the cells were fixed without 
permeabilization for 20 min at 4°C. After removal of PFA the cells were washed four 
times with PBS. The coverslips were mounted on microscopic slides using 
Fluoromount G (Southern Biotechnology Associates). After hardening overnight at 
room temperature in the dark the specimens were sealed at the edge of the cover 
slip employing clear nail polish and analyzed using a Zeiss LSM 510 Meta confocal 
microscope. 
 
PFA in PBS:  3% (w/v) PFA  
 
 For life cell imaging cells were grown to about 70% confluency in the presence 
of doxicycline in appropriate cell culture dishes and analyzed using a Zeiss LSM 510 
Meta confocal microscope. 
 
2.6.2 Immunostaining of cell surface proteins for confocal micros-
copy 
 
 Samples were prepared as described in 2.6.1. After fixation with PFA and two 
times washing with PBS, the samples were quenched by incubation with 250 µl 
quenching buffer for 10 min at 4°C followed by incubation with 250 µl blocking buffer 
(10 min, room temperature) to saturate unspecific antibody binding sites. Primary 
antibodies were added in the desired dilution in 250 µl blocking buffer per well for 1 h 
at room temperature. Following three times washing with PBS unspecific binding 
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sites were blocked again by incubation in 250 µl blocking buffer per well for 10 min at 
room temperature. Secondary antibodies were added in 250 µl blocking buffer per 
well and the specimens were incubated for 30 min at room temperature. After four 
times washing the samples were mounted as described in 2.6.1 and analyzed in a 
Zeiss LSM 510 Meta confocal microscope. 
 
Quenching buffer:  50 mM   NH4Cl 
        PBS 
 
Blocking buffer:   1% (w/v)  BSA  
        PBS 
 
Primary antibodies: Blocking buffer: 
 
Affinity-purified anti-GFP antibodies (acidic elution) 1:50 
Affinity-purified anti gal-1 antibodies (acidic elution) 1:50 
 
Secondary antibodies: Blocking buffer: 
 
Goat anti-rabbit or goat anti-mouse IgG antibodies Alexa 
546-coupled 1:750 
 
Results 
 
87 
3 Results 
 
 Some lectin-encoding genes are expressed constitutively (Stahl, 1992), 
whereas others are induced by gene activation under specific biological conditions 
(McEver, 1995; McEver et al., 1995). All membrane-bound and many soluble lectins 
are synthesized on ER-bound ribosomes and are delivered to their final destinations 
via the ER-Golgi pathway. Thus, the lectins themselves are often glycoproteins 
(Kjellen and Lindahl, 1991). However, a significant subset of soluble lectins such as 
galectins (Ahmed et al., 1996), heparin-binding growth factors and some cytokines 
are synthesized on free ribosomes and are delivered directly to the exterior of the cell 
by as yet poorly understood mechanisms involving translocation through the plasma 
membrane. By circumventing the conventional pathway of secretion, these molecules 
can avoid unwanted premature interactions with potential ligands that are 
synthesized within the same cell. In addition, some of these lectins, such as galectins 
(Barondes et al., 1994), are sensitive to the redox state of the environment and can 
remain active only in the reducing environment of the cytosol (Cho and Cummings, 
1995a). Upon entering the oxidizing environment of the extracellular space, they 
must therefore immediately bind to ligands. 
 
3.1 Identification of Gal-1 interacting proteins potentially 
involved in the export process of human Gal-1 
 
 Several crystal structures of animal lectins with their cognate ligands have been 
elucidated (Rini, 1995a; Rini, 1995b), allowing an understanding of these interactions 
at the level of atomic resolution. The principles that have emerged from these studies 
are as follows: First, the binding sites are of relatively low affinity and are found in 
shallow indentations on the surface of the proteins. Second, selectivity is mostly 
achieved via a combination of hydrogen bonds involving the hydroxyl groups of the 
sugars and by ‘van der Waals’ packing of the hydrophobic face of monosaccharide 
rings against aromatic amino acids side chains. Third, further selectivity can be 
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achieved by additional contacts between the saccharide and the protein, sometimes 
involving bridging water molecules or divalent cations. Finally, the actual region of 
contact between the saccharide and the polypeptide typically involves only one to 
three monosaccharide residues. As a consequence of all of the above, these lectins-
binding sites tend to be of relatively low affinity, but of high specifity. The ability of 
such low-affinity sites to mediate biologically relevant interactions in the intact system 
thus appears to require multivalency (Weis and Drickamer, 1996). 
 The natural ligands for most lectins are typically complex glycoconjungates that 
carry clustered arrays of the cognate carbohydrate, thus cooperating with clustered 
lectins-binding sites to generate high-avidity binding (Drickamer and Taylor, 1993; 
Varki, 1994), which is further enhanced by mass transport effects (high local 
concentrations of ligands) (Sharon, 1993). In some instances (e.g. selectins) the 
nature of this clustering is not easily defined (Rosen and Bertozzi, 1994), and 
cooperation with other aspects of the underlying polypeptide may be necessary to 
generate optimal binding. However, it should be emphasized that unless it is correctly 
glycosylated and/or otherwise modified, the polypeptide is not itself the ligand. 
Typically, these polypeptides are simply carriers of the true ligands for lectins, which 
are made up of combinations of glycan units (Kjellen and Lindahl, 1991). In addition, 
recombinant lectins that are often used to identify potential biological ligands are 
usually multimeric in structure and/or are presented in multivalent clustered arrays in 
soluble complexes or on solid supports (Weis and Drickamer, 1996). Thus, although 
a variety of molecules may be found to bind to a given recombinant lectin in a 
glycosylation-dependent manner, only a few of these “ligands” may be actually 
involved in mediating biologically significant interactions (Varki, 1997). The challenge 
then is to tell the difference between what can bind to a recombinant lectin in an in 
vitro experiment, and what actually does bind in vivo to the native lectin in a 
biologically relevant manner. Indeed, the term ligand should probably be reserved for 
the latter type of biologically relevant structures. 
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3.1.1 Identification of CA125 as a Gal-1 counter receptor 
 
 To search for ligands of human Gal-1, a recombinant GST-Gal-1 fusion protein 
was attached to glutathione sepharose beads. As a source for proteinaceous Gal-1-
binding partners S-HeLa cells were fractionated into a soluble and a membrane 
fraction. These fractions were incubated with the Gal-1 affinity matrix. Proteins bound 
to Gal-1 were eluted sequentially using lactose (Fig. 5, lanes 1-4) and glutathione 
(Fig. 5, lanes 5-8). This procedure allowed collecting proteins that interact with the 
Gal-1-matrix in a galactose-dependent manner, followed by elution of proteins bound 
to the matrix by a sugar-independent mechanism. As shown in Fig. 5, specifically 
bound proteins could be identified in lanes 2 (GST-Gal-1 matrix; soluble S-HeLa-
fraction; eluted by lactose), lane 4 (GST-Gal-1 matrix, S-HeLa membrane fraction; 
eluted by lactose), lane 6 (GST-Gal-1 matrix, soluble S-HeLa fraction, eluted with 
glutathione) and lane 8 (GST-Gal-1 matrix, S-HeLa membrane fraction, eluted by 
glutathione) in comparison with the corresponding GST control matrices (lane 1, 3, 5 
and 7).  
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Fig. 5 Identification of CA125 as a counter receptor of Gal-1. Affinity purification of Gal-1-
interacting proteins. Both soluble (lanes 1, 2, 5, 6) and membrane (lanes 3, 4, 7, 8) fractions 
of S-HeLa cells were incubated with either GST-Gal-1 beads (lanes 2, 4, 6, 8) or GST beads 
as a control (lanes 1, 3, 5, 7). Bound proteins were eluted sequentially with lactose (lanes 1-4) 
and glutathione (lanes 5-8), followed by separation on Novex NuPage 10% Bis-Tris gels. 
Protein bands were visualized using SilverQuest (Invitrogen).  
 
 Following mass spectrometry analyses, protein band # 2 was identified as a 
chondroitin sulfate proteoglycan, band # 3 was identified as the cell adhesion 
molecule L1-CAM, and band # 4 and  # 5 were identified as Gal-1. Recombinant Gal-
1 and S-HeLa-derived Gal-1 formed apparently a dimer that disassembled in the 
presence of lactose. Beside these known interactions, 16 tryptic peptides could be 
recovered from protein band # 1 whose masses were consistent with corresponding 
tryptic fragments of a potential ORF defined by cDNA clone AK024365 (NCBI 
database; Fig. 6, boxed sequences indicate peptides identified by mass spectro-
metry) 
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Fig. 6 Amino acid sequence of CA125-C-TERM. Boxed sequences indicate tryptic peptides 
derived from band 1 (Fig. 5 A, lane 2) as identified by mass spectrometry 
 
 In order to verify whether band # 1 is the gene product AK024365, a polyclonal 
antiserum against a recombinant protein corresponding to the N-terminal part (AA 1-
356; Mr: ~ 39 kDa) of AK024365 was generated. As shown in Fig. 7, immunoreactive 
material with a broad high-molecular-weight migration behavior was detected in lane 
2, 4, 6 and 8, which correspond to the various eluates of GST-Gal-1 matrix. No signal 
could be detected under control conditions. Binding of immunoreactive material to 
Gal-1 appeared to be mediated by a galactose-lectin interaction as more than 90% 
eluted upon treatment of the affinity matrix with lactose. About 80% of the total 
immunoreactive material was recovered from the soluble fraction, with the remaining 
population derived from the membrane fraction. 
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Fig. 7 Immunoblot analysis of the proteins eluted from the GST-Gal-1 and GST matrices, 
respectively. The fractions were loaded in the same order as shown in Fig. 5. The polyclonal 
antiserum against the N-terminal part of AK024365 was used as primary antibody followed by 
detection by ECL. 
 
 The AK024365 gene product was, found to represent a C-terminal fragment of 
1148 amino acids in length of a giant mucin-like glycoprotein (O'Brien et al., 2001), 
(Yin and Lloyd, 2001). This mucin is identical to the ovarian cancer antigen CA125, 
an integral membrane protein present on the cell surface of tumor cells that has 
originally been defined by the mAb OC125 (Bast et al., 1981). Therefore, the eluates 
from the Gal-1 affinity matrix were analyzed for immunoreactivity based on OC125. 
As shown in Fig. 8, the pattern of immunoreactive bands detected with OC125 is 
strikingly similar to the pattern detected with the polyclonal anti-AK024365 antiserum. 
Since CA125 was reported to represent an integral membrane protein with a single 
transmembrane span that is cleaved in the extracellular domain in order to release 
soluble fragments, we conclude that the pattern of immunoreactive bands eluted from 
the galectin affinity matrix represents both soluble and membrane anchored 
fragments of CA125 (from now on, the 1148 amino acids, C-terminal fragment of 
CA125, defined by cDNA clone AK024365, will be termed CA125-C-TERM). 
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Fig. 8 Immunoblot analysis as shown in Fig. 7 employing the anti-CA125 antibody OC125 for the 
detection of CA125-derived fragments. 
 
3.1.2 Specificity of CA125-mediated Galectin binding 
 
 All members of the galectin family tested so far bind to simple β-galactosides, 
but the affinity is relatively low, i.e. in the millimolar range. Surprisingly, the detailed 
glycan specificities for most galectins are not clear and each galectin may differ in its 
overall specificity (Lobsanov et al., 1993). All galectins appear to bind terminal β-
galactosides, but some galectins differ significantly in their recognition of galactosyl 
residues within oligosaccharides (Zhou and Cummings, 1990). For example, both 
Gal-1 and Gal-3 bind simple lactosaminyl units as well as polylactosamine. However, 
Gal-3 binding to oligosaccharides is enhanced if the penultimate galactosyl residues 
are substituted with Galα1-3, GalNAcα1-3, or Fucα1-2 residues (Leffler and 
Barondes, 1986). In contrast, such substitution dramatically decreases binding by 
Gal-1. Several studies on Gal-1 have revealed that it displays much higher affinity for 
larger glycans containing repeating galactosyl residues. Interestingly, at least for Gal-
1, its interaction with polylactosamine is not dependent on terminal galactose 
residues, but it does require at least two linear repeating disaccharide units. It is 
possible, that the interaction of Gal-1 with polylactosamine and other extended 
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glycans may be due to contributions of secondary binding sites on the protein. The 
potential endogenous glycoconjungate ligands have been investigated for only a few 
members of the galectin family. Potential ligands for Gal-1 and Gal-3 include 
basement membrane proteins, such as laminin and fibronectin, membrane receptors, 
such as integrinα7β1, CD43, and CD45, lysosome-associated membrane proteins 
(LAMPs) and even certain gangliosides. However, the precise carbohydrate 
structures on these macromolecules that are recognized by galectins are not well 
defined. It is possible that each galectin differs somewhat in both oligosaccharide 
binding specificity and affinity for macromolecular ligands. The fact that Gal-1, for 
example, binds to a limited set of glycoconjungates suggests that the mere presence 
of galactose residues on glycoconjungates is not sufficient to promote their high-
affinity binding to this lectin. 
 To analyze whether CA125 preferentially binds to certain β-galactoside specific 
lectins, we compared CA125 binding efficiency for Gal-1 with the efficiency for Gal-3, 
also a very well characterized member of the galectin family (Barondes et al., 1994; 
Hughes, 1999; Perillo et al., 1998; Rabinovich et al., 2002a). As shown in Fig. 9, S-
HeLa-derived fragments of CA125 bind to Gal-1 twice as efficiently compared with 
Gal-3 (Fig. 9 A, B; compare lanes 1 and 2 as well as lane 3 and 4). This difference is 
significant because comparable amounts of Gal-1 and Gal-3 fusion proteins were 
used (Fig. 9 A, compare lane 9 and 10). In addition the total pattern (Fig. 9 C) of 
sugar-dependent interactions partners reveal proteins that specifically bind to Gal-1 
and Gal-3, as well as proteins that bind equally efficient to Gal-1 and Gal-3, 
respectively. This shows that differential binding efficiency can be detected under the 
experimental conditions applied. 
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Fig. 9 CA125 displays differential binding efficiency towards Gal-1 when compared to Gal-3. 
A, Soluble (lanes 1 to 4) and membrane fractions (lanes 5 to 8) were prepared from S-HeLa 
cells followed by the incubation with either GST-Gal-1 (lanes 1, 3, 5 and 7) or GST-Gal-3 
(lanes 2, 4, 6 and 8) beads. The amounts of GST-Gal-1 and GST-Gal-3 fusion proteins, 
respectively, used for affinity purification of CA125-derived fragments were shown to be 
comparable by western blotting employing affinity-purified anti-GST antibodies (lanes 9 and 
10). Following extensive washing bound proteins were eluted sequentially with lactose (lanes 
1, 2, 5 and 6) and glutathione (lanes 3, 4, 7 and 8). Eluted proteins were separated on 10% 
Novex NuPage Bis-Tris gels and transferred to a blotting membrane. ECL detection of 
CA125-derived fragments was performed employing the monoclonal antibody OC125. B, 
Quantitative analysis of CA125-derived fragments in the fractions shown in panel A employing 
Bio-Rad® QuantityOne® Software. C, Total protein pattern of lactose-eluted proteins derived 
from the Gal-1 matrix (lane 1) and the Gal-3 matrix (lane 2). Eluted proteins were separated 
on NuPage Bis-Tris gels (Invitrogen) followed by silver staining according to standard 
procedures. Lables indicate examples for proteins that preferentially bind to Gal-1 (●), Gal-3 
(▲) or proteins that equally bind Gal-1 and Gal-3 (■). 
 
 To analyze further the binding efficiency of CA125 to galectins, CA125-C-TERM 
was expressed in adherent HeLa and CHO by retroviral transduction (3.2.1). A more 
defined protein band was observed (Fig. 10). CA125-C-TERM still has the ability of 
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full-length CA125 to bind to Gal-1. This observation is consistent with the fact that the 
CA125-C-TERM contains both the stalk domain of CA125 and almost three CA125 
repeats structures that are O-glycosylated (O'Brien et al., 2001). CA125-C-TERM 
expressed in HeLa cells shows the same characteristics as endogenous full-length 
CA125 with regard to Gal-1 interactions as it binds Gal-1 about twice as efficient as 
Gal-3 (Fig. 10). 
 
 
 
Fig. 10 An 1148 amino acids C-terminal fragment of CA125, CA125-C-TERM, retains the ability 
of CA125 to specifically bind Gal-1. CHO and HeLa cells were induced to express CA125-
C-TERM by retroviral transduction. For comparison, CHO and HeLa cells were included that 
were treated with retroviral control particles. A detergent lysate of the cells was prepared and 
incubated with either GST-Gal-1-, GST-Gal-3 or GST beads. Following extensive washing the 
beads were treated with lactose. Eluted proteins were separated on 10% Novex NuPage Bis-
Tris gels followed by transfer to a blotting membrane. CA125-C-TERM was then detected by 
OC125 staining employing ECL (panel A). For comparison, the pattern of CA125-derived 
fragments isolated from S-HeLa cells is shown in the leftmost lane (control). In panel B, the 
intensity of CA125-C-TERM-derived bands was quantified using Bio-Rad® QuantityOne® 
software. 
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 By contrast, CA125-C-TERM expressed in CHO cells binds Gal-1 more than 
seven times as efficient as Gal-3 (Fig. 10). This demonstrates that, besides N- and/or 
O-linked sugar moieties of CA125, the proteinaceous core structure of CA125 
contributes to the specificity of galectin recruitment. Moreover, a cell-type dependent 
galectin binding characteristics of CA125 was established.  
 
 In order to provide evidence for a direct interaction between CA125-C-TERM 
and Gal-1, crosslinking experiments were performed (Fig. 11). CA125-C-TERM 
bound to GST-Gal-1 beads was treated with the crosslinking reagent disuccinimidyl 
glutarate (DSG, Pierce). Crosslinking products with an apparent molecular mass of 
about 160-180 kDa can be detected using anti-Gal-1 antibody and anti-CA125 
antibody. This size corresponds to the approximate molecular weight of CA125-C-
TERM and Gal-1 in a 1:1 complex. The products have a smear-like appearance as 
expected for a glycoprotein-containing crosslinking product. This product is only 
observed in the presence of crosslinking reagent. Larger crosslinking products (> 180 
kDa), which could indicate an indirect interaction of CA125 with Gal-1, cannot be 
detected. 
Results 
 
98 
 
 
Fig. 11 A crosslinking experiment is shown employing disuccinimidyl glutarate (DSG; Pierce). 
CA125-C-TERM-expressing CHO cells were lysed with detergent followed by incubation of 
the cell-free supernatant with GST-Gal-1 beads. After extensive washing DSG was added at a 
final concentration of 0.5 mM. Crosslinking products were eluted with SDS sample buffer and 
analysed by SDS-PAGE and western blotting employing affinity-purified anti-Gal-1 and 
monoclonal anti-CA125 antibodies. The square bracket indicates crosslinking products with 
an apparent molecular mass of about 160 to 180 kDa positive for Gal-1 and CA125. In the 
range of 120 to 130 kDa other Gal-1-containing crosslinking products are observed. 
 
3.1.3 CA125-C-TERM binding to Gal-1 depends on O-linked β-ga-
lactose-terminated oligosaccharide chains 
 
 To characterize further the molecular mechanism of Gal-1 binding to CA125, 
interaction studies were performed using cell lysates derived from CA125-C-TERM-
expressing CHO cells grown in the presence of tunicamycin (Fig. 12). Under control 
conditions (Fig. 12 A, lanes 1-3), approximately 40% of CA125-C-Term could bind to 
GST-Gal-1 beads as calculated based on the input amount shown in lane 1 of Fig. 
11. This value was set to 100% (Fig. 12 B) and the ratio of Gal-1 binding efficiency of 
CA125-C-TERM derived from tunicamycin-treated cells was calculated (Fig. 12 A, 
lanes 4-6). As shown in Fig. 12 B binding efficiency was reduced to 65% in 
comparison to control conditions. When CA125-C-TERM was expressed in 
CHOclone13 cells that are incapable of translocating UDP-galactose into the lumen of 
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the Golgi and, therefore, neither form galactosylated glycoprotein nor glycolipids 
(Deutscher and Hirschberg, 1986), the binding capacity of CA125-C-TERM to GST-
Gal-1 was almost completely abolished (Fig. 12 A, lanes 14-16). Under all 
experimental conditions, CA125-C-TERM binding to Gal-1 was specific (Fig. 12 B).  
 
 
 
Fig. 12 Gal-1 binding to CA125-C-TERM largely depends on O-linked β-galactose-terminated 
oligosaccharide chains. CHOMCAT-TAM2 (wild-type background with regard to galactosylation 
of both proteins and lipids) and CHOclone13 cells (deficient with regard to galactosylation of both 
proteins and lipids; (Deutscher and Hirschberg, 1986)) stably expressing CA125-C-TERM 
were used to prepare cell-free detergent lysates followed by incubation with GST- and GST-
Gal-1 beads, respectively. Where indicated CHOMCAT-TAM2 were treated with 10 µg/ml 
tunicamycin for 18 hours at 37°C prior to cell lysis. In each experiment the CA125-C-TERM 
signal derived from 0.2% of the input was compared to 4% of the material bound to either 
GST- or GST-Gal-1 beads. Protein samples were separated on NuPage Bis-Tris gels (Novex) 
followed by CA125-C-TERM immunoblotting employing the monoclonal antibody OC125. A, 
Lysates derived from CA125-C-TERM-expressing CHOMCAT-TAM2 cells (lanes 1-3), CA125-C-
TERM-expressing CHOMCAT-TAM2 cells treated with tunicamycin (lanes 4-6), CA125-C-TERM-
deficient CHOMCAT-TAM2 cells (lanes 7-9), CA125-C-TERM-deficient CHOMCAT-TAM2 cells treated 
with tunicamycin (lanes 10-12), CA125-C-TERM-expressing CHOclone13 cells (lanes 14-16) 
and CA125-C-TERM-deficient CHOclone13 cells (lanes 17-19). In lane 13, HeLa-derived CA125 
eluted from GST-Gal-1 beads is shown as a control. B, Quantitation of the results shown in 
panel A. Based on the input signal (0.2% of starting material; panel A, lane 1) about 40% of 
CA125-C-TERM present in the cell lysate is recovered on GST-Gal-1 beads under the 
conditions used (panel A, lane 3, 4% of eluate) as based on quantitation employing Bio-Rad® 
QuantityOne® software. This value was set to 100% binding efficiency and compared to 
CA125-C-TERM-Gal-1 binding efficiencies measured with lysates either derived from 
tunicamycin-treated CHOMCAT-TAM2 cells or from CHOclone13 cells. The results shown represent 
mean values of two independent experiments. 
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 In order to investigate whether CA125-C-TERM binding to Gal-1 depends on O-
linked galactose-terminated oligosaccharides chains in vivo, binding studies of 
exogenously added GST-Gal-1 to untreated CHO, tunicamycin treated CHO and 
CHOclone13 cells were performed. As expected, untreated CHO cells show a high Gal-
1 surface staining employing flow cytometry (Fig. 13, dark-blue curve). The binding 
activity was not saturated under these conditions. This binding activity was 
significantly reduced when cells were pre-treated with tunicamycin (Fig. 13, red 
curve). GST-Gal-1 binding to the cell surface was almost abolished in CHOclone13 
cells (Fig. 13, dark green curve), which allowed determining whether expression of 
CA125-C-TERM under these conditions is capable of binding Gal-1. As shown in Fig. 
13, CA125-C-TERM cells surface expression does not alter cell-surface binding 
capacity for Gal-1 (Fig. 13 compare dark green and light green curves), demonstrat-
ing that Gal-1 binding to CA125-C-TERM requires its galactosylation. The combined 
data shown in Fig. 11, Fig. 12 and Fig. 13 suggest that the interaction between 
CA125-C-TERM and Gal-1 is direct. 
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Fig. 13 CA125-C-TERM cell surface expression in CHOclone13 cells does not result in increased 
binding capacity for exogenously added Gal-1. CA125-C-TERM-expressing- and CA125-
C-TERM-deficient CHOMCAT-TAM2- and CHOclone13 cells were grown to 70% confluency. Where 
indicated, cells were treated with 10 µg/ml tunicamycin for 18 hours at 37°C. Cells were then 
dissociated from the culture plates followed by incubation with 40 µg/ml recombinant GST-
Gal-1 for 30 min at room temperature. Following labeling with affinity-purified anti-Gal-1 
antibodies under native conditions, the various samples were analyzed for cell surface-bound 
recombinant Gal-1 employing FACS. Autofluorescence (filled light-blue curve: CHOMCAT-TAM2; 
filled grey curve:  CHOclone13) was determined based on cells not treated with antibodies). 
Untreated CHOMCAT-TAM2 cells are shown in dark blue. Tunicamycin-treated CHOMCAT-TAM2 cells 
are shown in red. CHOclone13 cells are shown in dark-green (CA125-C-TERM-expressing) and 
light-green (CA125-C-TERM-deficient), respectively. 
 
3.1.4 Despite lacking a N-terminal signal peptide, CA125-C-TERM 
is transported to the cell surface of CHO and HeLa cells 
 
 Endogenous CA125 is expressed on the cell surfaces of tumor cells (Bast et al., 
1981). Based on structural analyses (O'Brien et al., 2001; Yin and Lloyd, 2001) no 
obvious N-terminal or internal signal peptide is present in the full-length CA125 and 
of the CA125-C-TERM. Like the N-terminal ER signal sequences, the internal signal 
sequence is recognized by an SRP, which brings the ribosome to the ER membrane 
and serve as a start-transfer signal for single-pass transmembrane protein that 
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initiates the translocation of the protein. In order to know more about the molecular 
mechanism of CA125 cell surface expression CA125-C-TERM transport to the cell 
surface was investigated. CA125-C-TERM was expressed in CHO and HeLa cells 
using retroviral transduction (Engling et al., 2002). Cell surface expression was 
analyzed by flow cytometry using the monoclonal anti-CA125 antibody OC125 (Fig. 
14). 
 
 
 
Fig. 14 CA125-C-TERM is transported to the cell surface of both CHO- and HeLa cells as 
determined by FACS. CHOMCAT-TAM2 (panel A) and HeLaMCAT-TAM2 (panel B) cells, 
respectively, were transduced with retroviral particles encoding CA125-C-TERM. Following 3 
days of incubation at 37°C cells were dissociated from the culture plates using a protease-free 
buffer and processed with anti-CA125 antibodies (OC125). Primary antibodies were detected 
with anti-mouse antibodies coupled to Alexa488. CA125 cell surface localization was 
analyzed by FACS. Autofluorescence was determined with trypsin-treated cells (red curves). 
Non-transduced cells prepared in the absence of trypsin are indicated by green curves. 
CA125-C-TERM-transduced cells prepared in the absence of trypsin are indicated by blue 
curves. 
 
 Autofluorescence of CHO (Fig. 14 A) and HeLa (Fig. 14 B) was determined 
using trypsin-treated cells (red curves). Whereas CHO cells treated with retroviral 
control particles did not present endogenous CA125 on their cells surface. (Fig. 14 A, 
green curve), HeLa cells treated under identical conditions did contain small but 
significant amounts of endogenous CA125 on their surface (Fig. 14 B, green curve). 
After retroviral transduction of CA125-C-TERM, cell surface staining strongly 
increased for CHO and HeLa cells (Fig. 14 A, B; blue curves). The vast majority of 
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this signal disappeared when cells were treated with trypsin following flow cytometry 
analyses. Therefore, despite lacking a conventional signal peptide at the N-terminus, 
CA125-C-TERM is transported to the cell surface.  
 
3.1.5 CA125-C-TERM is transported to the cell surface via the 
ER/Golgi-dependent secretory pathway 
 
 To analyze if CA125-C-TERM enters the classical secretory pathway or if it 
makes use of some kind of nonclassical mechanism of transport way the subcellular 
distribution in permeabilized and non-permeabilized CHO and HeLa cells was 
investigated employing confocal microscopy. In non-permeabilized cells (Fig. 15 A-D, 
CA125-C-TERM was detected on the cell surface of CHO and HeLa. CA125-C-
TERM cell-surface staining was found not to be homogenous but rather appeared in 
subdomains with significant parts of the plasma membrane not stained at all. 
 
 Permeabilization of HeLa cells prior to anti-CA125 antibody treatment revealed 
that CA125-C-TERM expression results in its incorporation into membranes of the 
classical secretory pathway (Fig. 15 E-H), where it was colocalized with the Golgi 
marker p27 (Fullekrug et al., 1999; Jenne et al., 2002). This signal was specific, as it 
could not be observed when cells were treated with retroviral control particles (Fig. 
15 E).  
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Fig. 15 CA125-C-TERM is transported to the cell surface of both CHO- and HeLa cells as 
determined by confocal microscopy. CHOMCAT-TAM2 and HeLaMCAT-TAM2 cells, 
respectively, were grown on glass cover slips followed by transduction with retroviral particles 
encoding CA125-C-TERM or with retroviral control particles that lack a cDNA insert in the viral 
genome. After 3 days of incubation at 37°C the cells were fixed with paraformaldehyde. 
Specimens shown in panels A-D represent CHOMCAT-TAM2 cells that were not permeabi-
lized to visualize exclusively cell surface-localized CA125-C-TERM. Specimens shown in 
panels E-H represent TX-100-permeabilized HeLaMCAT-TAM2 cells in order to detect 
intracellular CA125-C-TERM. CA125-C-TERM was visualized with the monoclonal antibody 
OC125 (panels A, B, E-H). The Golgi marker p27 was detected with a polyclonal rabbit 
antiserum directed against a synthetic peptide that corresponds to the cytoplasmic tail of p27 
(panels C and D) (Jenne et al., 2002). Double staining was performed using secondary 
antibodies coupled to Alexa488 and Alexa546, respectively. Specimens were analyzed with a 
Zeiss LSM510 confocal microscope. 
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 Additionally, high-resolution confocal microscopy revealed CA125-C-TERM-
positive staining of the nuclear envelope (Fig. 16 B, D), which is indicative for ER 
localization. This was confirmed by double labeling experiments using antibodies 
directed against the ER marker calreticulin (Fig. 16 A) (Sonnichsen et al., 1994). 
Whereas most of the calreticulin staining was found to be ER associated, only low 
amounts of CA125-C-TERM were found in the ER compared with the high amounts 
in the Golgi (Fig. 16, compare A and B). These results indicate that, after insertion 
into the ER membrane, CA125-C-TERM is efficiently transported in an anterograde 
direction from the ER to the Golgi. In order to investigate whether CA125-C-TERM-
positive perinuclear structures represent endosomal compartments localized at the 
microtubal organizing center, CA125-C-TERM-expressing HeLa cells were treated 
with brefeldin A to disrupt the Golgi apparatus (Lippincott-Schwartz et al., 1989; Orci 
et al., 1991). As shown in Fig. 16 F, the compact perinuclear staining of CA125-C-
TERM (Fig. 16 D) disappears after brefeldin A treatment. The resulting staining 
pattern matches brefeldin A-induced distribution of an established marker protein of 
the cis-Golgi, the KDEL receptor (Fig. 16 C, E) (Lewis and Pelham, 1990; Lewis and 
Pelham, 1992a; Lewis and Pelham, 1992b) (Fullekrug et al., 1997). These data 
established that CA125-C-TERM travels through the ER and the Golgi apparatus on 
its way to the cell surface. 
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Fig. 16 Intracellular CA125-C-TERM is localized to organelles of the classical ER/Golgi-
dependent secretory pathway. HeLa cells stably expressing CA125-C-TERM were grown 
on glass cover slips. At about 70% confluency cells were treated with brefeldin A (5 µg/ml) for 
60 min or left untreated as a control. Following fixation with paraform aldehyde cells were 
treated with TX-100 to allow intracellular staining of antigens using antibodies directed against 
calreticulin, the KDEL receptor and CA125. Double staining was performed using secondary 
antibodies coupled to Alexa488 and Alexa546, respectively. Specimens were analyzed with a 
Zeiss LSM510 confocal microscope. A, anti-calreticulin, not treated with brefeldin A; B, anti-
CA125, not treated with brefeldin A; C, anti-KDEL receptor, not treated with brefeldin A; D, 
anti-CA125, not treated with brefeldin A; E, anti-KDEL receptor, treated with brefeldin A; F, 
anti-CA125, treated with brefeldin A. 
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 In order to functionally characterize the intracellular transport of CA125-C-
TERM, an in vivo cell-surface expression experiment based on flow cytometry was 
performed in the presence and the absence of brefeldin A (Fig. 17). CA125-C-TERM-
expressing HeLa cells were grown to about 70% confluency, followed by incubation 
for 90 minutes in the presence of brefeldin A. The cells were then trypsinized to 
remove pre-existing cell-surface CA125-C-TERM, spread onto new culture plates at 
the same cell density and were further incubated in the presence or absence of 
brefeldin A for 4 hours at 37°C, respectively. As a control, cells were applied to the 
same protocol without adding brefeldin A at any time point of the experiment. The 
amount of CA125-C-TERM transported to the cells surface within 4 hours in the 
absence of brefeldin A was set to 100% (Fig. 17 A, light green curve, Fig. 17 B, lane 
2). Comparing the level of cell surface CA125-C-TERM under steady state conditions 
(Fig. 17 A, red curve; Fig. 17 B, lane 1), approximately 50% of the cell surface 
population recovers after trypsinization within 4 hours of incubation (Fig. 17 B, lane 
2). When cells were treated with brefeldin A before trypsinization, followed by 
incubation for 4 hours in the absence of brefeldin A, the level of cell surface CA125-
C-TERM was reduced by about 60% (Fig. 17 A, dark green curve, Fig. 17 B, lane 3). 
When cells were treated with brefeldin A at all time, cell surface transport of CA125-
C-TERM was reduced up to 90% (Fig. 17 A, blue curve; Fig. 16 B, lane 4). These 
data combined with the confocal analysis of the subcellular distribution shown in Fig. 
16 establish that CA125-C-TERM is transported to the cell surface via conventional 
secretory transport involving the ER and the Golgi apparatus. 
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Fig. 17 CA125-C-TERM is transported to the cell surface via the classical ER/Golgi-dependent 
secretory pathway. HeLa cells stably expressing CA125-C-TERM were grown to 70% 
confluency. Where indicated brefeldin A was added to the medium at 5 µg/ml. Following 
incubation for 90 min at 37°C, cells were trypsinized to remove cell surface CA125-C-TERM 
and spreaded onto new culture plates at 70% confluency. The culture was then continued for 
4 hours at 37°C in the presence or absence of brefeldin A as indicated. CA125-C-TERM 
transported to the cell surface within this time period was quantified by FACS employing the 
monoclonal antibody OC125. A, FACS histograms. Autofluorescence was determined by 
analyzing cells that were not treated with antibodies (light blue curve, filled). The red curve 
represents cells under steady-state-conditions. The light green curve represents cells that 
were not treated with brefeldin A. Cells that were grown for 90 min in the presence of brefeldin 
A followed by incubation for 4 hours in its absence are shown in dark green. Cells that were 
incubated with brefeldin A over the whole course of the experiment are shown in dark blue. B, 
Statistical analysis of 4 independent experiments. The colours of the bars correspond to the 
conditions detailed above. 
 
3.1.6 Correlation of endogenous CA125 expression with increased 
cell surface expression of endogenous Gal-1 in CHO and 
HeLa cells 
 
 Our observation that CHO cells do not express detectable amounts of 
endogenous CA125 as opposed to HeLa cells (Fig. 14) is consistent with the fact that 
CHO cells are not derived from a tumor, whereas HeLa cells were isolated from 
cervix carcinoma (Gey et al., 1952). Therefore CA125-deficient CHO cells were com-
pared with CA125-expressing HeLa cells for various parameters with regard to Gal-1. 
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 Employing flow cytometry to analyze CHO and HeLa cells for the amount of cell 
surface expression of Gal-1, HeLa cells contain more than ten times as much Gal-1 
on their surface compared with CHO cells (Fig. 18). For this purpose auto-
fluorescence of CHO and HeLa cells was determined with trypsin treated cells and 
adjusted to the same value for both cell lines (Fig. 18 A, B; red curves). Using affinity-
purified anti-Gal-1 antibodies, a relatively small but significant population of 
endogenous Gal-1 (A; green curve) could be detected on the surface of CHO cells 
when the cells were not treated with trypsin prior to the FACS analysis. This 
observation is consistent with various studies that demonstrate cells surface 
expression of endogenous Gal-1 (Cho and Cummings, 1995a; Cho and Cummings, 
1995b; Lutomski et al., 1997). However, HeLa cells that express CA125 contain more 
than ten times the amount of endogenous Gal-1 on their cells surface (B; blue curve) 
compared with CA125-deficient CHO cells.  
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Fig. 18 Correlation of endogenous CA125 expression with cell surface expression of endoge-
nous Gal-1 in CHO- and HeLa cells. CHO (panel A) and HeLa cells (panel B) were 
dissociated from culture plates employing a protease-free buffer. Native cells were labeled 
with affinity-purified anti-Gal-1 antibodies derived from a polyclonal rabbit antiserum. Cell 
surface staining was analyzed by FACS using anti-rabbit secondary antibodies coupled to 
allophycocyanine to detect primary antibodies. Autofluorescence levels (red curves in panel A 
and B) were determined with cells treated with trypsin prior to the FACS analysis. Gal-1 cell 
surface levels are indicated in green (CHO, panel A) and blue (HeLa, panel B), respectively. 
Total Gal-1 expression levels in CHO and HeLa cells, respectively, were analyzed by 
quantifying Gal-1 in total SDS cell lysates based on a western blot analysis (panel C). Lanes 1 
and 4 represent the material of 20,000 cells, lanes 2 and 5 represent the material of 50,000 
cells and lanes 3 and 6 represent the material of 150.000 cells. The results from CHO cells 
are shown in lanes 1 to 3, the results from HeLa cells are shown in lanes 4 to 6. Gal-1 was 
detected with an affinity-purified rabbit antiserum directed against recombinant full-length Gal-
1. 
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 We then investigate whether this effect is due to i) different total Gal-1 
expression levels, ii) different cell surface binding capacities for Gal-1 or iii) different 
regulation of Gal-1 export in CHO and HeLa cells. As shown by Western blot analysis 
using affinity-purified anti-Gal-1 antibodies (Fig. 18 C), similar signals for Gal-1 were 
obtained from CHO and HeLa cells when the amount of SDS-lysed cells was titrated 
(20,000, 50,000 and 150,000 cells). Thus, CHO and HeLa cell do not differ to a 
significant extent in the total amount of Gal-1 expression.  
 Cell-surface binding capacity for Gal-1 was analyzed using FACS by titrating 
increasing amounts of a recombinant GST-Gal-1 fusion protein into cultures of CHO 
and HeLa cells, respectively. The total binding capacity for Gal-1 was found to 
exceed the amount of endogenous Gal-1 present on the cell surface of CHO and 
HeLa cells by a factor of more than 50-fold, with CHO cells being the cell type with an 
even higher Gal-1-binding capacity compare with HeLa cells. Therefore, the strikingly 
different amounts of endogenous cell-surface Gal-1 on CHO versus HeLa cells (Fig. 
18 A, B) cannot be due to a lower Gal-1 binding capacity of CHO cells. 
 On the basis of these experiments one possible explanation of these results 
would be that CA125-expressing HeLa cells possess a more active Gal-1 export 
pathway than CA125-deficient CHO cells. 
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3.1.7 CA125 expression does not stimulate Gal-1 export 
 
 Nowadays, RNA interference has become as a common technique to study the 
functional consequence of reducing the expression of specific genes in mammalian 
cells (Tuschl, 2001; Tuschl and Borkhardt, 2002). RNAi is induced by transfecting 
cells with small interfering RNAs, comprising hairpin-forming 45-50mer RNA 
molecules (Caplen et al., 2001) that are complementary to the gene of interest 
resulting in mRNA degradation. 
 To further investigate the relation between Gal-1 export and binding to CA125 
specific siRNAs directed against endogenous CA125 were generated to 
downregulate the expression of CA125 in adherent HeLa cells (termed HeLa RNAi 
CA125) (for sequence see material und method). A construct was generated in the 
retroviral expression vector pLNCD4 that upon transcription produces a siRNA 
directed against CA125 in HeLa cells (Brummelkamp et al., 2002; Sui et al., 2002). 
From this vector CD4 is constitutively expressed functioning as a cell surface marker. 
The vector pLNCD4 not containing an RNAi was introduced into HeLa cells as a 
control (termed HeLa RNAi CD4). A corresponding pool of CD4-positive HeLa cells 
was isolated by FACS sorting (3.2.1) using monoclonal anti-CD4 OC4 primary 
antibodies and APC-conjugated secondary antibodies. 
 
 The long-term goal of this RNAi approach was to analyze Gal-1 export from 
HeLa cells treated with RNAi against CA125 in comparison to HeLa cells expressing 
CA125 employing flow cytometry. To investigate downregulation of CA125 in trans-
duced HeLa cells, recombinant GST-Gal-1 fusion protein was attached to 
glutathione-coupled sepharose beads. Detergent lysates of HeLa wild-type, HeLa 
RNAi CD4, HeLa RNAi CA125 and S-HeLa as a positive control for binding of CA125 
to Gal-1 were generated and incubated with the GST-Gal-1-affinity matrix. 
Comparable amounts of proteins were incubated with the Gal-1 affinity matrix. 
Proteins bound to Gal-1 were eluted sequentially using lactose (Fig. 19, lane 1-4) 
and glutathione (Fig. 19, lane 5-8). Bound material was separated by SDS PAGE and 
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Western blot analysis using monoclonal anti-CA125 antibody and anti-mouse POD-
conjugated secondary antibodies. 
 
 
 
Fig. 19 Adherent HeLa cells do not express CA125 on their cell surface to a significant extent. 
Detergent lysates of HeLa cells (lane 1 and 5), HeLa transfected with a control RNAi (lane 2 
and 6), HeLa cells stably transfected with RNAi directed against CA125 (lane 3 and 7) and S-
HeLa (lane 4 and 8) were prepared and incubated with GST-Gal-1 beads (o/n, 4°C). 
Following extensive washing the beads were sequentially treated with lactose (lanes 1 to 4) 
and glutathione (lanes 5 to 8). Eluted proteins were separated on SDS-gels followed by trans-
fer to a blotting membrane. CA125 was detected by OC125 staining (Zymed) employing ECL. 
As positive control CA125-derived fragments isolated in former experiments from S-HeLa 
cells were used (lane 9) (see 3.1).  
 
 The positive control for binding of CA125 to Gal-1 generated from S-HeLa cells 
showed the typical pattern for CA125 (Fig. 19, compare lane 4 and lane 9). CA125 
bound to Gal-1 could not be detected in HeLa (Fig. 19, lane 1), HeLa RNAi CD4 (Fig. 
19, lane 2) and HeLa RNAi CA125 (Fig. 19, lane 3) cells indicating that adherent 
HeLa cells do not express significant amounts of CA125 on their cell surface. As 
CA125 is not detectable in the control cell lines, these data suggest that the higher 
export efficiency observed for human Gal-1 in HeLa cells as shown in Fig. 18 is not 
related to CA125 expression. 
Results 
 
114 
3.2 Establishment of experimental systems to study un-
conventional secretion of Gal-1 
 
 Although galectins are secreted from cells, no galectin shows any evidence for 
a typical signal peptide, implying a non-classical export signal (Hirabayashi and 
Kasai, 1993; Hirabayashi et al., 1992; Marschal et al., 1992; Pfeifer et al., 1993). 
Non-classical secretion of Gal-1 has been first studied in skeletal muscle, where the 
protein moves from a diffuse intracellular to an extracellular location during in vivo 
development (Barondes et al., 1981; Cooper and Barondes, 1990; Harrison, 1991). 
In cultured myoblasts, Gal-1 remains in the cytosol until it is externalized during 
differentiation (Cooper and Barondes, 1990; Harrison and Wilson, 1992). There is 
also evidence for secretion of other galectins. A 14-kDa chicken galectin has been 
found in intestinal epithelial cells and directly shown to be secreted into the intestinal 
lumen (Beyer and Barondes, 1982). The reason why galectins are secreted by non-
classical pathways is not known. One explanation is to segregate them from 
complementary glycoconjungate ligands that are externalized by the classical 
pathway to prevent interaction before externalization. Another possibility is that, in 
contrast to the unique classical secretion pathway, there may be multiple non-
classical secretory mechanisms allowing selective secretion of different galectins in 
response to specific signals. 
 In order to investigate the mechanism of unconventional secretion in 
mammalian cells a novel assay was established that reconstitute secretion of 
unconventionally secreted protein such as Gal-1. By using stable cell lines and flow 
cytometry, Gal-1-GFP (termed Gal-1-GFP), GFP-Gal-1 (termed GFP-Gal-1) and 
GFP-CGL-2 can be determined on a quantitative basis. CGL-2 was identified as 
fungal galectin also unconventionally secreted by Coprinopsis cinerea. It is an 
orthologue to Gal-1 with 20% homologies. The homology to Gal-1 lies in the typical 
galectin fold of a CGL-2 monomer. The oligomeric state of this lectin is tetrameric 
and not dimeric like Gal-1. So far it was not known whether the mammalian export 
machinery recognizes this galectin as an export substrate (Walser et al., 2004; 
Walser et al., 2005).  
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3.2.1 Generation of cell lines 
 
 To generate CHO model cell lines expressing defined GFP fusion proteins in a 
doxicycline-dependent manner the following steps were performed. First, the murine 
orthologue of the cationic amino acid transporter MCAT-1 (Albritton et al., 1989; 
Davey et al., 1997) was stably transfected into CHOwild-type cells. Cell surface 
expression of MCAT-1 renders CHO cells permissive for retroviral transduction 
based on the ecotropic envelope protein of murine leukemia virus (Albritton et al., 
1989; Davey et al., 1997). In a second step, CHOMCAT-1 cells were transduced with an 
ecotropic retrovirus carrying a bicistronic construct encoding the doxicycline-sensitive 
transactivator rtTA2-M2 (Urlinger et al., 2000) and a truncated version of CD2 (Liu et 
al., 2000) that was used as a cell surface marker. A pool of CD2-positive cells was 
isolated by FACS sorting (from now on termed CHOmt) and subjected to another 
round of retroviral transduction (Fig. 20). 
 
 
 
Fig. 20 Schematic overview: retroviral transduction to generate reporter cell lines 
 
 To analyze the export efficiency of human Gal-1 mutants stable CHO cell lines 
were generated. Due to the use of the viral vector pRevTRE2, a stable integration of 
the constructs into the genome of target cells (CHOmt) was possible. Furthermore, a 
doxicycline/transactivator-responsive element in the vector pRevTRE2 allows 
doxicycline-dependent protein expression of Gal-1 and CGL-2 as GFP fusion 
proteins. A schematic overview of the GFP fusion proteins expressed in the 
corresponding CHO cell line is shown in Fig. 21. The calculated size of these GFP 
fusion proteins is about 40 kDa. 
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Fig. 21 Schematic overview: cDNA constructs 
 
 Retroviral particles carrying the reporter constructs (Fig. 21) were produced by 
HEK 293T cells and used for gene transfer. After viral transduction, reporter molecule 
expression was induced by adding doxicycline to the cell culture medium (standard 
condition: 1 µg/ml doxicycline, 48 h). The virally transduced cells were subjected to a 
FACS-based sorting procedure to generate clonal CHOmt cell lines. Three days after 
retroviral transduction doxicycline was added to the cell culture medium for 24 h. 
Following this incubation period cells were detached from cell culture dishes using a 
protease-free buffer system and processed for FACS analysis. Dead cells were 
identified by staining with propidium iodide that intercalates into DNA of damaged 
and dead cells. 50,000 cells from each cell line were isolated by FACS sorting based 
on GFP fluorescence using a FACSVantage sorting device (Becton Dickinson, 
Heidelberg). 
 The obtained pools of cells were incubated for 7 days in the absence of doxi-
cycline followed by the isolation of 50,000 cells from each population that did not 
display any GFP fluorescence. 
 Each of these cell pools was cultured for another period of 7 days including 24 
h in the presence of doxicycline (1 µg/ml) at the end of the incubation. 50,000 cells 
were obtained by FACS sorting based on GFP fluorescence. Exemplarily, the results 
of the sorting procedure for all generated mutant cell lines of human Gal-1 are 
displayed for the cell line Gal-1-GFP, GFP-Gal-1, GFP-CGL-2 and GFP in Fig. 22 
(panel A, Gal-1-GFP; panel B, GFP-Gal-1; panel C, GFP-CGL-2, panel D, GFP).  
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Fig. 22 FACS sorting based on GFP fluorescence to isolate reporter cell lines. Cells were 
detached from cell culture dishes using a protease-free buffer system and processed for 
FACS analysis to measure GFP fluorescence. Sort 1 displays cells 3 days after viral 
transduction incubated in the presence of 1 µg/ml doxicycline for 24 h. FL1-H represents the 
green channel measuring GFP fluorescence, FL3-H shows the red channel displaying 
propidium iodide staining (dead cells). 50,000 cells were sorted within the sorting window. 
Sort 2 shows cells grown for 7 days in the absence of doxicycline after sort 1. Again, 50,000 
cells were sorted within the sorting window. Sort 3 shows cells 7 days after sort 2 incubated in 
the presence of 1µg/ml doxicycline for 24 h. In panel A the sorting procedure for Gal-1-GFP is 
shown, in panel B for GFP-Gal-1, in panel C for GFP-CGL-2 and in panel D for GFP. 
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3.2.2 Quantitative analysis of export of reporter constructs as ana-
lyzed by flow cytometry 
 
 The clonal CHO cell lines described above (see 3.2.1) were cultivated in the 
presence of doxicycline (1 µg/ml, 48 h) and prepared for FACS analysis using the 
plate labeling procedure described in material and methods. To detect the reporter 
molecules on the cell surface, exported material was labeled using affinity-purified 
anti-GFP primary antibodies and allophycocyanin-coupled secondary antibodies. 
Analysis was performed using a BD FACSCalibur system. 
All cell lines expressed the corresponding GFP reporter construct in a doxicycline-
dependent manner as shown by an increase of GFP fluorescence compared to CHO 
cells not transduced with the reporter construct (Fig. 23; GFP expression level, panel 
A, B, C, D, E,).  
 Concerning cell surface staining all galectin constructs showed a significant 
signal (Fig. 23; cell surface; panel B, C, D). However, the signal for the GFP-Gal-1 
construct was lowered (Fig. 23, panel C) compared to the cell surface staining 
observed for Gal-1-GFP (Fig. 23, panel B).  
 The secretion of GFP-CGL-2 was analyzed in order to investigate whether the 
fungal galectin orthologue CGL-2 is a substrate for the Gal-1 export pathway in 
mammalian cells, although homologies between Gal-1 and CGL-2 are weak at the 
level of both the primary and the quaternary structure. Strikingly, GFP-CGL-2 fusion 
protein (Fig. 23, cell surface, panel D) was found to be exported with a similar 
efficiency as compared to Gal-1-GFP (Fig. 23, panel D). 
 As expected, probing for cell surface staining showed no signals for the control 
cell line CHOGFP (Fig. 23, cell surface, panel E). 
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Fig. 23 Galectins are transported to the cell surface of CHO cells as determined by FACS. 
Following incubation with doxicycline (1 µg/ml) for 48 h, CHO cells expressed the corres-
ponding fusion protein (Gal-1-GFP (panel B), GFP-Gal-1 (panel C), GFP-CGL-2 (panel D) and 
GFP (panel E). Cells were processed with affinity-purified anti-GFP antibodies. Primary 
antibodies were detected with APC-conjugated secondary antibodies. Cells were dissociated 
from cell culture plates using a protease-free buffer. GFP fusion protein localization was 
analyzed by FACS. Autofluorescence was determined employing CHO cells (panel A). 
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 As shown in Fig. 23, employing flow cytometry, it was possible to quantitatively 
access unconventional secretion of Gal-1-GF, GFP-Gal-1 and GFP-CGL-2 fusion 
proteins in vivo. 
 
3.2.3 Export of reporter constructs as analyzed by a cell surface 
biotinylation assay 
 
 To confirm the cell surface localization of the reporter molecules using an 
independent method, a biotinylation assay was used (Stegmayer et al., 2005). 
Therefore the CHO Gal-1-GFP, GFP-Gal-1, GFP-CGL-2 and GFP were cultivated in 
the presence of doxicycline for 48 h. Additionally, the cell culture medium of the cells 
was subjected to immunoprecipitation using affinity-purified anti-GFP antibodies 
coupled to protein A sepharose beads (Amershan). The cell surface biotinylation 
assay was combined with immunoprecipitation of the cell culture medium in order to 
detect galectin GFP fusion proteins bound to the cell surface as well as non-bound 
material present in the medium of cells. 
 The cells were incubated with a membrane-impermeable biotinylation reagent 
(EZ-link sulfo-NHS-SS-biotin, Pierce). The biotinylation reagent binds covalently to 
cell surface proteins via the ε-amino group of all accessible lysine residues. After 
detergent mediated cell lysis biotinylated and non-biotinylated proteins were 
separated using streptavidin-coupled beads. The biotinylated fraction (Fig. 24, lane 
1), the non-biotinylated fraction (Fig. 24, lane 2), representing exported and not 
exported material, respectively, and the medium fraction (Fig. 24, lane 3) were 
analyzed by SDS-PAGE and Western blot analysis using affinity-purified anti-GFP 
antibodies and monoclonal anti-rabbit clone RG16 secondary antibodies. 
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Fig. 24 Biochemical analysis of export of various galectin-GFP fusion proteins from CHO cells 
employing cell surface biotinylation and immunoprecipitation from cell culture super-
natants. The fusion proteins indicated were expressed in CHO cells for 48 h at 37°C (6-well 
plates; 70% confluency; 1 µg/ml doxicycline) The medium was removed and subjected to 
immunoprecipitation using affinity-purified anti-GFP antibodies. Cells were treated with a 
membrane-impermeable biotinylation reagent. Following detergent-mediated cell lysis 
biotinylated and non-biotinylated proteins were separated employing streptavidin beads. 
Aliquots from the input material (lane 1; 1%), the biotinylated fraction (lane 2; 10%) and the 
immunoprecipitate from the cell culture medium fraction (lane 3; 50%) were analyzed by SDS 
PAGE and Western blotting using affinity-purified anti-GFP antibodies. 
 
 As shown in Fig. 24 all four reporter constructs were expressed at similar levels 
(Fig. 24, lane 1; 1%). The CHO cell lines expressing Gal-1-GFP, GFP-Gal-1 and 
GFP-CGL-2 secrete the corresponding reporter constructs efficiently as shown by the 
signals for biotinylated proteins in the eluate fractions and for non-bound proteins 
precipitated from the cell culture medium. Most of the extracellular Gal-1-GFP, GFP-
Gal-1 and GFP-CGL-2 population was found to be associated with the cell surface of 
CHO cells (Fig. 24, lane 2, 10%) with only a minor portion being found in the medium 
(Fig. 24; lane 3, 50%). As expected and consistent with the flow cytometry data (Fig. 
23, GFP, cell surface staining) GFP could not be detected on the cell surface (Fig. 
24, lane 2). A small amount of GFP is detectable in the cell culture medium 
employing immunoprecipitation of the medium. This signal is likely to be derived from 
damaged cells. 
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 The data obtained from the cell surface biotinylation assay are consistent with 
the observations made in the flow cytometry analysis (Fig. 23). Both assays are func-
tional as exported protein is detectable on the cell surface.  
 
3.2.4 Quantitative analysis of Galectin binding to cell surfaces 
using flow cytometry 
 
 Galectins are β-galactoside-specific lectins being associated with components 
of the extracellular matrix and counter receptors on the cell surface of mammalian 
cells (Barondes, 1984). One aim of this work was to identify the targeting motif 
mediating unconventional secretion of Gal-1. Therefore single amino acids were 
mutated. These mutations may influence the ability of Gal-1 to bind to natural 
ligands. In order to probe the binding ability of Gal-1 wild-type and mutant forms an in 
vivo binding assay was established.   
 Gal-1-GFP, GFP-Gal-1, GFP-CGL-2 and GFP proteins were expressed in CHO 
cells by incubating the corresponding cell lines in the presence of doxicycline (1 
µg/ml) for 48 h at 37°C. Cell-free supernatants were prepared by homogenization 
combining freeze-thaw cycles with sonication. Membranes were removed in two 
steps by centrifugations at 13,000 gav (10 min at 4°C) and 100,000 gav (1 h at 4°C). 
The resulting supernatants were analyzed for the amounts of fusion protein based on 
GFP fluorescence as measured with a fluorescence plate reader (Molecular Devices 
SpectraMax Gemini XS). Normalized amounts of cell-free supernatants (150 GFP 
units corresponding to about 1.5 µg GFP) were incubated with CHO cells not 
expressing the various GFP fusion proteins for 1 h at 4°C to allow cell surface 
binding. Following treatment with affinity-purified anti-GFP antibodies and APC-
conjugated secondary antibodies, cell surface binding was quantified by flow 
cytometry (Engling et al., 2002; Seelenmeyer et al., 2003). 
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Fig. 25 Analysis of β-galactoside binding efficiency of various galectin-GFP fusion proteins 
based on binding to CHO cells. The various fusion proteins indicated were expressed in 
CHO cells. Cell-free supernatants were prepared and normalized by GFP fluorescence. The 
various supernatants were then incubated with CHO cells for 1 h at 4°C to allow cell surface 
binding. Following treatment with affinity-purified anti-GFP antibodies and APC-conjugated 
secondary antibodies, cell surface binding was quantified by flow cytometry. 
 
 The reporter molecules Gal-1-GFP and GFP-CGL-2 showed a strong cell 
surface signal demonstrating a highly efficient binding to CHO cells (Fig. 25, panel B 
and panel D). GFP-CGL-2 even bound with a higher efficiency to the outer leaflet of 
CHO cells than Gal-1-GFP, whereas GFP-Gal-1 exhibited a strongly reduced but 
significant cell surface signal (Fig. 25, compare panel A, B and C). As expected the 
signal observed for GFP was only slightly over background indicating that no cell 
surface binding occurred (Fig. 25, compare panel A and panel E). 
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 Employing this experimental approach it is possible to determine the binding 
efficiencies of different galectin reporter constructs to β-galactoside-containg 
receptors in vivo.  
 
3.2.5 Biochemical analysis of Galectin binding to counter recep-
tors using lactose-coupled beads 
 
 To further analyze the β-galactoside binding ability of the reporter molecules 
with an independent biochemical method, an in vitro binding assay was established. 
Galectin GFP fusion proteins were expressed in CHO cells by incubation in the 
presence of doxicycline (1 µg/ml) for 48 h at 37°C. Following detachment of cells 
from the cell culture dishes using PBS/EDTA, cells were sedimented and lysed using 
PBS/TX-100. Insoluble material was removed by sequential centrifugation at 13,000 
gav (10 min at 4°C) and at 100,000 gav (1 h at 4°C). The resulting supernatant was 
analyzed for the amounts of fusion proteins based on GFP fluorescence as 
measured with a fluorescence plate reader (Molecular Device SpectraMax Gemini 
XS). Normalized amounts of detergent lysates (50 GFP units corresponding to about 
0.5 µg GFP) were then incubated with lactose-coupled beads (Sigma) for 1 h at 4°C. 
Following extensive washing in TX100-containing buffer bound material was eluted 
using SDS sample buffer. Input and flow-through fractions as well as the SDS 
eluates were analyzed by SDS PAGE and Western blotting using affinity-purified 
anti-GFP antibodies and POD-conjugated secondary antibodies. 
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Fig. 26 Analysis of β-galactoside binding efficiency of various galectins expressed as GFP 
fusion proteins based on binding to lactose-coupled beads. Detergent lysates normalized 
by GFP fluorescence were incubated with lactose beads for 1 h at 4°C. The non-bound 
fraction was separated and, following extensive washing, bound material was eluted with SDS 
sample buffer. Input (lane 1, 5%), non-bound material (lane 2; 5%) and bound material (lane 
3; 5%) were analyzed by SDS PAGE and Western blotting using affinity-purified anti-GFP 
antibodies. 
 
 When analyzing the binding efficiency of the fusion proteins Gal-1-GFP, GFP-
Gal-1, GFP-CGL-2 and GFP in the in vitro binding assay, the data were consistent 
with the observations made in the in vivo analysis. Western blot analysis revealed 
that comparable amounts of all four reporter constructs were used for incubation with 
lactose-coupled beads (Fig. 26, lane 1, 5%). The reporter molecule Gal-1-GFP 
bound to the lactose affinity matrix indicated by a distinct band (Fig. 26, Gal-1-GFP, 
lane 3, 5%). Consistently with the observation made in the in vivo binding assay, 
binding efficiency of GFP-Gal-1 was reduced about 4-fold (Fig. 26, GFP-Gal-1, lane 
3, 5%). The fungal galectin GFP-CGL-2 bound with a higher efficiency to the lactose 
affinity matrix since there was no detectable protein in the flow-through fraction and 
the intensity of the eluate was comparable with the signal obtained for Gal-1-GFP as 
the input signal is decreased. As expected GFP as a negative control for binding to 
lactose-coupled beads showed no signal in the bound fraction (Fig. 26; GFP, lane 3). 
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 Taken together, both the in vivo and the in vitro binding assay are robust 
methods to investigate binding efficiencies of galectin fusion proteins to β-
galactosides. 
 
3.3 Mutational analysis of the export-targeting motif in 
human Gal-1 
 
 The canonical carbohydrate recognition domain (CRD) of galectins consists of 
approximately 130 amino acids, although only a small number of these residues 
directly contact carbohydrate ligands. A comparison of the sequences of approxi-
mately 30 galectins from many different organisms reveals that eight residues, which 
have been shown to be involved in the carbohydrate binding by X-ray crystallo-
graphic analysis, are invariant (in Gal-1: His 45, Asn 47, Arg 49, Val 60, Asn 62, Trp 
69, Glu 72 and Arg 74 (Barondes et al., 1994). Although all galectins share a high 
degree of homology in their CRDs, two general subgroups of galectins can be 
distinguished, based on sequence homologies: the Gal-1 subfamily, which includes 
Gal-1 and -2, and the Gal-3 subfamily, which includes all others. Human Gal-1 and 
the fungal galectin CGL-2 from Coprinopsis cinerea show an overall identity about 
20%. 
 
3.3.1 Random mutagenesis of Gal-1  
 
 In order to investigate the export-targeting motif of Gal-1 a random mutagenesis 
of the human Gal-1 ORF employing low fidelity PCR was performed. As PCR 
template human Gal-1 ligated into the vector pGEM-T was used. The random 
mutations were generated using a concentration of 100 µM MnCl2 in the PCR 
reaction mix. Under these conditions, during temperature cycling by AmpliTaq DNA 
polymerase, which has no proofreading activity like PfuTurbo polymerase, 8-12 
mutations per 400 basepairs were inserted into the Gal-1 ORF (408 bp). Following 
digestion with BamHI and AgeI, the various mutated Gal-1 inserts were cloned into 
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the retroviral vector pRevTRE2/GFP. Employing this method 100 single retroviral 
DNA plasmids were generated having multiple distinct mutations. Following retroviral 
transduction of CHO cells (3.2.1), the export behavior of these Gal-1 mutants was 
analyzed by flow cytometry (3.2.2). Additionally, the β-galactoside binding ability of 
Gal-1 mutants was determined using the in vivo (3.2.4) and in vitro binding assay 
(3.2.5). Based on these experiments 14 export-deficient Gal-1 mutants were 
identified. The sequences of the corresponding DNA plasmids were determined and 
based on the observed mutations human Gal-1 was mutated by site-directed 
mutagenesis resulting in Gal-1-GFP mutants carrying individual mutations (3.3.2). In 
Table 3 the mutations identified in the random mutagenesis are shown.  
 
Plasmid number (internal nomenclature) Mutation 
11 C3Y, N34S, D55G, N57Y, D135A 
17 H45R, F51S, N57H, D103V 
19 F46L, F80L, E87V, M121V 
22 V60M, A95P, I118V, D126G 
27 H53P, F92L, K118Q 
64 N9F, H45N, E116D, K130T, D135Y 
71 A52T, S84R, I90F 
72 N34D, E75G, E106G 
80 C3G, F109L, Y120C 
82 N41I, G66S, M121L 
86 E16K, N40D, Q84L, CV131W 
89 A7T, V60M, A122S 
92 N9G, C61S, F127I 
97 E16K 
 
Table 3 Mutated amino acids resulting in an export defect identified in the random muta-
genesis screen employing low fidelity PCR 
 
3.3.2 Site-directed mutagenesis  
 
 Site-directed mutagenesis was used to introduce point mutations, to switch 
amino acids and to delete multiple amino acids. The site-directed mutagenesis 
method was performed using PfuTurbo DNA polymerase, which has a 6-fold higher 
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fidelity in DNA synthesis than Taq DNA polymerase (Cline et al., 1996). The basic 
procedure utilizes a double-stranded DNA vector (pGEM-T) with the insert of interest 
(human Gal-1 and fungal CGL-2) and two synthetic oligonucleotide primers 
containing the desired mutation (see material and methods). The oligonucleotide 
primers, each complementary to opposite strands of the vector, were extented during 
temperature cycling by PfuTurbo DNA polymerase. Incorporation of the oligo-
nucleotide primers generated mutated plasmids containing staggered nicks. 
Following temperature cycling, the product was treated with the endonuclease DpnI. 
DpnI is specific for methylated DNA and was used to digest the parental DNA 
template to select for newly synthesized DNA containing the desired mutation. This is 
possible since DNA isolated from almost all E. coli strands is methylated and 
therefore susceptible to DpnI digestion. The nicked vector DNA containing the 
desired mutation in Gal-1 was introduced into DH5α (Invitrogen) competent cells or 
XL-1 blue (2.2.1). Following digestion of isolated DNA with BamHI and AgeI the 
various mutated inserts were ligated into the retroviral vector pRevTRE2/GFP. 
 
3.3.3 Characterization of Gal-1 mutants regarding export and 
binding to β-galactosides 
  
 In order to elucidate the export targeting motif 97 individual CHO cell lines 
expressing single mutants of Gal-1, 10 truncated versions of human Gal-1 and 3 
truncated forms of CGL-2 were generated by stable integration of the corresponding 
DNA constructs using retroviral transduction (3.2.1) (Table 4). As control cell lines 
CHOGal-1-GFP, CHOGFP-Gal-1, CHOGFP-CGL-2 and CHOGFP were used. The individual 
mutants were selected in three different ways: i) targeted mutagenesis based on the 
results obtained from the random mutagenesis approach ii) targeted mutagenesis of 
surface residues based on the crystal structure of Gal-1 iii) targeted mutagenesis of 
residues conserved between human Gal-1 and CGL-2 from Coprinopsis cinerea 
(3.3.2) 
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 In Table 4 the individual Gal-1 mutants expressed in CHO cells as GFP fusion 
proteins in a doxicycline-dependent manner are listed. In addition to single amino 
acid mutations, N- and C-terminally truncated versions of human Gal-1 expressed as 
GFP fusion proteins were generated (Table 5). 
 
Mutation (Gal-1-GFP) Selection procedure 
Gal-1-GFP  
C3A Random mutagenesis 
V6A Conserved between Gal-1 and CGL-2 
A7I Random mutagenesis 
N9A Random mutagenesis 
K13A Conserved between Gal-1 and CGL-2 
P14A Conserved between Gal-1 and CGL-2 
E16A Random mutagenesis 
V20A Random mutagenesis 
R21A Conserved between Gal-1 and CGL-2 
V32A Conserved between Gal-1 and CGL-2 
V32G Conserved between Gal-1 and CGL-2 
V32E Conserved between Gal-1 and CGL-2 
V32S Conserved between Gal-1 and CGL-2 
V32W Conserved between Gal-1 and CGL-2 
N34A Random mutagenesis / conserved between Gal-1 and CGL-2 
L35A Random mutagenesis 
K37E Surface exposure 
D38E Surface exposure 
D38K Surface exposure 
N40A Random mutagenesis 
N41A Random mutagenesis / conserved between Gal-1 and CGL-2 
L44A Conserved between Gal-1 and CGL-2 
L44D Conserved between Gal-1 and CGL-2 
L44F Conserved between Gal-1 and CGL-2 
L44S Conserved between Gal-1 and CGL-2 
H45A Random mutagenesis / conserved between Gal-1 and CGL-2; Scott and 
Zhang, 2002 
F46A Random mutagenesis 
R49A Conserved between Gal-1 and CGL-2; Scott and Zhang, 2002; Ford et al., 
2003 
N51A Random mutagenesis / 
A52I Random mutagenesis 
H53A Surface exposure / random mutagenesis / conserved between Gal-1 and 
CGL-2; López-Lucendo et al., 2004 
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H53E Surface exposure / random mutagenesis / conserved between Gal-1 and 
CGL-2; López-Lucendo et al., 2004 
H53G Surface exposure / random mutagenesis / conserved between Gal-1 and 
CGL-2; López-Lucendo et al., 2004 
G54A Random mutagenesis and conserved between Gal-1 and CGL-2 
D55A Random mutagenesis 
N57A Random mutagenesis 
V60A Random mutagenesis 
C61A Random mutagenesis 
D65A Surface exposure 
D65K Surface exposure 
G66A  Random mutagenesis 
G67A Conserved between Gal-1 and CGL-2 
A68I Conserved between Gal-1 and CGL-2 
W69G Conserved between Gal-1 and CGL-2; Hirabayashi et al., 1991 
G70A Conserved between Gal-1 and CGL-2 
E72A Conserved between Gal-1 and CGL-2; Hirabayashi et al., 1991 
R74A Conserved between Gal-1 and CGL-2 
E75A Random mutagenesis 
F80A Random mutagenesis and conserved between Gal-1 and CGL-2 
F80K Random mutagenesis and conserved between Gal-1 and CGL-2 
F80S Random mutagenesis and conserved between Gal-1 and CGL-2 
P82A Conserved between Gal-1 and CGL-2 
S84A Random mutagenesis 
E87A Random mutagenesis 
I90A Random mutagenesis and conserved between Gal-1 and CGL-2 
F92A Random mutagenesis 
A95I  Random mutagenesis 
D103A Random mutagenesis 
G104A Conserved between Gal-1 and CGL-2 
E106A Random mutagenesis 
F109A Random mutagenesis 
R112A Conserved between Gal-1 and CGL-2;  
R112H Conserved between Gal-1 and CGL-2; lopez-Lucendo 2004 
N114A Conserved between Gal-1 and CGL-2 
E116A Random mutagenesis 
A117I Conserved between Gal-1 and CGL-2 
I118A Random mutagenesis and conserved between Gal-1 and CGL-2 
N119E Surface exposure 
N119K Surface exposure 
N119W Surface exposure 
Y120A Random mutagenesis and conserved between Gal-1 and CGL-2 
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Y120D Random mutagenesis and conserved between Gal-1 and CGL-2 
M121A Random mutagenesis 
A122I Random mutagenesis and conserved between Gal-1 and CGL-2 
D126A Random mutagenesis 
F127A Random mutagenesis and conserved between Gal-1 and CGL-2 
F127D Random mutagenesis and conserved between Gal-1 and CGL-2 
I129R Surface exposure 
K130A Random mutagenesis 
V132A Surface exposure 
V132E Surface exposure 
V132R Surface exposure 
F134E Surface exposure 
F134R Surface exposure 
GFP-CGL-2  
W72G Conserved between Gal-1 and CGL-2 
 
Table 4 Single amino acids changes in human Gal-1 and fungal CGL-2 based on the 
procedure and/or references shown in the right column. 
 
Truncations 
Gal-1-GFP 
Gal-1-GFP ∆N5 
Gal-1-GFP ∆N10 
Gal-1-GFP ∆N20 
Gal-1-GFP ∆N10-C129 
GFP-Gal-1 
GFP-Gal-1 ∆C4 
GFP-Gal-1 ∆C9 
GFP-Gal-1 ∆C20 
GFP-Gal-1 ∆C30 
GFP-Gal-1 ∆C40 
GFP-Gal-1 ∆C50 
GFP-CGL-2 
GFP-CGL-2 ∆C11 
GFP-CGL-2 ∆C111/S134E 
GFP-CGL-2 ∆C16 
 
Table 5 Truncated forms of human Gal-1 and fungal CGL-2 
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 Using CHO cells expressing either the wild-type form of Gal-1, or the wild-type 
form of CGL-2 as positive controls as well as GFP as a negative control, the 
generated Gal-1 mutant cell lines were analyzed regarding export efficiency 
employing the FACS-based secretion assay and the biotinylation assay. Moreover, 
all mutant Gal-1 proteins were analyzed for their capability to interact with counter 
receptors based on binding to both CHO cells (Fig. 29; Fig. 33; Fig. 41) and lactose-
coupled to beads (Fig. 30; Fig. 34; Fig. 42). These studies allowed to investigate 
whether a reduced surface signal of individual mutants results from a reduced 
binding efficiency to β-galactoside-containing glycolipids and glycoproteins on the cell 
surface. Based on these assays it was possible to identify 26 mutants, which showed 
the same phenotype as wild-type Gal-1 regarding export and binding ability (Table 6). 
43 mutants were identified as being deficient in binding to β-galactoside-containing 
counter receptors by both the in vivo and the in vitro assay (Table 7). Some of these 
have been reported previously to be impaired in terms of binding to β-galactosides. 
15 mutant forms of Gal-1 were characterized by controversial results regarding 
export and binding to their counter receptors (3.3.3.3) (Hirabayashi and Kasai, 1991). 
The phenotypes of truncated forms of Gal-1 are shown separately (3.3.3.4).  
 
3.3.3.1 Gal-1 mutants without phenotype regarding export and 
binding to β-galactosides 
 
 To study the export of Gal-1 mutants the wild-type and the mutant forms of Gal-
1 were expressed in a doxicycline-dependent manner and three independent experi-
ments employing flow cytometry were performed. In order to be able to compare cell 
surface signals obtained from mutant cell lines expressing the reporter molecules at 
different levels, the expression of the wild-type form of Gal-1 was induced at different 
concentrations of doxicycline (1 µg/ml (1:1,000); 0.2 µg/ml (1:5,000); 0.1 µg/ml 
(1:10,000); 0.02 µg/ml (1:50,000); 0.01 µg/ml (1:100,000) doxicycline). The 
expression level and the cell surface staining of wild-type Gal-1-GFP under standard 
conditions (1 µg/ml doxicycline, 48 h, 37°C) were set to 100%. GFP-CGL-2 was used 
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as an additional positive control for unconventional secretion of galectins in CHO 
cells. 
 As shown in Fig. 27 (blue bar) the expression levels of the GFP fusion proteins 
varied for the various Gal-1 mutants. The single amino acid changes K13A, P14A, 
V32A, V32S, K37E, N40A, D65A, D65K, S84A and N118E of Gal-1-GFP showed 
approximately the same expression level under standard conditions (1 µg/ml 
doxicycline; 48 h, 37°C) as compared to the wild-type form of Gal-1-GFP. The 
mutations C3A, A7I, E16A, R21A, A52I, G66A, E75A, P82A, D103A, G104A, E106A, 
N114A, E116A, A117I, I118A and M121A in Gal-1-GFP resulted in a lower 
expression level indicated by decreased GFP fluorescence under standard 
conditions (1 µg/ml doxicycline, 48 h, 37°C). GFP used as a negative control for 
export from CHO cells and cell surface staining, showed an expression level 
comparable to Gal-1-GFP. 
 Related to different expression levels, all GFP fusion proteins of the mutated 
Gal-1 (Fig. 27; red bar) were detectable on the cell surface indicating that neither the 
export process nor the binding ability of these mutants are influenced by the 
individual single amino acid changes of each mutant form of Gal-1. The mutants 
P14A and M121A showed a reduced cell surface staining employing flow cytometry 
compared to the wild-type form of Gal-1. However, both mutants showed a significant 
signal for exported protein being associated with the plasma membrane as the signal 
is increased compared to the GFP negative control (Fig. 27). 
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Fig. 27 Quantitative analysis of export of various galectin-GFP fusion proteins from CHO cells 
employing flow cytometry. CHO cells were grown on 6-well plates and induced with 
doxicycline for 48 h at 37°C to express the fusion proteins indicated. Following removal of 
medium, cells were labeled with affinity-purified anti-GFP antibodies followed by detachment 
of the cells using PBS/EDTA. GFP (expression level; blue) and APC-derived fluorescence 
(cell surface; red) were quantified by flow cytometry using Becton Dickinson FACSCalibur 
system (n=4) 
 
 In order to quantitatively study the export of Gal-1 mutants using an 
independent method, the cell surface biotinylation assay (Stegmayer et al., 2005) 
was combined with immunoprecipitation of Gal-1-GFP fusion proteins from the 
medium of expressing cells employing affinity-purified anti-GFP antibodies (3.2.3). 
Consistent with the data acquired by flow cytometry, the biochemical approach (Fig. 
28) revealed that the wild-type and the mutant forms of Gal-1-GFP were expressed in 
a doxicycline-dependent manner. The input fraction (Fig. 28; lane 1; 1%) indicates 
the expression level of each fusion protein. The expression levels of the mutant A7I, 
E16A, K37E, E106A and V32S were low compared to the wild-type form of Gal-1-
GFP. Western blot analysis revealed comparable amounts of all other mutants 
expressed in the corresponding CHO cell line. Most of the extracellular Gal-1-GFP 
wild-type population was associated with the cell surface of CHO cells (Fig. 28; lane 
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2; 10 %) with only a minor portion being found soluble in the medium (Fig. 28; lane 3; 
50%). Strikingly, all mutant forms of Gal-1-GFP (Fig. 28; lane 2 and lane 3) identified 
in the FACS-based assay as being exported from CHO cell and detectable on the 
cell surface could also be detected bound to the cell surface of CHO cells employing 
the biotinylation assay. Although the signals for cell surface localized material of Gal-
1 mutants A7I, E16A, K37E, E106A and M121A were weak (Fig. 28; lane 2), these 
mutant forms were not export deficient since the overall expression levels are 
reduced. These observations were consistent with the flow cytometry data. For all 
reporter molecules only a small fraction was found soluble in the medium of 
expressing cells as detected by immunoprecipitation employing affinity-purified anti-
GFP antibodies.  
 CHO cells expressing Gal-1-GFPS84A (Fig. 28; Gal-1-GFPS84A, lane 2 and 3) 
seemed to export the mutated GFP fusion protein to a higher extent compared to the 
wild-type form of Gal-1 (Fig. 28; Gal-1-GFP wt, lane 2 and 3) which is consistent with 
the observation made by flow cytometry (Fig. 27).   
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Fig. 28 Biochemical analysis of export of various galectin-GFP fusion proteins from CHO cells 
employing cell surface biotinylation and immunoprecipitation from cell culture super-
natants. The fusion proteins indicated were expressed in CHO cells for 48 h at 37°C (6-well 
plates; 70% confluency; 1 µg/ml doxicycline) The medium was removed and subjected to 
immunoprecipitation using affinity-purified anti-GFP antibodies. Cells were treated with a 
membrane-impermeable biotinylation reagent. Following detergent-mediated cell lysis 
biotinylated and non-biotinylated proteins were separated employing streptavidin beads. 
Aliquots from the input material (lane 1; 1%), the biotinylated fraction (lane 2; 10%) and the 
immunoprecipitate from the cell culture medium fraction (lane 3; 50%) were analyzed by SDS 
PAGE and Western blotting using affinity-purified anti-GFP antibodies. 
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 All mutant Gal-1 proteins were now analyzed for their capability to interact with 
counter receptors based on binding to both CHO cells (Fig. 29) and lactose-coupled 
beads (Fig. 30). 
 For the in vivo assay (Fig. 29) after detachment from cell culture plate CHO 
cells not expressing the GFP reporter molecule were incubated with cell-free super-
natants prepared from CHO cells expressing the various Gal-1-GFP fusion proteins 
(3.2.4). Following treatment with affinity-purified anti-GFP antibodies and APC-
conjugated secondary antibodies, binding of exogenously added GFP reporter 
molecules to the cell surface was analyzed by flow cytometry. The wild-type forms of 
Gal-1 and CGL-2 were used as positive controls for binding to the cell surface and 
the Gal-1 binding capacity was set to 100%, GFP served as a negative control. Some 
mutants such as A7I, V32A, V32S K37E, N40A, P82A, A117I, M121A and the wild-
type form of CGL-2 bound even better to the cell surface of CHO cells (Fig. 29) when 
compared to Gal-1-GFP. The mutations C3A, P14A, A52I, E75A, D103A, G104A 
N114A and E116A showed approximately the same binding ability to the cell surface 
as Gal-1 wild-type. Amino acid changes K13A, E16A, R21A, D65A, D65K, G66A, 
I118A and N119E resulted in a reduced binding ability to β-galactosides on the cell 
surface.  
 The cell surface staining of mutant proteins S84A and E106A was reduced 
(S84A; 30%; E106A, 21%), but the signals differ significantly from the GFP negative 
control. These observations are consistent with the flow cytometry data. All mutants 
exported from CHO cells are also capable of binding to cell surface counter receptors 
in vivo.  
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Fig. 29 Analysis of β-galactoside binding efficiency of various galectin-GFP fusion proteins 
based on binding to CHO cells. The various fusion proteins indicated were expressed in 
CHO cells. Cell-free supernatants were prepared and normalized by GFP fluorescence. The 
various supernatants were then incubated with CHO cells for 1 h at 4°C to allow cell surface 
binding. Following treatment with affinity-purified anti-GFP antibodies and APC-conjugated 
secondary antibodies, cell surface binding was quantified by flow cytometry. 
 
 To verify the data obtained by the in vivo assay the biochemical binding assay 
was performed. For this purpose detergent lysates of the various Gal-1 constructs 
were incubated with lactose-coupled beads (3.2.3). Input, flow-through and bound 
fractions were analyzed by SDS PAGE and Western blotting using affinity-purified 
anti-GFP antibodies.   
 As shown in Fig. 30 the amounts incubated with the lactose-coupled beads 
(Fig. 30, lane 1) varied between the various GFP fusion proteins although the input 
was normalized by measuring the GFP fluorescence of the fusion proteins employing 
a fluorescence plate reader. The input of Gal-1-GFP C3A, R21A, K37E, D65A, 
G104A and N119E was very low, but sufficient to detect bound material (Fig. 30; lane 
3) on lactose-coupled beads. The only exception was R21A where no bound material 
is detectable. (Fig. 30, R21A, lane 3). The same observation could be made 
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regarding the mutants N40A and P82A, which seem to be impaired in binding to 
lactose-coupled beads. These observations are not consistent with the in vivo 
binding studies and with the secretion assays. In all three assays it was shown that 
these mutants were able to bind to their counter receptors. 
 All remaining mutants clearly bind to lactose-coupled beads as the various 
signals for bound materials were increased compared to the GFP negative control  
(Fig. 30; GFP, lane 3). Additionally they showed a similar binding ability compared to 
the positive controls Gal-1-GFP and GFP-CGL-2 (Fig. 30, Gal-1-GFP wt and GFP-
CGL-2; lane 3). Consistently with the in vivo binding assay the mutants A7I and V32A 
and the wild-type form of CGL-2-GFP had an even higher β-galactoside binding effi-
ciency in vitro (compare Fig. 29 and Fig. 30). 
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Fig. 30 Analysis of β-galactoside binding efficiency of various galectin-GFP fusion proteins 
based on binding to lactose-coupled beads. Detergent lysates normalized by GFP fluores-
cence were incubated with lactose beads for 1 h at 4°C. The non-bound fraction was removed 
and, following extensive washing, bound material was eluted with SDS sample buffer. Input 
(lane 1, 5%), non-bound material (lane 2; 5%) and bound material (lane 3; 5%) were analyzed 
by SDS PAGE and Western blotting using affinity-purified anti-GFP antibodies. 
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 Taken together, all Gal-1 mutants listed in Table 6 result in a similar phenotype 
as the wild-type form of human Gal-1 concerning secretion and binding to β-galacto-
sides.  
 
Mutation Phenotype 
Gal-1-GFP  
C3A Lower expression level in the FACS-based and biotinylation assay; cell surface signal, binding ability 
comparable to wild-type in both binding assays 
A7I Lower expression level in the FACS-based assay, highly reduced in the biotinylation assay; cell surface 
signal in both assays; binding capacity higher than wild-type in both binding assays 
K13A Approximately the same expression level and cell surface signal in both secretion assays than the wild-
type; no binding defect  
P14A Approximately the same expression level and cell surface signal in both secretion assay than the wild-
type; no binding defect 
E16A Lower expression level in the FACS-based and biotinylation assay; cell surface signal; binding capacity 
comparable to wild-type in both binding assays 
R21A Lower expression level in the FACS-based and biotinylation assay; cell surface signal in both assays; 
binding capacity comparable to wild-type in the in-vivo assay; reduced signal in the in-vitro binding assay 
V32A Approximately the same expression level and cell surface signal in both secretion assay than the wild-
type; no binding defect 
V32S Approximately the same expression level and cell surface signal in both secretion assay than the wild-
type; no binding defect 
K37E Approximately the same expression level and cell surface signal in the FACS-based assay than the wild-
type; in the biotinylation assay reduced cell surface signal, increased signal in the cell culture medium; no 
binding defect 
N40A Approximately the same expression level and cell surface signal in the FACS-based assay and 
biotinylation assay than the wild-type; no binding defect 
A52I Approximately the same expression level and cell surface signal in the FACS-based secretion assay than 
the wild-type; reduced cells surface in the biotinylation assay; higher binding capacity in the in-vivo assay; 
reduced binding in the in vitro assay 
D65A Approximately the same expression level and cell surface signal in the FACS-based assay and 
biotinylation assay than the wild-type; no binding defect 
D65K Approximately the same expression level and cell surface signal in the FACS-based assay and 
biotinylation assay than the wild-type; no binding defect 
G66A Reduced expression in the FACS-based assay; good expression in the biotinylation assay; cell surface 
staining; no binding defect 
E75A Reduced expression in the FACS-based assay; good expression in the biotinylation assay; cell surface 
signal; no binding defect 
P82A Reduced expression in the FACS-based assay; good expression in the biotinylation assay; cell surface 
signal; no binding defect 
S84A Approximately the same expression level and cell surface signal in the FACS-based and biotinylation 
assay than the wild-type, even higher; no binding defect 
D103A Reduced expression in the FACS-based assay; good expression in the biotinylation assay; cell surface 
signal; no binding defect 
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G104A Reduced expression in the FACS-based assay; good expression in the biotinylation assay; cell surface 
signal; no binding defect 
E106A Reduced expression in the FACS-based assay and in the biotinylation assay; cell surface signal; no 
binding defect 
N114A Reduced expression in the FACS-based assay; good expression in the biotinylation assay; cell surface 
signal; no binding defect 
E116A Reduced expression in the FACS-based assay; good expression in the biotinylation assay; cell surface 
signal; no binding defect 
A117I Reduced expression in the FACS-based assay; good expression in the biotinylation assay; cell surface 
signal; no binding defect 
I118A Reduced expression in the FACS-based assay; good expression in the biotinylation assay; cell surface 
signal; no binding defect 
N119E Approximately the same expression level and higher cell surface signal in the FACS-based assay than 
the wild-type, even higher; Expression and cell surface signal in the biotinylation assay comparable to the 
wild-type; no binding defect in vivo, reduced binding in vitro 
M121A Reduced expression in the FACS-based assay; good expression in the biotinylation assay; cell surface 
signal; no binding defect 
 
Table 6 Summary of various human Gal-1 mutants without phenotype compared to the wild-
type form of Gal-1-GFP 
   
3.3.3.2 Identification of Gal-1 mutants deficient in binding to β-
galactosides in glycoproteins and glycolipids 
 
 Based on findings that the glycolipid/glycoprotein composition of the cell surface 
may influence the export behavior of human Gal-1 (3.1.7) it was hypothesized that 
binding to counter receptors plays a role in non-classical export of human Gal-1. With 
this hypothesis in mind, mutants were analyzed whether they were defective in 
binding to β-galactosides in both assays (in vivo 3.2.4 and in vitro binding assay 
3.2.5). Following FACS and biotinylation analysis the identified Gal-1 mutants defi-
cient in cell surface localization in both secretion assays were carefully studied 
regarding the influence of the corresponding single amino acid mutations on ligand 
binding. 
 Using the wild-type forms of Gal-1-GFP and GFP-CGL-2 as positive controls for 
the unconventional secretion of galectins and GFP as a negative control, 43 Gal-1 
mutants were identified not to be present on the outer leaflet of the plasma 
membrane employing flow cytometry (Fig. 31). As already described above the wild-
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type and the mutant forms of Gal-1-GFP and GFP-CGL-2 fusion proteins were 
expressed in corresponding CHO cell lines by incubating the cells in the presence of 
doxicycline for 48 h at 37°C under standard conditions (3.2.2). The expression of the 
wild-type form of Gal-1 was induced at different concentrations of doxicycline (1 
µg/ml (1:1,000); 0.2 µg/ml (1:5,000); 0.1 µg/ml (1:10,000); 0.02 µg/ml (1:5,0000); 
0.01 µg/ml (1:100,000) doxicycline) in order to be able to compare cell surface 
signals obtained from mutant cell lines expressing the reporter molecules at different 
levels. The expression level and the cell surface staining of wild-type Gal-1-GFP 
under standard condition (1 µg/ml doxicycline, 48 h, 37°C) were set to 100%. Three 
independent experiments were performed to analyze export of the wild-type and the 
mutant forms of Gal-1-GFP.  
 As shown in Fig. 31 (blue bar) the expression level of the various GFP fusion 
proteins varied between the different generated CHO cell lines. Compared to Gal-1-
GFP the mutant cell lines V6A, V20, D38E, L44F, H45A, R49A, H53A, H53E, H53G, 
W69A, E72A, R74A, F80A, F80S, R112A, N119K, N119W, Y120A, A122I, F127A 
V132A, F134E, F134R, the wild-type form of GFP-CGL-2 and GFP as a negative 
control for export showed approximately the same expression level as Gal-1-GFP. 
The GFP fusion proteins of Gal-1 mutants N34A, D38K, N41A, L44A, L44D, L44S, 
F46A, D55A, N57A, V60A, G67A, F80K, F109A, Y120D, F127D, I129R, V132E, 
V132R and the CGL-2 mutant W72G expressed the GFP reporter molecule to a 
lower extent (1 µg/ml doxicycline, 48 h, 37°C). The mutants N9A and G54A were 
expressed at very low levels. Strikingly, related to different expression levels almost 
all mutants showed clearly no cell surface staining as they did not differ from the GFP 
negative control to a significant extent. The mutations V20A, L44F, H53A, G67A, 
F109A, N119K, N119W, F127A, V132A, F134E and F134R showed a weak cell 
surface staining indicating that the fusion proteins were partially exported and bound 
to the cell surface (for further characterization see cell surface biotinylation assay; 
Fig. 32). The expression level and the cell surface staining of the mutant N9A, L44D, 
L44S and G54A were largely reduced. Independently of the low protein expression, 
reduced cell surface signals indicated that there was no exported GFP fusion protein 
bound to the cell surface (compare (1:100,000) doxicycline of the wild-type form of 
Gal-1). 
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Fig. 31 Quantitative analysis of export of various galectin-GFP fusion proteins from CHO cells 
employing flow cytometry. CHO cells were grown on 6-well plates and induced with 
doxicycline for 48 h at 37°C to express the fusion protein indicated. Following removal of 
medium, cells were labeled with affinity-purified anti-GFP antibodies followed by detachment 
of the cells using PBS/EDTA. GFP (expression level; blue) and APC-derived fluorescence 
(cell surface; red) were quantified by flow cytometry using Becton Dickinson FACSCalibur 
system (n=4) 
 
 However, using the flow cytometry assay, only exported protein that is able to 
bind to the cell surface can be detected. Negative signals for cell surface staining can 
be explained by one of the following scenarios: i) because of the mutation the various 
proteins of Gal-1-GFP are not recognized any more as export substrates by the 
export machinery in CHO cells. ii) Export still occurs but the exported mutant proteins 
are not able to bind to counter receptors on the cell surface. Secreted GFP reporter 
molecules should then be detectable in the medium of expressing CHO cells. iii) The 
mutant forms showing the indicated phenotype in Fig. 31 are not secreted and are 
also not able to bind to β-galactosides so that the reporter molecules are neither 
detectable on the cell surface nor in the medium of expressing cells. 
 To distinguish between these three possibilities the following experiment was 
performed: conditioned medium from CHO cells expressing the various GFP reporter 
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molecules was removed and subjected to immunoprecipitation to detect soluble, 
secreted GFP fusion proteins. The cells were treated with a membrane-impermeable 
biotinylation reagent. After detergent-mediated cell lysis the biotinylated and the non-
biotinylated fraction were separated employing streptavidin beads. The input (Fig. 32, 
lane 1, 1%) indicates the expression level of the various GFP fusion proteins. As 
shown in Fig. 32, most of the extracellular Gal-1-GFP was found to be associated 
with the cell surface of CHO cell (Fig. 32, Gal-1-GFP wt, lane 2; 10%). Only a minor 
portion could be precipitated from the medium (Fig. 32, Gal-1-GFP wt, lane 3; 50%). 
Regarding GFP-CGL-2 as a positive control, most of the secreted population was 
bound to the cell surface (Fig. 32, GFP-CGL-2 wt, lane 2; 10%) and only a minor 
portion was found soluble in the cell culture medium (Fig. 32, GFP-CGL-2 wt, lane 3; 
50%). As expected GFP as a negative control was not associated with the cell 
surface (Fig. 32, GFP, lane 2, 10%). A weak signal could be detected in the medium 
of GFP-expressing CHO cells and, therefore, which is likely to be derived from 
damaged cells, was considered as background.  
 As depicted in Fig. 32 none of the mutants showed a significant signal of 
exported protein neither bound the cell surface nor soluble in the medium compared 
to the GFP negative control (Fig. 32, lane 2 and lane 3). Some mutants (N41A, L44D, 
R49A, H53E, G54A, R74A, F80K, F80S, R112A, Y120D, F127D, V132R and GFP-
CGL-2 W72G) showed a weak population bound to the cell surface (Fig. 32, lane 2; 
10%). This exported surface-bound fraction might be caused by unspecific release 
and was considered as background. 
 The mutants N34A, D38K, L44S, H45A, F46A, H53A, H53G, N57A, V60A, 
W69G, E72A and V132E were clearly defective in both export and binding as they 
neither show GFP reporter molecules bound to the cell surface nor exported protein 
soluble in the cell culture medium. One possible explanation might be that 
degradation of mutated Gal-1-GFP fusion protein causes the absence of such signals 
on the cell surface and the medium. As mutated proteins were expressed the specific 
mutation may cause a stability problem. Therefore mutants, which are not able any 
more to bind to ligands, needed to be investigated for stability (3.3.3.2.1).  
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Fig. 32 Biochemical analysis of export of various galectins as GFP fusion proteins from CHO 
cells employing cell surface biotinylation and immunoprecipitation from cell culture 
supernatants. The fusion proteins indicated were expressed in CHO cells for 48 h at 37°C (6-
well plates; 70% confluency; 1 µg/ml doxicycline) The medium was removed and subjected to 
immunoprecipitation using affinity-purified anti-GFP antibodies. Cells were treated with a 
membrane-impermeable biotinylation reagent. Following detergent-mediated cell lysis biotiny-
lated and non-biotinylated proteins were separated employing streptavidin beads. Aliquots 
from the input material (lane 1; 1%), the biotinylated fraction (lane 2; 10%) and the immuno-
precipitate from the cell culture medium fraction (lane 3; 50%) were analyzed by SDS PAGE 
and Western blotting using affinity-purified anti-GFP antibodies. 
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 Some of the mutant forms of Gal-1 shown in Fig. 32 (H45A, R49A (Scott and 
Zhang, 2002); H53A/E/G, (Lopez-Lucendo et al., 2004); W69G, E72A, R74A 
(Hirabayashi and Kasai, 1991) have been reported previously to be impaired in terms 
of binding to β-galactoside-containing counter receptors (Table 3). Therefore all 
mutants were analyzed regarding their binding ability to β-galactosides employing 
CHO cells and lactose-coupled beads. 
 
 As already shown before the wild-type form of Gal-1-GFP and GFP-CGL-2 bind 
to β-galactosides (Fig. 33) and were detectable on the cell surface of CHO employing 
flow cytometry (3.2.4) The cell surface signal of bound Gal-1-GFP was set to 100%. 
Almost all mutants were clearly defective in binding to β-galactosides on CHO cells 
as the cell surface signal of bound protein is comparable to the GFP negative control.  
 
 
 
Fig. 33 Analysis of β-galactoside binding efficiency of various galectin-GFP fusion proteins 
based on binding to CHO cells. The various fusion proteins indicated were expressed in 
CHO cells. Cell-free supernatants were prepared and normalized by GFP fluorescence. The 
various supernatants were then incubated with CHO cells for 1 h at 4°C to allow cell surface 
binding. Following treatment with affinity-purified anti-GFP antibodies and APC-conjugated 
secondary antibodies, cell surface binding was quantified by flow cytometry.  
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 Additionally, the identified mutants deficient in binding to CHO cell surface were 
analyzed using the in vitro binding assay employing lactose-coupled beads (3.2.5). 
Input (Fig. 34, lane 1, 5%), flow-through (Fig. 34, lane 2, 5%) and bound material 
(Fig. 34, lane 3, 5%) were analyzed by SDS PAGE and Western blotting using 
affinity-purified anti-GFP antibodies.   
 As shown in Fig. 34, the Western blot analysis revealed that similar amounts of 
Gal-1-GFP, GFP-CGL-2 as positive controls (Fig. 34, lane 1) and of the mutants 
N34A, D38K, N41A, L44A, L44D, L44S, H45A, R49A, H53A, H53E, H53G, G54A, 
N57A, V60A, W69G, E72A, R74A, F80a, F80S, R112A, Y120D, F127D, I129R, 
V132E, V132R and CGL-2-GFP W72G were applied to lactose-coupled beads, 
whereas the amount of Gal-1-GFP F46A was much lower. As shown in Fig. 34, the 
wild-type form of Gal-1-GFP and CGL-2-GFP clearly bound to the lactose-coupled 
beads, as there was a reduced signal for the non-bound fraction (Fig. 34; lane 2, 5%) 
and a clear signal for lactose-bound material (Fig. 34; lane 3, 5%). All mutants were 
clearly defective in binding to lactose, since they did not differ from the GFP negative 
control (Fig. 34, lane 3). These data are consistent with the observation made in the 
corresponding in vivo binding studies (Fig. 33). 
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Fig. 34 Analysis of β-galactoside binding efficiency of various galectin-GFP fusion proteins 
based on binding to lactose-coupled beads. Detergent lysates normalized by GFP fluores-
cence were incubated with lactose beads for 1 h at 4°C. The non-bound fraction was sepa-
rated and, following extensive washing, bound material was eluted with SDS sample buffer. 
Input (lane 1, 5%), non-bound material (lane 2; 5%) and bound material (lane 3; 5%) were 
analyzed by SDS PAGE and Western blotting using affinity-purified anti-GFP antibodies 
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 Taken together, all mutants listed in Table 7 were found to be deficient both in 
β-galactoside binding and export as they were neither detectable on the cell surface 
nor in the medium of the corresponding cell lines. These observations indicate that 
the interaction of Gal-1 with β-galactoside-containing cell surface receptors is a 
prerequisite for its unconventional secretion. 
 However, an alternative explanation for the absence of mutant forms of Gal-1-
GFP from the medium would be that the GFP reporter molecule is degraded under 
non-reducing conditions present outside cells. To investigate the stability of a 
mutated protein a degradation assay was established (3.3.3.2.1).  
 
Mutation Phenotype 
Gal-1-GFP  
V6A Expression level comparable with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
N9A Very low expression level comparable with the wild-type in the FACS-based assay; low expression level 
in the biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding 
defect in both assays 
V20A Expression level comparable with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
N34A Lower expression level than with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
D38E Expression level comparable with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; reduced signal of exported protein employing flow cytometry and biotinylation assay; 
binding defect in both assays 
D38K Lower expression level than with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
N41A Lower expression level than with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
L44A Lower expression level than with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
L44D Lower expression level than with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
L44F Expression level comparable with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; reduced signal of exported protein employing flow cytometry and biotinylation assay; 
binding defect in both assays 
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L44S Lower expression level than with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
H45A Expression level comparable with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
F46A Lower expression level than with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
R49A Expression level comparable with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
H53A Expression level comparable with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
H53E Expression level comparable with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
H53G Expression level comparable with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
G54A Very low expression level comparable with the wild-type in the FACS-based assay; good expression 
employing the biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; 
binding defect in both assays 
D55A Lower expression level than with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
N57A Lower expression level than with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
V60A Lower expression level than with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
G67A Lower expression level than with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
W69G Expression level comparable with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
E72A Expression level comparable with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
R74A Expression level comparable with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
F80A Expression level comparable with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
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F80K Lower expression level than with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
F80S Expression level comparable with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
F109A Lower expression level than with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
R112A Expression level comparable with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
N119K Expression level comparable with the wild-type in the FACS-based assay; low expression level in the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
N119W Expression level comparable with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
Y120A Expression level comparable with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
Y120D Lower expression level than with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
A122I Expression level comparable with the wild-type in the FACS-based assay; low expression level in the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
F127A Expression level comparable with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; reduced signal of exported protein employing flow cytometry and biotinylation assay; 
binding defect in both assays 
F127D Lower expression level than with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
I129R Lower expression level than with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
V132A Expression level comparable with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
V132E Lower expression level than with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
V132R Lower expression level than with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
F134E Expression level comparable with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
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F134R Expression level comparable with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
GFP-CGL-2  
GFP-CGL-2 
W72G 
Lower expression level than with the wild-type in the FACS-based assay; good expression employing the 
biotinylation assay; no exported protein employing flow cytometry and biotinylation assay; binding defect 
in both assays 
 
Table 7 Summary of various human Gal-1 mutants being deficient in both binding to β-
galactosides and export from CHO cells. 
 
3.3.3.2.1 Gal-1 mutants deficient for binding to β-galactosides are 
not degraded in conditioned medium derived from CHO 
cells 
 
 In the case of galectins binding to β-galactoside is of great importance. 
Galectins are highly sensitive to the redox state of the environment and can remain 
active only in the reducing environment of the cytosol. Following export galectins 
must immediately bind to their counter receptors on the cell surface in order to fulfill 
their function.  
 Based on the known secretion (Fig. 31 and Fig. 32) and binding assays (Fig. 33 
and Fig. 34) 43 mutants were identified to be deficient regarding export from CHO 
cells and binding to β-galactosides. Stable mutant proteins, which lost their ability to 
bind to the cell surface, should be detectable in the cell culture medium of expressing 
CHO cells if export occurs. An alternative explanation for the absence of mutated 
proteins from the cell culture medium is that these proteins are subjected to degrada-
tion since they cannot bind to their counter receptors.  
 Therefore these Gal-1 mutants deficient in β-galactoside binding were analyzed 
with regard to their stability in conditioned medium derived from CHO cells in order to 
test whether protein degradation causes their absence from the supernatants of 
expressing cells. Cell-free supernatants of the various proteins deficient in binding to 
β-galactosides were prepared (Table 7). Normalized amounts (150 GFP units corres-
ponding to about 1.5 µg GFP) measured with a fluorescence plate reader were 
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added to conditioned medium. The corresponding Gal-1-GFP mutant protein diluted 
in conditioned medium was either subjected immediately to immunoprecipitation 
using affinity-purified anti-GFP antibodies or incubated for 48 h at 37°C (the 
experimental condition of a secretion assay employing the cell surface biotinylation 
assay and the FACS-based secretion assay) followed by immunoprecipitation. 
Following SDS PAGE degradation of the various Gal-1-GFP mutants were analyzed 
by Western blotting using affinity-purified anti-GFP antibodies. 
 
 As shown in Fig. 35, the wild-type forms of Gal-1-GFP, GFP-CGL-2 and GFP 
were used as negative controls for degradation. 33 mutant forms of Gal-1 and one 
mutant of CGL-2 deficient in binding were analyzed for degradation. The wild-type 
form of Gal-1 and CGL-2, GFP and the β-galactoside-binding mutants were not 
degraded when incubated with condition CHO medium at 37°C for 48 hours (Fig. 35, 
compare lane 1, 10%, and lane 2, 10%) since Western blot analysis revealed the 
same amounts for non-incubated and incubated fractions. Human Gal-1 and fungal 
CGL-2 are highly stable under the experimental conditions applied. Additionally, 
mutations of single amino acid in Gal-1 and CGL-2 causing in a defect in binding to 
counter receptors did not result in their degradation. Regarding the mutants N41A, 
L44A and V60A there was a slightly reduced signal indicating that these proteins are 
partially degraded (Fig. 35, lane 1 and 2). 
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Fig. 35 Stability of galectin-GFP fusion proteins in conditioned media derived from CHO cells. 
The fusion protein indicated were expressed in CHO cells for 48 h at 37°C (6-well paltes; 70% 
confluency). From each cell line, a cell-free supernatant was prepared. Normalized amounts 
(GFP fluorescence) were incubated in conditioned medium derived from CHO cells for the 
times indicated followed by immunoprecipitation (lanes 1 and 2) using affinity-purified anti-
GFP antibodies. The samples were analyzed by SDS PAGE and Western blotting using 
antibodies directed against GFP. Lane 1: no incubation (IP, 10%); lane 2: incubation for 48 h 
at 37°C (IP, 10%). 
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3.3.3.2.2 Wild-type forms of both Gal-1 and CGL-2 fail to be ex-
ported from CHO cells lacking functional counter recep-
tors for Galectins 
 
 To address the question whether counter receptors play a direct role in the 
export mechanism of galectins, another experimental approach was taken. For this 
purpose, cell lines expressing various forms of Gal-1 (Gal-1-GFP, Gal-1-GFPW69G, 
Gal-1-GFPE72A) and CGL-2 (GFP-CGL-2, GFP-CGL-2W72G) as GFP fusion proteins 
were generated based on a CHO mutant cell line termed clone 13 (3.1.3; Fig. 12). In 
this mutant cell line, the Golgi-resident transporter for UDP-galactose is defective 
and, therefore, these cells cannot produce galectin counter receptors since 
galactosyltransferases in the Golgi lumen do not receive activated galactose residues 
as substrates (Deutscher and Hirschberg, 1986). As a result, both glycoproteins and 
glycolipids derived from clone 13 cells do not contain β-galactosides in their sugar 
moieties and, therefore, do not bind galectins on their cell surface (Fig. 13). If β-
galactosides localized to the cell surface are necessary for Gal-1 export into the 
extracellular space, the wild-type form of Gal-1 and CGL-2 expressed as GFP fusion 
proteins should not be secreted from CHOclone13 cells.  
 Following retroviral transduction of CHOclone13 cells all proteins were stably ex-
pressed as GFP fusion proteins using the doxicycline-dependent transactivator 
system (3.2.1). CHO cells expressing the corresponding reporter molecules were 
used as positive controls. 
 The cell surface biotinylation assay combined with immunoprecipitation of the 
various GFP fusion proteins from the medium of expressing CHO and CHOclone13 
cells was performed under standard conditions (1 µg/ml doxicycline, 48 h, 37°C).  
 As shown in the cell surface biotinylation experiments (Fig. 36) both Gal-1-GFP 
(panel A; lanes 2 and 3) and CGL-2-GFP (panel D; lanes 11 and 12) were efficiently 
exported from CHOwild-type cells as inducated the combined signals for cell surface 
and medium fractions. 
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Fig. 36 Comparative analysis of export of galectin-GFP fusion proteins from CHOwild-type and 
CHOclone 13 cells employing cell surface biotinylation and immunoprecipitation from cell 
culture supernatants. The fusion proteins indicated were expressed in both CHOwild-type 
(panels A-F) and CHOclone 13 cells (panels G-L9) for 48 h at 37°C (6-well plates; 70% 
confluency; 1 µg/ml doxicycline). The medium was removed and subjected to immuno-
precipitation using affinity-purified anti-GFP antibodies. Cell surfaces were treated with a 
membrane-impermeable biotinylation reagent. Following detergent-mediated cell lysis, 
biotinylated and non-biotinylated proteins were separated employing streptavidin beads. 
Aliquots from the input material (lane 1; 0.25%), the biotinylated fraction (lane 2; 25%) and the 
immunoprecipitate from the cell culture medium fraction (lane 3; 25%) were analyzed by SDS 
PAGE and Western blotting using affinity-purified anti GFP antibodies. 
 
 By contrast, when expressed in CHOclone13 cells, the wild-type forms of Gal-1 
and CGL-2 GFP fusion proteins failed to get access to the extracellular space as the 
combined signals for cell surface and medium fractions (Fig. 36, panels G; lanes 2 
and 3; and J; lanes 11 and 12) did not differ significantly from the GFP negative 
control (Fig. 36; panel F and L; lanes 17 and 18) and were largely reduced as 
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compared to those observed in CHOwild-type cells (panels A and D). As expected, 
export of β-galactoside binding deficient mutants (Fig. 36; Gal-1-GFPW69G, Gal-1-
GFPE72A and CGL-2-GFPW72G) were not only blocked in CHOwild-type cells (Fig. 36, 
panels B, C and E; Fig. 36, panels B, C and E) but also in CHOclone13 cells (Fig. 36, 
panels H, I and K).  
 
 In Fig. 37 export from both CHOwild-type and CHOclone13 cells of the various 
Galectin-GFP fusion proteins (calculating the signals resulting from cells surface 
biotinylation and immunoprecipitation from the cell culture supernatants) was 
quantified using fluorescent secondary antibodies employing a LI-COR Odyssey 
imaging system. For each fusion protein, the combined signals derived from cell 
surface biotinylation and material from the cell culture supernatant were expressed 
as percentage of the overall expression level of a given fusion protein. To compare 
export of the various fusion proteins, secretion of Gal-1-GFP from CHOwild-type cells 
was set to 100%. The wild-type forms of both Gal-1-GFP and CGL-2-GFP are 
secreted from CHOwild-type cells; however, export is largely reduced when Gal-1-GFP 
and CGL-2-GFP are expressed in CHOclone13 cells. The various mutant forms of Gal-
1 and CGL-2 are neither exported from CHOwild-type nor from CHOclone13 cells to a 
significant extent. 
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Fig. 37 Quantification of export of galectin-GFP fusion proteins from CHOwild-type and CHOclone13 
cells employing cell surface biotinylation and immunoprecipitation from cell culture 
supernatants. The fusion proteins indicated were expressed in both CHOwild-type and 
CHOclone13 cells for 48 h at 37°C (6-well plates; 70% confluency). The medium was removed 
and subjected to immunoprecipitation using affinity-purified anti-GFP antibodies. Cell surfaces 
were treated with a membrane-impermeable biotinylation reagent. Following detergent-
mediated cell lysis, biotinylated and non-biotinylated proteins were separated employing 
streptavidin beads. Aliquots from the input material (0.25%), the biotinylated fraction (25%) 
and the immunoprecipitate from the cell culture medium fraction (25%) were analyzed by SDS 
PAGE and Western blotting using affinity purified anti-GFP antibodies. Primary antibodies 
were detected with alexa 680-coupled anti-rabbit secondary antibodies. Signal for Gal-1-GFP 
fusion proteins and GFP were quantified using a Li-COR Odyssey imaging system. The 
combined signals for the cell medium and the material associate with the cell surface were 
calculated as a percentage of total amounts of galectin-GFP fusion protein expressed in each 
case. These data were corrected for unspecific release as monitored by GFP present in the 
medium of the cells. The extracellular population of Gal-1-GFP secreted from CHOwild-type cells 
was set to 100%. 
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3.3.3.2.3 Subcellular distribution of Gal-1-GFP and CGL-2-GFP re-
porter molecules in CHOwild-type and CHOclone13 cells 
 
 Galectins are synthesized on free ribosomes in the cytosol and delivered to the 
outer leaflet of the plasma membrane. Mutations of single amino acids in human Gal-
1 and fungal CGL-2 may result in a change of cytosolic distribution leading to an 
export defect. To compare the subcellular distribution of Gal-1 and CGL-2 mutant 
forms with the corresponding wild-type proteins, the cell lines described above 
(3.3.3.2.2) were analyzed by confocal microscopy (Fig. 38).  
 In Fig. 38 a typical subset of Gal-1- and CGL-2-GFP reporter molecules 
deficient in export and binding to β-galactosides was analyzed employing confocal 
microscopy. CHO cells and CHOclone13 cells were grown on glass cover slips for 48 h 
at 37°C in the presence of doxicycline. In contrast to the live-imaging cells, fixed 
CHO cells and CHOclone13 cells were incubated with affinity-purified anti-GFP 
antibodies and anti-rabbit alexa 546 antibodies to detect GFP fusion protein bound to 
the cell surface. 
 When living CHOwild-type cells were visualized, all reporters were found in the 
cytoplasm as well as to some extent to the nucleus (Fig. 38, first column). In general, 
a similar picture was observed following fixation both for CHOwild-type and CHOclone13 
cells (Fig. 38, second and fourth column); however, in some cases aggregates or 
particulate structures were observed that apparently represent fixation artifacts. 
Consistent with the FACS experiments shown in Fig. 27, cell surface staining of all 
cell lines employing affinity-purified anti-GFP antibodies revealed an extracellular 
population in CHOwild-type cells only for the wild-type forms of Gal-1-GFP and CGL-2-
GFP (Fig. 38, third column). In CHOclone13 cells, cell surface staining could not be 
detected for any of the reporter molecules including the wild-type forms of Gal-1 and 
CGL-2 (Fig. 38, fifth column). 
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Fig. 38 Subcellular distribution of Gal-1-GFP and CGL-2-GFP reporter molecule in CHOwild-type 
and CHOclone13 as revealed by confocal microscopy. 1st row, Gal-1-GFP; 2nd row, Gal-1-
GFPW69G; 3rd row, Gal-1-GFPE72A; 4th row, CGL-2-GFP; 5th row, CGL-2-GFPW72G; 6th row, GFP. 
1st column, GFP live imaging; 2nd column, GFP imaging of fixed CHOwild-type cells; 3rd column, 
cell surface staining of fixed CHOwild-type cells employing affinity-purified anti-GFP antibodies; 
4th column, GFP imaging of fixed CHOclone13 cells; 5th column, cell surface staining of fixed 
CHOclone13 cells employing affinity-purified anti-GFP antibodies. 
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3.3.3.3 Characterization of Gal-1 mutants showing inconsistent 
phenotypes regarding export and binding to β-galactosides 
 
 Data obtained for some Gal-1 mutants were not consistent employing the 
known assays (3.2.2, 3.2.3, 3.2.4, 3.2.5) and therefore it was not possible to classify 
the various mutants. They do not have the same characteristics as the wild-type form 
of Gal-1 regarding export and binding ability employing the secretion and binding 
assays. However, they do also not behave like the identified mutants deficient in 
binding and export.  
 
 Fig. 39 shows the average of three independent experiments of the FACS-
based secretion assay. The expression level and the cell surface staining of wild-type 
Gal-1-GFP as positive control for secretion (standard condition: 1 µg/ml doxicycline, 
48 h), detected by affinity-purified anti-GFP antibodies followed by treatment with 
APC-conjugated secondary antibodies, was set to 100%. Several doxicycline con-
centrations ranging from 1 µg/ml to 0.02 µg/ml were applied to be able to compare 
cell surface signals obtained from mutant cell lines expressing the reporter molecules 
at different levels. GFP was used as a negative control for secretion (3.2.2). 
 To confirm independently the export behavior of the various mutant proteins the 
cell surface biotinylation assay in combination with immunoprecipitation from the cell 
culture medium was performed (Fig. 40). It is of great importance to combine these 
secretion assays with the analysis of β-galactoside binding ability to characterize 
each mutant. Therefore the binding ability was investigated using the CHO cell-based 
in vivo assay (Fig. 41) and the in vitro assay employing lactose-coupled beads (Fig. 
42). 
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Fig. 39 Quantitative analysis of export of various galectin-GFP fusion proteins from CHO cells 
employing flow cytometry. CHO cells were grown on 6-well plates and induced with 
doxicycline for 48 h at 37°C to express the fusion protein indicated. Following removal of 
medium, cells were labeled with affinity-purified anti-GFP antibodies followed by detachment 
of the cells using PBS/EDTA. GFP (expression level; blue) and APC-derived fluorescence 
(cell surface; red) were quantified by flow cytometry using Becton Dickinson FACSCalibur 
system (n=4) 
 
 The cell lines CHO Gal-1-GFPN51A, CHO Gal-1-GFPC61A, CHO Gal-1-GFPG70A, 
CHO Gal-1-GFPE87A and CHO Gal-1-GFPA95I showed inconsistent results concerning 
export and binding to β-galactoside-containing counter receptors. This is probably 
due to a reduced stability of the mutated proteins as indicated by low expression 
levels determined by the GFP fluorescence measured in the FACS-based assay. 
 
 Regarding the results of the secretion assays (Fig. 39 and Fig. 40) the mutants 
I90A, F92A, D126A and K130A were expressed and exported at levels comparable 
to the wild-type form of Gal-1. These observations are not consistent with the fact 
that these mutants were deficient in binding to β-galactosides employing lactose-
coupled beads (Fig. 42). Employing the in vivo binding assay all mutant showed a 
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reduced binging ability to β-galactoside-containing counter receptors on the cell 
surface of CHO cells (Fig. 41).  
 
Gal-1-GFPV32E: 
 
 The expression of the mutant protein V32E was slightly reduced (Fig. 39). 
However, the amount of expressed protein was sufficient to investigate the secretion 
from CHO cells employing flow cytometry and the cell surface biotinylation assay. 
The cell surface staining employing both secretion assays was reduced (Fig. 39, 10% 
cell surface staining; Fig. 40, lane 2 and 3). This mutant was able to bind to counter 
receptors analyzed by binding to CHO cells (Fig. 41, 52%) and to lactose-coupled 
beads (Fig. 42, lane 3). According to the ability to bind to its counter receptors, the 
mutation seems to cause a partial export defect independent of the ability to bind to 
β-galactosides.  
 
Gal-1-GFPV32W: 
 
 Changing the amino acid valin on position 32 into tryptophane (V32W) did not 
result in a reduced binding capacity to counter receptors (Fig. 41, 67%; Fig. 42, lane 
3). However, the cell surface signal employing flow cytometry (Fig. 39, 36%) and the 
biotinylation assay (Fig. 40, lane 2 and 3) was slightly reduced indicating that this 
mutant is also partially defective in export mutant without being impaired in binding to 
β-galactosides.  
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Gal-1-GFPL35A: 
 
 The FACS-based secretion assay (Fig. 39) and the cell surface biotinylation 
assay (Fig. 40) of the Gal-1 mutant L35A indicated no export and binding defect. In 
both assays there was protein bound to the cell surface comparable to the wild-type 
form of Gal-1. Investigating the binding properties of this mutant the binding ability 
was highly reduced (Fig. 41, 26%). Strikingly, no binding to lactose-coupled beads 
was detectable (Fig. 42, lane 3). According to both assays (Fig. 41 and Fig. 42) no 
exported protein should be able to bind to the cell surface. The cell surface signal 
may result from unspecific binding of this mutated protein. However, regarding the 
secretion assays this mutant seems to be exported. 
 
 
 
Fig. 40 Biochemical analysis of export of various galectin-GPF fusion proteins from CHO cells 
employing cell surface biotinylation and immunoprecipitation from cell culture super-
natants. The fusion proteins indicated were expressed in CHO cells for 48 h at 37°C (6-well 
plates; 70% confluency; 1 µg/ml doxicycline) The medium was removed and subjected to 
immunoprecipitation using affinity-purified anti-GFP antibodies. Cells were treated with a 
membrane-impermeable biotinylation reagent. Following detergent-mediated cell lysis 
biotinylated and non-biotinylated proteins were separated employing streptavidin beads. 
Aliquots from the input material (lane 1; 1%), the biotinylated fraction (lane 2; 10%) and the 
immunoprecipitate from the cell culture medium fraction (lane 3; 50%) were analyzed by SDS 
PAGE and Western blotting using affinity-purified anti-GFP antibodies. 
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Gal-1-GFPK37E: 
 
 The data obtained for the mutant Gal-1 K37E were highly inconsistent. Employ-
ing flow cytometry (Fig. 39) the expression level was comparable to the wild-type 
form of Gal-1. The cell surface staining detecting exported protein bound to the cell 
surface was reduced indicating that there is reduced export efficiency (Fig. 39, 26%). 
These results were confirmed by the cell surface biotinylation assay in combination 
with immunoprecipitation from cell culture medium (Fig. 40, lane 2, cell surface and 
lane 3, immunoprecipitation of the medium of expressing cell). Employing the in vivo 
binding assay the mutant was able to bind to the cell surface even better than the 
wild-type indicating that this mutation results in an export defect. Regarding the in 
vitro binding assay, which was not consistent with the in vivo assay, the binding 
ability was reduced, indicating that this mutant is impaired in binding and export. 
Taken together this mutant protein seems to be exported to a lower extent compared 
to the wild-type form of Gal-1.  
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Fig. 41 Analysis of β-galactoside binding efficiency of various galectin-GFP fusion proteins 
based on binding to CHO cells. The various fusion proteins indicated were expressed in 
CHO cells. Cell-free supernatant were prepared and normalized by GFP fluorescence. The 
various supernatants were then incubated with CHO cells for 1 h at 4°C to allow cell surface 
binding. Following treatment with affinity-purified anti-GFP antibodies and APC-conjugated 
secondary antibodies, cell surface binding was quantified by flow cytometry. 
 
Gal-1-GFPA68I: 
 
 The mutant A68I seemed to be impaired in binding and export. Both secretion 
assays (Fig. 39 and Fig. 40) indicated a reduced cell surface signal, which is 
consistent with hypothesis that binding to β-galactosides is required for Gal-1 export. 
The binding efficiency in the in vivo assay was reduced (Fig. 41, 20%), however, as 
analyzed by the in vitro assay, the ability to bind to lactose-coupled beads is 
comparable to the wild-type form of Gal-1.  
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Fig. 42 Analysis of β-galactoside binding efficiency of various galectin-GFP fusion proteins 
based on binding to lactose-coupled beads. Detergent lysates normalized by GFP fluores-
cence were incubated with lactose beads for 1 h at 4°C. The non-bound fraction was sepa-
rated and, following extensive washing, bound material was eluted with SDS sample buffer. 
Input (lane 1, 5%), non-bound material (lane 2, 5%) and bound material (lane 3, 5%) were 
analyzed by SDS PAGE and Western blotting using affinity-purified anti-GFP antibodies. 
 
Gal-1-GFPR112H: 
 
 The expression level of the mutant R112H based on the GFP fluorescence 
measured by the FACS was comparable to the wild-type form of Gal-1-GFP (Fig. 39, 
95%), whereas the exported fraction indicated by cell surface staining is largely 
reduced (Fig. 40, 27.5%). This is consistent with the data obtained from the cell 
surface biotinylation assay. There was an exported population bound to the cell 
surface, but the signal was clearly reduced compared to the wild-type form of Gal-1-
GFP. It is known from literature that this mutant does not result in a binding defect to 
β-galactosides (Lopez-Lucendo et al., 2004). Analyzing the binding ability employing 
the in vivo assay this observation could be confirmed (Fig. 41, 105%). However, the 
results obtained from the in vitro binding assay (Fig. 42) are not consistent with these 
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data. These observations suggest that mutant R112H is export-deficient without 
losing the ability to bind to its counter receptors. 
 
Mutation Phenotype 
Gal-1-GFP  
V32E Reduced expression in both secretion assays; reduced cell surface staining in both assays; no binding 
defect 
V32W Comparable expression in both secretion assays; reduced cell surface staining in both assays; no binding 
defect 
L35A No export and binding defect indicated by both secretion assays; binding ability is reduced in both binding 
assays 
K37E Employing flow cytometry, no binding and no export defect; employing biotinylation assay reduced cell 
surface staining; no binding defect in the in-vivo binding assay; reduced binding ability employing the in-
vitro binding assay 
N51A Very low expression level in both secretion assays; no cell surface staining; reduced binding ability in both 
binding assays 
C61A Low expression level in the FACS-based assay and biotinylation assay; binding defect 
A68I Impaired in binding and export employing flow cytometry, biotinylation assays and the in vivo binding 
assay; inconsistent data employing the in-vitro binding assay 
G70A Cell surface staining in both secretion assay; impaired in binding to β-galactosides in both binding assays 
E87A Cell surface staining employing the biotinylation assay; no cell surface staining employing flow cytometry; 
impaired in binding to β-galactosides in both binding assays 
I90A Cell surface staining in both secretion assay; impaired in binding to β-galactosides in both binding assays 
F92A Cell surface staining in both secretion assay; impaired in binding to β-galactosides in both binding assays 
A95I No detectable population on the cell surface employing flow cytometry; cell surface staining in the 
biotinylation assay; impaired in binding to β-galactosides in both binding assays 
R112H Reduced cell surface staining in both secretion assays; no binding defect employing both binding assays. 
D126A Cell surface staining in both secretion assay; impaired in binding to β-galactosides in both binding assays 
K130A Cell surface staining in both secretion assay; impaired in binding to β-galactosides in both binding assays 
 
Table 8 Summary of various human Gal-1 mutants 
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3.3.3.4 Characterization of truncated human Gal-1 
 
 The molecular structure of human Gal-1 involves a β-sandwich consisting of two 
antiparallel β-sheets of five (Fi-F5) and six (S1-S6a/b) strands, respectively. The N- 
and C-terminus of each monomer are positioned at the dimer interface and the 
carbohydrate recognition domains are located at the far ends of the same face of the 
surface, which presents a long negatively charged cleft in the cavity (Fig. 3). Dimer 
formation of galectins is important for their biological roles, based on bivalency, Gal-1 
has cross-linking properties. So far it is not known if Gal-1 is secreted as monomer or 
as homodimer. In order to investigate the influence of the dimer formation on the 
unconventional secretion of Gal-1, CHO cells expressing truncated versions of 
human Gal-1 as GFP fusion proteins were generated by retroviral transduction. 
Therefore either the N-terminus (Gal-1-GFP ∆N5, ∆N10 and ∆N20) or the C-terminus 
of Gal-1 (GFP-Gal-1 ∆C4, ∆C9, ∆C20, ∆C30, ∆C40, ∆C50) was deleted. Additionally, 
a clonal CHO cell line was generated expressing Gal-1 truncated at the N-terminus 
and the C-terminus (Gal-1-GFP ∆N10-C129). The orthologue CGL-2 was again used 
as additional positive control. Accordingly, CHO cells were generated to express 
truncated forms of CGL-2. The truncated galectins were investigated regarding 
export from CHO cells and β-galactoside binding ability employing the secretion and 
binding assays described in the previous sections. 
 
Fig. 43 shows the FACS-based secretion assay of the truncated Gal-1 fusion 
proteins. The expression level and the cell surface staining of Gal-1-GFP were set to 
100%.  
 
Results 
 
171 
 
 
Fig. 43 Quantitative analysis of export of various galectin-GFP fusion proteins from CHO cells 
employing flow cytometry. CHO cells were grown on 6-well plates and induced with 
doxicycline for 48 h at 37°C to express the fusion protein indicated. Following removal of 
medium, cells were labeled with affinity-purified anti-GFP antibodies followed by detachment 
of the cells using PBS/EDTA. GFP (expression level; blue) and APC-derived fluorescence 
(cell surface; red) were quantified by flow cytometry using Becton Dickinson FACSCalibur 
system (n=4). 
 
 The CHO cell lines Gal-1-GFP∆N10, CHO Gal-1-GFP∆N10-C129, CHO Gal-1-
GFP∆C4, CHO Gal-1-GFP∆C9, CHO Gal-1-GFP∆C20, CHO Gal-1-GFP∆C30, CHO Gal-1-
GFP∆C40, CHO Gal-1-GFP∆C50, CHO CGL-2-GFP∆C11, CHO CGL-2-GFP∆C11/S134E and 
CHO CGL-2-GFP∆C16 express the various GFP fusion protein at very low levels 
measured by the GFP fluorescence employing flow cytometry. This is most likely 
caused by reduced stability of these truncated proteins. Due to the low expression 
level it was difficult to analyze these mutants for their export behavior in CHO cells 
(Fig. 43).  
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Fig. 44 Biochemical analysis of export of various galectin-GPF fusion proteins from CHO cells 
employing cell surface biotinylation and immunoprecipitation from cell culture super-
natants. The fusion proteins indicated were expressed in CHO cells for 48 h at 37°C (6-well 
plates; 70% confluence; 1 µg/ml doxicycline) The medium was removed and subjected to 
immunoprecipitation using affinity-purified anti GFP antibodies. Cells were treated with a 
membrane-impermeable biotinylation reagent. Following detergent-mediated cell lysis biotiny-
lated and non-biotinylated proteins were separated employing streptavidin beads. Aliquots 
from the input material (lane 1; 1%), the biotinylated fraction (lane 2; 10%) and the immuno-
precipitate from the cell culture medium fraction (lane 3; 50%) were analyzed by SDS PAGE 
and Western blotting using affinity-purified anti-GFP antibodies. 
 
 To confirm the observations made by the FACS-based secretion assay, CHO 
cells expressing the truncated Gal-1 and CGL-2 GFP fusion proteins in a doxicycline-
dependent manner, were subjected to cell surface biotinylation assay in combination 
with immunoprecipitation of the cell culture medium to detect soluble exported 
protein. Since there was no cell surface signal and no precipitated material observed, 
it can be concluded that all these mutated proteins failed to get externalized by the 
mammalian export machinery (Fig. 44, lane 2). 
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Fig. 45 Analysis of β-galactoside binding efficiency of various galectin-GFP fusion proteins 
based on binding to CHO cells. The various fusion proteins indicated were expressed in 
CHO cells. Cell-free supernatant were prepared and normalized by GFP fluorescence. The 
various supernatants were then incubated with CHO cells for 1 h at 4°C to allow cell surface 
binding. Following treatment with affinity-purified anti-GFP antibodies and APC-conjugated 
secondary antibodies, cell surface binding was quantified by flow cytometry. 
 
Investigating the binding ability of these mutant proteins to β-galactoside-containing 
counter receptors, cell-free supernatant of the various GFP reporter molecules was 
incubated with CHO cells in order to allow binding of the truncated GFP fusion 
proteins to the cell surface. Following incubation with affinity-purified anti-GFP 
antibodies and secondary APC-conjugated antibodies, binding to cell surface was 
measured by flow cytometry (Fig. 45). Binding of Gal-1-GFP to CHO cell was set to 
100% and GFP was used as negative control. For the in vitro assay detergent lysates 
of the various GFP fusion proteins were incubated with lactose-coupled beads. The 
binding ability was analyzed by SDS-PAGE and Western blotting using affinity-
purified anti-GFP antibodies. None of the GFP fusion protein was able to bind to its 
ligand employing the in vivo and the in vitro binding assay (Fig. 45 and Fig. 46). 
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Fig. 46 Analysis of β-galactoside binding efficiency of various galectin-GFP fusion proteins 
based on binding to lactose-coupled beads. Detergent lysates normalized by GFP fluores-
cence were incubated with lactose beads for 1 h at 4°C. The non-bound fraction was sepa-
rated and, following extensive washing, bound material was eluted with SDS sample buffer. 
Input (lane 1, 5%), non-bound material (lane 2, 5%) and bound material (lane 3, 5%) were 
analyzed by SDS PAGE and Western blotting using affinity purified anti-GFP antibodies. 
 
 As shown in Fig. 43 the expression of the N-terminal truncations ∆N5 and ∆N20 
was induced in the presence of doxicycline. The cell surface signal of Gal-1-GFP∆N5 
was slightly reduced as compared to Gal-1-GFP. The export efficiency of Gal-1-
GFP∆N20 was similar to the wild-type form of Gal-1-GFP as indicated by the cell 
surface signal employing flow cytometry. The data obtained in the biotinylation assay 
were consistent with the observations made in the FACS-based secretion assay (Fig. 
44). Investigating binding to the cell surface and to lactose-coupled beads Gal-1-
GFP∆N5 was able to interact with β-galactosides in both assays (Fig. 45 and Fig. 46). 
The truncation ∆N20 resulted in a loss of binding ability to counter receptors in the in 
vivo and in the in vitro assay. However, these observations are not consistent with 
the fact that ∆N20 was detectable bound to the cell surface employing both secretion 
assays (Fig. 45 and Fig. 46). Further studies are needed to clarify this contradiction. 
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 Taken these observations together it is difficult to conclude whether dimer 
formation is required for export. However, if the deletion of the N- or C-termini results 
in a defect in binding to counter receptors on the cell surface, an export defect was 
observed, consistent with the hypothesis that binding to β-galactosides is required for 
the unconventional secretion of Gal-1. 
Discussion 
 
176 
4 Discussion 
 
 The majority of extracellular proteins is exported from mammalian cells by the 
ER/Golgi-dependent secretory pathway, which is well characterized at the molecular 
level. All eukaryotic cells from yeast to man are characterized by this secretory 
machinery that recognizes signal peptide-containing proteins resulting in their trans-
location across the membrane of the endoplasmic reticulum (ER) (Schatz and 
Dobberstein, 1996). Once localized to the lumen of the ER, secretory proteins are 
packaged into transport vesicles provided they pass ER quality control measures, a 
process that results in cargo delivery to the Golgi apparatus (Lee et al., 2004). Upon 
fusion of post-Golgi transport carriers with the plasma membrane, classical secretory 
proteins get released into the extracellular space (Keller and Simons, 1997; Palade, 
1975).  
 In addition to signal peptide-containing secretory proteins, a heterogeneous 
group of extracellular proteins has been discovered that does not make use of signal 
peptide-dependent secretory transport. Both the release mechanisms and the 
molecular identity of the secretory machineries involved have remained elusive while 
these secretory proteins have defined extracellular functions, they do not contain 
functional signal peptides and, consistently, are rejected by the ER membrane 
translocation machinery (Cleves, 1997; Hughes, 1999; Nickel, 2003; Nickel, 2005; 
Prudovsky et al., 2003). Furthermore, the extracellular appearance of such molecules 
is not compromised in the presence of brefeldin A (BFA), a drug that blocks 
ER/Golgi-dependent secretory transport. These observations led to the postulation of 
alternative secretory mechanisms in eukaryotic cells that are fully functional in the 
absence of an intact ER/Golgi system. Interestingly, unconventional secretory 
proteins comprise a group of molecules of high biomedical relevance such as the 
proangiogenic growth factor FGF-2. FGF-2 is a tumor-produced, direct-acting 
stimulator of angiogenesis, a process that is essential for tumor growth and 
metastasis (Nugent and Iozzo, 2000). Other examples include inflammatory 
cytokines such as interleukin 1β (Braddock and Quinn, 2004) and migration inhibitory 
factor (MIF) (Lue et al., 2002) as well as a family of stage-regulated surface 
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molecules from Leishmania parasites termed hydrophilic acylated surface proteins 
(HASP) implicated in host cell infection (Denny et al., 2000; Stegmayer et al., 2005).  
 
 Gal-1 is another remarkable member of unconventionally secreted proteins. 
This lectin of the extracellular matrix is involved in many cellular processes like 
differentiation, proliferation, cell adhesion and tumor-mediated immune suppression 
(Perillo et al., 1995) and binds to β-galactosides on glycoproteins and glycolipids of 
the plasma membrane. By elucidating the molecular machinery, it would be possible 
to develop or to find inhibitors, which specifically block secretion of Gal-1. Therefore 
one aim of the present thesis was to establish an experimental system based on 
genetically modified CHO cell lines to investigate the export of Gal-1 in vivo. 
Additionally, interacting proteins with Gal-1 were isolated and analyzed for a potential 
function in the molecular export mechanism of Gal-1 employing the established cell 
system. Furthermore, based on this system single amino acid mutants of Gal-1 were 
generated to identify the export targeting motif by investigating their export behavior 
and their binding ability to β-galactosides.  
 
4.1 Identification and characterization of CA125 as a Gal-1 
counter receptor  
 
 Protein-protein and protein-carbohydrate interaction studies were performed in 
order to affinity-purify proteins that interact with human Gal-1. Employing mass 
spectrometry one of the obtained Gal-1 interacting partners was identified as CA125. 
This conclusion was drawn from the fact that 16 tryptic peptides could be identified 
as parts of the translation product of the cDNA clone AK024365 (NCBI) that, based 
on sequence information reported by laboratories of Lloyd and O’Brien, encodes the 
1148 C-terminal amino acids of CA125 (CA125-C-TERM) (O'Brien et al., 2001; Yin 
and Lloyd, 2001). These results were confirmed by immunological identification of 
CA125-derived antigens by both the original anti-CA125 antibody OC125 (Bast et al., 
1981) and a rabbit antiserum directed against the N-terminal 356 amino acids of 
CA125-C-TERM. Since the majority of the material bound to the Gal-1 affinity matrix 
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was eluted with lactose, it was concluded that the interaction is galactose dependent. 
These data were confirmed by experiments demonstrating that the interaction 
between CA125-C-TERM and Gal-1 both in vitro and in vivo is almost completely 
abolished when CA125-C-TERM is expressed in a CHO mutant that is deficient for 
galactosylation of glycoproteins and glycolipids (Deutscher and Hirschberg, 1986). 
Interestingly, CA125-C-TERM binding to Gal-1 is only partially inhibited when cells 
were grown in the presence of tunicamycin, a drug that inhibits N-glycosylation. 
These data demonstrated that the interaction of CA125-C-TERM with Gal-1 largely 
depends on O-linked β-galactose-terminated oligosaccharide chains.  
 
 CA125 was originally discovered by Bast and colleagues using the ovarian cell 
line OVCA433 as an immunogen for the generation of monoclonal antibodies (Bast et 
al., 1981). However, ever since, the molecular identity and biological function of the 
CA125 cancer antigen has remained elusive. From immunological studies, CA125 is 
known to be present on the cell surface of ovarian cancer cells; however, it has also 
been found in other carcinomas and, to a limited extent, in normal secretory tissues 
(Hardardottir et al., 1990; O'Brien et al., 2001; Zurawski et al., 1988). The results may 
provide the first insight into a potential biological function of CA125, as there exists a 
link to a family of β-galactoside-specific lectins of the ECM, the galectins (Barondes 
et al., 1994; Hughes, 1999; Perillo et al., 1998; Rabinovich et al., 2002a). This 
observation might be of significant biomedical importance, since galectins 
themselves are tumor markers involved in the regulation of cell proliferation and 
tumor progression (Perillo et al., 1998). In this context, CA125 cell surface 
expression by tumor tissues might effect cell attachment to the ECM in a Gal-1-
dependent manner (Seelenmeyer et al., 2003). 
 Two research groups independently succeeded in cloning the gene that 
encodes CA125 (O'Brien et al., 2001; Yin and Lloyd, 2001), showing that CA125 is a 
giant mucin-like glycoprotein that consists of more than 11,000 amino acids. Full-
length CA125 has been suggested to represent a type I transmembrane protein with 
a single membrane-spanning domain close to the C-terminus. The extracellular 
domain contains repeat structures that are likely to be heavily O-glycosylated 
(O'Brien et al., 2001). Besides its nature as an integral membrane protein, soluble 
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fragments of CA125 have been observed (Fendrick et al., 1997; Lloyd and Yin, 
2001). Apparently, phosphorylation of the cytoplasmic domain causes extracellular 
cleavage of the N-terminal domain, which results in the release of soluble fragments 
into the extracellular space (Fendrick et al., 1997; Lloyd and Yin, 2001). 
 
4.2 Specificity of CA125 binding to Galectins 
  
 Gal-1 is the primary ligand for CA125 in comparison to Gal-3 (Seelenmeyer et 
al., 2003), the second most-abundant member of the galectin family. The observed 
interaction does not appear to represent a simple carbohydrate-lectin-interaction but 
rather depends on additional aspects of specificity based on the proteinaceous 
environment. Moreover, as CA125-C-TERM expressed in CHO cells showed an even 
higher preference towards binding to Gal-1, it seems that the cellular background in 
which CA125 is expressed also has a significant influence on its binding efficiency for 
members of the galectin family. Therefore, on the basis of these experiments, CA125 
represents a specific galectin counter receptor with Gal-1 as the primary ligand. 
Since CA125 expression appears to be largely restricted to tumor cells, it seems 
likely that tumor cell attachment to the ECM can be modulated in a Gal-1 dependent 
manner (Seelenmeyer et al., 2003). 
 CA125-C-TERM encodes about three O-glycosylated repeat structures and the 
N-and O-glycosylated stalk structure of the extracellular domain, the transmembrane 
span and the cytoplasmic domain of full-length CA125. These structural features are 
consistent with the finding that CA125-C-TERM retains binding activity towards Gal-
1. Intriguingly, expression of this construct in both CHO and HeLa cells results in 
CA125-C-TERM cell surface expression. In spite of the lack of an N-terminal signal 
peptide in both full-length CA125 and CA125-C-TERM, CA125-C-TERM cell-surface 
localization is mediated by ER/Golgi dependent secretory transport. Thus, CA125 
represents a classical secretory cargo protein whose molecular mechanism of 
insertion into the membrane of the ER might be interesting to investigate. As signal-
peptide-independent mechanisms of protein insertion into the ER have been 
described (Kutay et al., 1995), it will also be of interest to analyze how CA125 ER 
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insertion compares with these known processes. In the case of CA125 its signal 
sequence might to be internal. An internal signal sequence leads the ribosome to the 
ER membrane. Like the N-terminal ER signal sequence, the internal signal sequence 
is recognized by an SRP, which brings the ribosome to the ER membrane and 
serves as a start-transfer signal that initiates the translocation of the protein. After 
release from the translocator, the internal start transfer sequence remains in the lipid 
bilayer as a single membrane-spanning α-helix. Internal start-transfer sequences can 
bind to the translocation apparatus in two orientations. The orientation of the inserted 
start-transfer sequence determines, which protein segment is moved across the 
membrane into the ER lumen. In one case, the resulting membrane protein has its C-
terminus on the luminal side, while in other, it has its N-terminus on the luminal side. 
The orientation of the start-transfer sequence depends on the distribution of nearby 
charged amino acids. Moreover, given its huge size of more than 11.000 amino acids 
additionally the mucin-like levels of glycosylation, questions arise about the mode of 
intracellular transport on its way to the cell surface.  
 In order to investigate the relevance of the reported interaction regarding the 
origin of the cell lines used, non-tumor derived CHO cells (Puck et al., 1958) and the 
Cervix carcinoma cell line S-HeLa (Gey et al., 1952; Scherer et al., 1953) were 
compared for CA125 expression. While fragments of endogenous CA125 from the S-
HeLa cell line could be isolated, no CA125 fragments bound to the Gal-1 affinity 
matrix could be detected when CHO cells were used as source for Gal-1 interacting 
proteins. This observation is consistent with the detection of endogenous cell surface 
CA125 in HeLa cells and the lack of surface localized CA125 in CHO cells based on 
flow cytometry. Moreover, these data are consistent with studies that suggest that 
CA125 is expressed primarily in tumor tissues. Employing the FACS based in vivo 
assay, developed in this thesis, HeLa cells were characterized by more than tenfold 
higher levels of cell-surface Gal-1 when compared with CHO cells. It was shown that 
CHO and HeLa cells do not differ with regard to total expression levels of Gal-1 as 
well as cell surface binding capacity for Gal-1. Therefore, HeLa cells seem to be 
significantly more efficient in the unconventional secretion of Gal-1 compared to CHO 
cells (Seelenmeyer et al., 2003).  
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4.3 CA125 expression does not stimulate Gal-1 export 
 
 On the basis of the experimental observations mentioned above, it was 
postulated that CA125-expressing HeLa cells possess a more efficient export 
pathway for Gal-1 than CA125-deficient CHO cells. However, CA125 expression 
does not stimulate Gal-1 export as HeLa cells express CA125 on their cell surface 
only in small amounts. The reason for the more efficient Gal-1 export from HeLa cells 
compared to CHO cells is likely to be the altered glycosylation pattern on the cell 
surface of tumor-derived cells rather than a single counter receptor present on the 
cell surface. Changes in glycan composition are a universal feature of cancer cells 
(Hakomori, 1986; Wickus and Robbins, 1973), and certain types of glycan structures 
are well-known markers for tumor progression (Feizi, 1985; Hakomori, 1986). Like 
normal cells during embryogenesis, tumor cells undergo activation and rapid growth, 
adhere to a variety of other cell types and cell matrices, and invade tissues. 
Embryonic development and cellular activation in vertebrates are typically 
accompanied by changes in cellular glycosylation profiles. Thus, it is not surprising 
that glycosylation changes are also a universal feature of malignant transformation 
and tumor progression (Bhaumik et al., 1998; Kang et al., 1996).  
 The classic reports of increased size of tumor cell glycopeptides have been 
convincingly explained (Yoshimura et al., 1995) by an increase in β1-6 branching of 
N-glycans, which results from an enhanced expression of GlcNAc transferase V 
(Demetriou et al., 1995; Hakomori, 1986). GlcNAc transferase V plays a very im-
portant role in cancer biology (Demetriou et al., 1995). The increased expression of 
GlcNAc transferase V may cause an increase of polylactosamine chains, which are 
recognized by galectins. The higher amount of Gal-1 counter receptors seems to be 
responsible for the more efficient export of Gal-1.  
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4.4 Analysis of Gal-1 and CGL-2 regarding export to the 
cell surface and binding to β-galactosides 
 
 The phenomenon of non-classical protein secretion has been known for more 
than 15 years (Cooper and Barondes, 1990; Rubartelli et al., 1990); however, the 
molecular machinery mediating this process remains elusive. It is even unclear 
whether the various proteins known to be secreted by non-conventional means make 
use of a common molecular mechanism (Hughes, 1999). In fact, distinct machineries 
seem to mediate different export processes. For example, the mechanism of IL-1β 
secretion seems to involve intracellular vesicles (Andrei et al., 1999) whereas Gal-1 
is likely to be externalized by plasma membrane blebbing (Mehul and Hughes, 1997). 
Another example are the distinct characteristics of FGF-1 versus FGF-2 secretion 
since FGF-1 export is sensitive to heat shock (Jackson et al., 1992), whereas FGF-2 
export is not (Mignatti et al., 1992). The relatively poor knowledge about the 
molecular components involved in these processes emphasizes the need for 
establishing novel experimental systems in order to reveal the molecular 
mechanisms of unconventional secretory processes. 
 A key aspect of this study was to reconstitute Gal-1 secretion in living cells 
based on read-out methods that provide a precise and quantitative analysis of its 
export process. Therefore, genetically modified CHO cell lines stably expressing N- 
and C-terminally GFP-tagged Gal-1 in a doxicycline-dependent manner were 
generated as follows: CHO cells were transfected with the mouse orthologue of the 
cationic amino acid transporter (MCAT-1), thereby making them permissive to 
ecotropic retroviruses (Albritton et al., 1989; Davey et al., 1997). After virus-mediated 
introduction of a doxicycline-sensitive transactivator (Urlinger et al., 2000) the various 
galectin-GFP cDNA constructs were integrated into the genomic DNA of the host 
cells by retroviral transduction (Engling et al., 2002). Following several rounds of 
FACS sorting cell pools were isolated and functionally characterized with regard to 
non-conventional secretion of the galectin reporter molecules. Two independent 
approaches were established to analyze the export of Gal-1-GFP fusion proteins.  
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i) FACS-based secretion assays. Based on this assay, it was possible to 
quantitatively assess the amount of Gal-1 released to the extracellular 
space in living cells. Following its unconventional secretion Gal-1-GFP 
binds to β-galactosides of glycolipids and glycoproteins on the outer leaflet 
of the plasma membrane. This allows specific detection of secreted Gal-1-
GFP with affinity-purified anti-GFP antibodies under native conditions. 
Following antibody processing the cells could be analyzed with regard to 
GFP fluorescence and cell surface signal by flow cytometry. GFP-derived 
fluorescence was used to normalize the overall expression of the reporter 
molecule under various experimental conditions. 
 
ii) Biochemical secretion assay employing cell surface biotinylation. In order 
to demonstrate an external population of Gal-1-GFP fusion proteins 
associated with cell surface using an independent approach, a biochemical 
method was established employing a membrane-impermeable biotinylation 
reagent. After detergent-mediated cell lysis exported biotinylated proteins 
bound to the plasma membrane were isolated by streptavidin-coupled 
beads. This assay was combined with immunoprecipitation analysis of the 
cell culture medium using affinity-purified anti-GFP antibodies. Based on 
this approach, it was possible to investigate exported Gal-1 bound to 
counter receptors on the cell surface (Stegmayer et al., 2005) as well as 
soluble material potentially present in the cell culture supernatant 
(Seelenmeyer et al., 2005).   
 
 One aim of this thesis was to identify an export targeting motif in Gal-1 which 
directs the protein to its export machinery. Therefore single site mutations were 
generated in Gal-1. Since mutations in Gal-1 potentially result in an altered binding 
ability to β-galactosides, binding properties of N- and C-terminal GFP-tagged Gal-1 to 
β-galactosides were investigated as well. Therefore, two independent assays were 
established. 
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iii) In vivo binding of Gal-1-GFP to β-galactoside-containing counter receptors 
on the cell surface of CHO cells. For the in vivo binding assay cell-free 
supernatants of CHO cells expressing the various Gal-1 reporter molecules 
were incubated with CHO cells not expressing the GFP fusion protein to 
allow binding to the cell surface. This assay allows analyzing Gal-1 binding 
under native conditions employing flow cytometry using affinity-purified 
anti-GFP antibodies. 
 
iv) In vitro binding of Gal-1 to lactose. This in vitro assay was developed to 
assess the lactose binding capacity of Gal-1. For this purpose detergent 
lysates of CHO cells expressing various Gal-1-GFP reporter molecules 
were generated. After incubation with lactose-coupled beads, binding was 
analyzed by Western blotting using affinity-purified anti-GFP antibodies. 
However, binding to lactose-coupled beads does not reflect the conditions 
present in the extracellular space in vivo, as the proteinaceous environ-
ment can also influence binding of Gal-1 to its natural ligands 
(Seelenmeyer et al., 2003). 
 
 These four mentioned assays were used to characterize Gal-1 mutants 
obtained by random mutagenesis, site-directed mutagenesis and N-and C-terminal 
truncations.  
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4.5 Mutational analysis of the export targeting motif of 
Gal-1 and CGL-2 
 
 In order to identify a putative export targeting motif in Gal-1, the experimental 
systems described above were used to systematically analyze Gal-1 mutant proteins. 
97 individual CHO cell lines expressing single mutants and truncated versions of Gal-
1-GFP and CGL-2-GFP fusion proteins were generated by stable integration of the 
corresponding DNA constructs into the genome of CHO cells using retroviral 
transduction. As control cell lines CHOGal-1-GFP, CHOGFP-Gal-1, CHOGFP-CGL-2 and 
CHOGFP were used.  
 
 The individual mutants were selected in three different ways:  
 
i) Targeted mutagenesis based on results obtained from a random muta-
genesis approach. A low fidelity PCR was performed in the presence of 
100 µM MnCl2 using the ORF of Gal-1 as template, thereby multiple 
mutants were randomly inserted into Gal-1. After retroviral transduction of 
CHO cells with the corresponding plasmids Gal-1-GFP mutants character-
ized by an altered secretion and binding efficiency as compared to Gal-1-
GFP were identified. All amino acid changes were individually introduced 
into Gal-1 by site-directed mutagenesis in order to investigate the effect of 
every single amino acid exchange regarding export and binding of mutated 
Gal-1-GFP proteins. 
 
ii) Targeted mutagenesis of surface residues based on the crystal structure of 
Gal-1 (Liao et al., 1994). The crystal structure of human Gal-1 was ana-
lyzed for amino acids exposed on the protein surface as potential sites for 
interactions with other proteins responsible for the translocation process. 
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iii) Targeted mutagenesis of residues conserved between human Gal-1 and 
CGL-2 from Coprinopsis cinerea. The primary structures of human Gal-1 
and the fungal galectin CGL-2 were analyzed for conserved amino acids 
although the homology between these two lectins is very weak at the level 
of both the primary and the quaternary structure (Lobsanov et al., 1993) 
(Walser et al., 2004). However, the tertiary structure of CGL-2 shows the 
typical galectin fold and, additionally, CGL-2 specifically binds to β-galacto-
sides.  
 
iv) Dimerization. It has been shown for FGF-1 to be released as a homodimer 
in an unconventional manner in response to temperature stress (Tarantini 
et al., 1995). One feature of Gal-1 that has particular biological relevance is 
the quaternary structure that is important with regard to ligand cross-linking 
and Gal-1-mediated signal transduction (Lopez-Lucendo et al., 2004). 
Kinetic studies of wild-type and mutant CGL-2 proteins demonstrate that 
the tetrameric organization is essential for functionality (Walser et al., 
2004). Therefore the N-terminus and the C-terminus, which form the dimer 
interface in Gal-1, were truncated in order to investigate whether dimer 
formation influences the translocation process. 
 
 Generally, the original amino acids were replaced by alanine residues, which 
represents a small, uncharged hydrophobic amino acid that is considered as neutral. 
The various mutations were generated by site-directed mutagenesis and the corres-
ponding constructs were stably integrated into the genome of CHO cells by retroviral 
transduction. Cell pools expressing the corresponding mutated Gal-1-GFP fusion 
protein in the presence of doxicycline were generated by FACS sorting (Fig. 22). 
These pools were characterized regarding unconventional secretion and binding 
efficiency to β-galactoside-containing counter receptors. About 31% of the analyzed 
CHO mutants showed the same phenotype as the wild-type form of Gal-1-GFP. 51% 
of the mutants were found to be impaired in export and binding to β-galactosides. 6% 
of the generated mutant cell lines resulted in low expression levels as measured by 
the GFP fluorescence indicating that the mutation causes overall protein instability. 
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The analysis of about 12% of the generated mutant proteins did not provide 
consistent results regarding quantitation of unconventional secretion and binding to 
β-galactosides.  
 
4.5.1 Galectin mutants deficient in binding to β -galactosides are 
also deficient in export from CHO cells  
 
 Various mutated Gal-1-GFP reporter molecules were stably integrated into the 
genome of CHO cells (4.4). After FACS sorting based on GFP fluorescence the 
generated cell pools expressed the corresponding GFP reporter molecules in a 
doxicycline-dependent manner. With these inducible cell lines it was possible to 
investigate the binding and export behavior of mutated Gal-1-GFP fusion proteins. As 
already mentioned it was suggested that counter receptors might influence the export 
efficiency of unconventionally secreted proteins (Seelenmeyer et al., 2003). 
Therefore, a focus of the mutational analysis was to identify Gal-1 mutants that are 
deficient in binding to β-galactosides. Employing the described binding assays (4.4) 
43 single site mutations in Gal-1 were identified which result in a binding defect to β-
galactoside-containing ligands. To analyze whether these binding mutants are also 
defective in export, secretion of the mutated Gal-1-GFP fusion proteins was analyzed 
employing flow cytometry and the biotinylation assay. Since only proteins bound to 
the cell surface are detectable by these methods, no signals were observed when 
analyzing β-galactoside binding deficient mutants. To investigate whether exported 
Gal-1-GFP mutant proteins can be found in the cell culture medium of expressing 
cells, immunoprecipitation was performed using affinity-purified anti-GFP antibodies. 
Strikingly, not a single Gal-1 mutant deficient in binding to β-galactosides could be 
detected in the extracellular space (3.3.3.2). A similar observation was made 
concerning the unconventionally secreted protein FGF-2, which binds to heparan 
sulfate proteoglycans (HSPG) on the cell surface of CHO cells (Schäfer et al., 2004). 
To analyze the influence of HSPGs on the export process sodium chlorate was 
added to CHO cells. This substance competes with sulfate ions for binding to the 
ATP-sulfyrulase and inhibits thereby the generation of heparan sulfates (Klaassen 
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and Boles, 1997; Safaiyan et al., 1999). Subsequently, plasma membrane derived 
inside-out vesicles were generated from these cells and applied to an in vitro 
secretion assay that allows to analyze the translocation process of exogenously 
added FGF-2 by protease protection experiments (Schäfer et al., 2004). Interestingly, 
FGF-2 failed to traverse the membrane of inside-out vesicles derived from sodium 
chlorate treated CHO cells (Tobias Schäfer, personal communication). In addition, it 
was shown that CHOpgsA-745 cells, a CHO mutant cell line which lack glycosyl-
aminoglycans on their cell surface, do not secrete FGF-2 employing flow cytometry 
and the cell surface biotinylation assay (Christoph Zehe, personal communication). 
 
 It was shown previously that single site mutations can influence the stability of 
Gal-1 (Cho and Cummings, 1995a; Hirabayashi and Kasai, 1991; Lopez-Lucendo et 
al., 2004) and galectins are generally sensitive to the redox state of the environment. 
Upon entering the oxidizing milieu of the extracellular space, stabilization of galectins 
is achieved through binding to their ligands (Cho and Cummings, 1995a). Therefore, 
when a mutation results in a binding defect to β-galactosides, it is of great importance 
to investigate whether the absence of Gal-1 reporter molecules in the medium is due 
to an export defect or a result of protein degradation. Therefore, cell-free 
supernatants of the various Gal-1-GFP fusion proteins were diluted in conditioned 
medium derived from CHO cells. The proteins were either immediately subjected to 
immunoprecitation using affinity-purified anti-GFP antibodies or first incubated under 
the experimental conditions applied in the secretion assays, as they were found to be 
stable up to 48 hours of incubation at 37°C. 
 Employing this assay it was possible to exclude that the absence of Gal-1-GFP 
in the cell culture medium of expressing cells results from degradation of the various 
mutated proteins. 
 
 To further verify that a functional interaction between Gal-1 and its counter 
receptors is essential for its translocation process, secretion was analyzed in a 
somatic CHO mutant cell line (CHOclone13) defective in a Golgi-resident transporter 
that is required for translocation of activated galactose from the cytoplasm into the 
lumen of the Golgi, a process essential for the generation of β-galactoside-containing 
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glycolipids and glycoproteins (Deutscher and Hirschberg, 1986). Intriguingly, wild-
type Gal-1 fails to get exported from this mutant cell line demonstrating that indeed 
secretion of Gal-1 from mammalian cells strictly depends on a functional interaction 
between Gal-1 and its counter receptors. Interestingly, Gal-1 from CHOclone13 cells 
export can be reconstituted when the cells co-cultivated with CHOwild-type cells that do 
not express the fusion protein (Julia Ritzerfeld, personal communication). In this case 
CHOwild-type cells provide the β-galactoside-containing counter receptors on the cell 
surface required for the unconventional secretion of Gal-1-GFP. 
 Additionally, these data are supported by findings on CGL-2, a distant relative 
of Gal-1 from the multicellular fungus Coprinopsis cinerea. Even though similarities 
between CGL-2 and Gal-1 are very weak at the level of the primary structure 
(Lobsanov et al., 1993; Walser et al., 2004), CGL-2 is recognized by mammalian 
cells as an export substrate. Strikingly, a single-site mutation (W72G) that is known 
to cause CGL-2 binding deficiency to β-galactosides (Walser et al., 2004) results in a 
block of export of CGL-2 from CHO cells, consistent with our findings that functional 
interactions with counter receptors are essential for the overall export process. 
 
4.5.2 Characterization of N- and C-terminal truncated forms of  
Gal-1 
 
 As already mentioned Gal-1 is able to form homodimers consisting of 14 kDa 
subunits each containing a single carbohydrate-binding site. The lectin is synthesized 
in the cytosol of mammalian cells where it accumulates in a monomeric form and is 
actively, but slowly secreted (
  
! 
t
1 2
"  20 h). The exported form requires glycoconjugate 
ligands to fold properly and acquire stability. The functional lectin exists in a 
monomer-dimer equilibrium with a Kd of ~ 7 µM and a slow equilibrium rate 
(
  
! 
t
1 2
"  10 h) (Cho and Cummings, 1995b). To explore functional differences between 
monomeric and dimeric forms regarding the unconventional secretion of human Gal-
1, mutants truncated at the extreme N- and C-terminus, which are involved in subunit 
interactions, were generated. After retroviral transduction of the truncated reporter 
molecules, the corresponding CHO cells expressed the GFP fusion proteins in a 
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doxicycline-dependent manner. These CHO cells were characterized with regard to 
secretion and binding efficiency to β-galactosides employing the four read-out 
systems described above (4.4). All truncated versions of Gal-1-GFP resulted in 
decreased protein stability as indicated by lowered protein amounts per cell except 
Gal-1-GFP∆N5 and Gal-1-GFP∆N20, which were characterized by normal expression 
levels and export efficiency as compared to the wild-type form of Gal-1-GFP. 
Additionally, all of these truncated forms of Gal-1-GFP including Gal-1-GFP∆N20 were 
impaired in binding to their counter receptors, whereas Gal-1-GFP∆N5 showed wild-
type characteristics. Based on the stability problems of these truncated versions it 
was difficult to analyze their export behavior.  
 Hydrophobic interactions between amino acid side chains seem to occur mainly 
between amino acids on the first β-strands (residues 5-8) at the N-terminus and 
amino acids on the last β-strand (residues 127-133) at the C-terminus. Precisely, 
dimer formation appears to result mainly from interactions between Val 6 of monomer 
A and Ala 7 on monomer B, Ile 129 on monomer A and Phe 134 of monomer B, and 
Phe 134 on monomer A and Ile 129 of monomer B. Mutating these amino acid 
residues to hydrophilic amino acids results in impaired dimer formation (Cho and 
Cummings, 1996). Therefore, in addition to the N- and C-terminal truncations 
described above, the mutant cell lines CHO Gal-1-GFPV6A, CHO Gal-1-GFPI129R, 
CHO and CHO Gal-1-GFPF134E were generated and analyzed regarding export and 
binding to β-galactosides.  
 Cho and colleagues investigated the mutant Gal-1V6D for binding to lactosyl-
sepharose and observed that this mutation drastically affects carbohydrate-binding 
activity (Liao et al., 1994). Results of native gel electrophoresis, density gradient 
sedimentation, and size-exclusion HPLC demonstrate that Gal-1V6D exists as 
monomeric species. It was reasoned that the apparent reduced affinity of Gal-1V6D to 
lactosyl-sepaharose could result from its inability to dimerize. Further experiments 
are needed to analyze the influence of dimer formation on the unconventional 
secretion of Gal-1-GFP and on the binding ability. Analysis of GFPV6A, Gal-1-
GFPI129R, Gal-1-GFPF134E and Gal-1-GFPF134E by native gel electrophoresis, density 
gradient sedimentation and size-exclusion HPLC of Gal-1- may give new insights in 
the translocating process of Gal-1 in mammalian cells. 
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4.6 Detailed analysis of Gal-1-GFPR112H  
 
 Reflecting the strict conservation of a set of crucial amino acid residues as 
galectin sequence signature, the general architecture of the carbohydrate-binding 
site in human Gal-1 is very similar to that observed in other members of the galectin 
family, encompassing the antiparallel β-strands S4-S6a/S6b on the concave face of 
one β-sheet. The highly conserved amino acid residues involved in interactions with 
the bound disaccharide lactose are His 45, Asn 47, Arg 49, Val 60, Asn 62, Trp 69, 
Glu 72 and Arg 74 and they are invariably found in these β-strands (Lopez-Lucendo 
et al., 2004). In particular, Trp 69 participates in stacking interactions with carbons 
C3, C4 and C5 on the b-face of the galactose ring. This moiety is crucial to 
distinguish galactose from glucose through its preference for the axial hydroxyl-group 
on C4. With respect to the R112H mutant the substitution introduced accounts for a 
notable alteration of the architecture of the carbohydrate-binding site. As a 
consequence of this mutation the highly conserved amino acids His 53 and Trp 69 
are shifted from their original position. This shift did not result in loosing the ability to 
bind to β-galactosides as demonstrated by thermodynamic binding studies (Lopez-
Lucendo et al., 2004). Although this observation was confirmed by the in vivo binding 
assay (Fig. 41) the recognition of β-galactosides may be influenced as binding to 
lactose-coupled beads did not longer occur (Fig. 42). This observation provides 
evidence that beside sugar moieties a carbohydrate-lectin interaction depends on 
additional aspects of specificity based on the proteinaceous environment 
(Seelenmeyer et al., 2003). Similar results regarding export and binding to β-
galactosides were obtained for Gal-1-GFPV32E. 
 A possible explanation for the potential export deficiency of Gal-1-GFPR112H and 
Gal-1-GFPV32E is that a specific transporter exists, which is not able to recognize 
these mutated proteins independent of sugar binding ability. An alternative 
explanation might be that the described mutants are impaired in dimer formation. 
Further studies are required to characterize the decreased export efficiency.  
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4.7 Potential models for the unconventional secretion of 
Gal-1 
 
 Regarding the molecular mechanism of Gal-1 export from mammalian cells, 
there are three possible scenarios that would be consistent with the presented data. 
On the one hand, galectin counter receptors on the cell surface might be part of a 
molecular trap through which secreted Gal-1 molecules would be removed from 
equilibrium between an intracellular and an extracellular pool of Gal-1 (Fig. 47 panel 
A). In principle, the extracellular galectin trap could be necessary for sustained Gal-1 
export of the cytoplasmic pool. However, in the absence of functional interactions 
between Gal-1 and its counter receptors, secretion is apparently fully blocked. 
Therefore, the trapping mechanism does not satisfactorily explain our observation, as 
Gal-1 transport should be observed at least to a certain extent until equilibrium 
between intra- and extracellular pools is reached.  
 In a second model, β-galactoside-containing cell surface molecules might be 
tightly coupled to the translocation machinery (Fig. 47 panel B) and function by 
exerting a pulling force at the extracellular side of a putative translocation pore 
required for directional transport of Gal-1 across the plasma membrane.  
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Fig. 47 Schematic overview of potential mechanisms mediating Gal-1 membrane translocation. 
A. Gal-1 is removed from an equilibrium (sink mechanism). B. Counter receptors exert a 
pulling force on Gal-1. C. Counter receptors act as export receptors. For details see text. 
 
 An alternative explanation of the presented results would be that β-galactoside-
containing counter receptors act as export receptors for Gal-1 (Fig. 47, panel C). It 
might be speculated that Gal-1 interactions with counter receptors are not restricted 
to the extracellular space but rather already occur on the cytoplasmic side of the 
plasma membrane. This assumption is not consistent with the established view that 
for instant glycolipids are exclusively localized to the extracellular leaflet of the 
plasma membrane with glycan moieties being exposed to the extracellular space. 
However, it appears possible that a subpopulation of β-galactoside-containing glyco-
lipids which probably would not be detectable under steady-state conditions gets 
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translocated to the inner leaflet of the plasma membrane. This translocation might be 
catalyzed by a plasma membrane resident flippase. In this model, re-translocation of 
counter receptors occupied by Gal-1 would mediate export to the extracellular space. 
 
 All described models (Fig. 47) indicate a direct translocation of Gal-1 across the 
plasma membrane. Mehul and colleagues reported that Gal-3 is transported directly 
to the plasma membrane prior to secretion and released into the extracellular space 
by vesicular budding from cos-7 and J774.2 cells because they were able to isolate 
extracellular vesicles containing Gal-3 by isopycnic centrifugation (Mehul and 
Hughes, 1997). Additionally, vesicular structures budding of cos-7 cell surface were 
detected employing confocal microscopy using polyclonal anti-Gal-3 antibodies. 
Membrane blebbing is a common feature at the periphery of many cell types, 
including fibroblasts (Lee et al., 1993), neutrophils (Stein and Luzio, 1991) and 
chondrocytes (Hale and Wuthier, 1987), that is regulated by intracellular calcium in 
some cases (Shukla et al., 1978). Although the results of pulse-chase analyses 
suggest an intermediate role of extracellular vesicles in the export of Gal-3 from 
macrophage J774.2 cells, the possibility that at least a part of the lectin may be 
translocated directly from plasma membrane domains into the extracellular space 
could not be excluded since a small but significant amount of the lectin was detected 
in the soluble fraction of conditioned medium obtained from cos-7 and J774.2 cells. 
As the isolated vesicles were not analyzed for apoptotic markers like Annexin V it 
might be that they result from apoptotic cells (Miller, 2004). 
 Independently, Cooper et al. demonstrated that Gal-1 expressed in myoblasts is 
externalized upon differentiation, whereas creatine kinase and lactate dehydro-
genase - markers for unspecific release - remain intracellularly (Cooper and 
Barondes, 1990). Therefore, extracellular Gal-1 cannot be due to cell death or 
transient membrane disruption of a small fraction of the cultured cell population. As 
myoblasts differentiate, Gal-1 also appears to be concentrated directly underneath 
the plasma membrane as visualized by confocal microscopy. Concentrated patches 
of ectoplasmic Gal-1 are then evaginated from the plasma membrane and form 
extracellular vesicles enriched in the lectin. The final step in externalization of Gal-1 
is presumed to occur when evaginated vesicles are disrupted (Cooper and Barondes, 
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1990). However, employing confocal microscopy of CHO cells expressing Gal-1-GFP 
in a doxicycline dependent manner, no membrane blebs were detectable neither in 
living nor in fixed cells indicating that Gal-1 is externalized by a mechanism 
independent of vesicular structures (Seelenmeyer et al., 2005). 
 
 While the proposed export models are certainly speculative at this point, they 
are consistent with several observations that have been made previously. First, 
galectin membrane translocation has been reported to occur at the level of the 
plasma membrane (Cooper and Barondes, 1990; Hughes, 1999; Mehul and Hughes, 
1997; Nickel, 2003; Schäfer et al., 2004). Second, Huet and colleagues recently 
reported pharmacological evidence that Gal-4 secretion is impaired in epithelial cells 
following treatment with 1-benzyl-2-acetamido-2-deoxy-α-D-galactopyranoside, an 
inhibitor of glycosylation (Delacour et al., 2005). Third, evidence has been reported 
that membrane translocation of both FGF-2 and Gal-1 occurs in a folded state 
(Backhaus et al., 2004).  
 In the context of the current study, this finding is of particular interest since the 
models described above can only be true if the β-galactoside binding site of Gal-1 
remains functional during membrane translocation. In this regard, the putative trans-
location machinery might be functionally related to the bacterial twin arginine trans-
location system mediating protein secretion in a fully folded state (Oates et al., 2005; 
Robinson and Bolhuis, 2004). 
 
 The findings presented in this work also provide a potential explanation for the 
apparent non-existence of a linear targeting motif in Gal-1. The presented data 
conclusively point to a direct role of counter receptors as export adaptors and the β-
galactoside binding motif of Gal-1 as the primary targeting element. In this context, it 
is interesting to note that secretion from Saccharomyces cerevisiae of both rat Gal-1 
and Coprinospsis cinerea CGL-2 has been reported (Cleves et al., 1996) (Boulianne 
et al., 2000). This organism does not contain endogenous galectins and the exis-
tence of glycolipids and glycoproteins containing β-galactosides has not yet been 
clarified. Therefore, it remains to be investigated whether secretion of galectins from 
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Saccharomyces cerevisiae occurs by a molecular mechanism similar to that of 
mammalian cells.  
 Finally, it is of note that the secretory mechanism being postulated in this thesis 
provides a functional basis for quality control in the overall process of Gal-1 se-
cretion. As the β-galactosides binding motif of Gal-1 is shown to be the primary 
targeting element for secretion, quality control is in place since only properly folded 
Gal-1 will be recognized by the export machinery (Nickel, 2005). 
 
4.8 Future perspectives 
 
 The established Gal-1 secretion assays employing flow cytometry and cell 
surface biotinylation analysis were shown to be robust methods to investigate non-
classical export processes in molecular detail. To clarify if β-galactoside-containing 
glycoproteins or glycolipids are involved in the export mechanism, the mutagenized 
subclone GM95 of the murine melanoma cell line B16 (Ito and Komori, 1996; Komori 
et al., 1999; Smith et al., 2003) will be analyzed for secretion of Gal-1-GFP 
expressed in a doxicycline-dependent manner. This cell line lacks the ceramide-
glucosyl transferase gene and does not present glycolipids on the cell surface. MEB4 
cells represent the parental cell line of GM95 cells containing a functional ceramide-
glucosyl transferase gene (Spilsberg et al., 2003) and, unlike GM95, produce 
functional glycolipids and glycoproteins. Based on these cell lines it will be possible 
to distinguish between the postulated models (Fig. 47). If the export machinery in 
GM95 cells is functional and exported Gal-1-GFP is detectable on the cell surface 
bound to β-galactoside-containing glycoproteins, it can be excluded that the trans-
location of Gal-1-GFP is mediated by a membrane-resident flippase. 
 The FACS based Gal-1 secretion assay will form the basis for a number of 
future applications such as the systematic screening for specific inhibitors from 
complex compound libraries. Additionally, systematic screening using RNAi libraries 
will be conducted in future experiments. For example, both an RNAi library directed 
against all ABC transporters known in the human genome and a complex library 
covering all genes (≈ 22.000 genes) in the human genome will be tested regarding 
Discussion 
 
197 
export efficiency of Gal-1-GFP under knock-down conditions in HeLa cells. Based on 
this it might be possible to isolate a single counter receptor for Gal-1, which mediates 
specifically the translocation process across the plasma membrane.  
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